Treatment of liver disease with cell death-inducing DFFA-like effector B (CIDEB) inhibitors
Patent Information
- Application Number
- JP2023538855
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-19
- Filing Date
- 2021-12-22
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for chronic liver diseases such as alcoholic and non-alcoholic liver disease and cirrhosis are lacking, and there is a need for effective therapeutic targets to address these conditions, particularly in identifying subjects at increased risk based on genetic variants.
The use of CIDEB, PNPLA3, and HSD17B13 inhibitors, administered based on genetic analysis of variant nucleic acid molecules, to treat or prevent liver disease, with dosage adjustments tailored to individual genetic profiles.
This approach allows for personalized treatment strategies that reduce the risk of developing severe liver disease by targeting specific genetic variants associated with reduced disease risk, providing effective therapeutic compositions and inhibitors for liver disease management.
Abstract
Description
[Technical field]
[0001] Reference to sequence listing This application contains a Sequence Listing that has been submitted electronically as a text file entitled 18923806202SEQ, created on December 21, 2021, having a size of 2,576 kilobytes. The Sequence Listing is incorporated herein by reference.
[0002] The present disclosure relates generally to treatment of subjects having liver disease with a cell death-inducing DFFA-like effector B (CIDEB) inhibitor, a patatin-like phospholipase domain-containing 3 (PNPLA3) inhibitor, or a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor, or any combination thereof, and to methods of identifying subjects at increased risk for developing liver disease. [Background technology]
[0003] Chronic liver disease and cirrhosis are the leading causes of morbidity and mortality in the United States, accounting for 38,170 deaths in 2014 (1.5% of total deaths) (Non-Patent Document 1). In the United States, the most common causes of cirrhosis are alcoholic liver disease, chronic hepatitis C, and non-alcoholic fatty liver disease (NAFLD), which accounted for approximately 80% of patients awaiting liver transplantation between 2004 and 2013 (Non-Patent Document 2). The estimated prevalence of NAFLD in the United States ranges from 19 to 46 percent (Non-Patent Document 3, Non-Patent Document 4, and Non-Patent Document 5), and has been increasing over time, likely in conjunction with rising obesity rates, one of the main risk factors for NAFLD (Non-Patent Document 6) (Non-Patent Document 7). While there have been significant advances in the treatment of hepatitis C, there are currently no evidence-based treatments for alcoholic or non-alcoholic liver disease or cirrhosis. Identifying naturally occurring gene variants that protect against liver damage and liver disease outcomes may be a route to identifying novel therapeutic targets for liver disease (Non-Patent Document 8).
[0004] CIDEB is expressed in the liver and small intestine and has been shown to play a role in regulating various aspects of lipid metabolism. CIDEB may be involved in lipid metabolism by controlling lipid droplet fusion and very low density lipoprotein (VLDL) lipidation through interaction with ApoB. CIDEB is also required for the biogenesis of VLDL transport vesicles and for chylomicron lipidation in the small intestine. CIDEB also controls hepatic SREBP activation (a master regulator of lipid metabolism) by selectively promoting the delivery of SREBP / SCAP complexes from the endoplasmic reticulum to the Golgi apparatus. Sterol depletion induces SCAP to interact with CIDEB, which also binds Sec12, a GEF for Sar1, thereby concentrating SCAP / SREBP at ER exit sites and increasing the packaging of SREBP / SCAP into COPII-coated vesicles. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Kochanek et al.,Nat'l.Vital Stat.Rep.,2016,65,1-122 [Non-Patent Document 2] Wong et al.,Gastroenterology,2015,148,547-555 [Non-Patent Document 3] Browning et al.,Hepatology,2004,40,1387-1395 [Non-Patent Document 4] Lazo et al.,Am.J.Epidemiol.,2013,178,38-45 [Non-Patent Document 5] Williams et al.,Gastroenterology,2011,140,124-131 [Non-Patent Document 6] Cohen et al.,Science,2011,332,1519-1523 [Non-Patent Document 7] Younossi et al.,Clin.Gastroenterol.Hepatol.,2011,9,524-530 [Non-Patent Document 8] Abul-Husn et al.N.Engl.J.Med.,2018,378,1096-106 Summary of the Invention [Means for solving the problem]
[0006] The present disclosure provides a method of treating a subject having or at risk of developing liver disease, the method comprising administering a CIDEB inhibitor to the subject. The disclosure also provides a method of treating a subject with a CIDEB inhibitor, the subject having or at risk of developing liver disease, the method comprising the steps of obtaining or obtaining a biological sample from the subject; and determining whether the subject has a CIDEB variant nucleic acid molecule by performing or performing a sequence analysis on the biological sample to determine whether the subject has a genotype that includes a CIDEB variant nucleic acid molecule; and administering or continuing administration of a standard dosage of the CIDEB inhibitor to a CIDEB reference subject; and administering or continuing administration of a dosage of the CIDEB inhibitor that is the same as or less than the standard dosage to a subject who is heterozygous or homozygous for the CIDEB variant nucleic acid molecule, wherein the presence of a genotype that includes a CIDEB variant nucleic acid molecule indicates that the subject has a reduced risk of developing liver disease or has a reduced risk of developing a more severe form of liver disease.
[0007] The present disclosure also provides a method of identifying a subject having an increased risk of developing liver disease, the method comprising determining or having determined the presence or absence of a CIDEB variant nucleic acid molecule in a biological sample obtained from the subject, where if the subject is a CIDEB reference, then the subject has an increased risk of developing liver disease; if the subject is heterozygous or homozygous for the CIDEB variant nucleic acid molecule, then the subject has a decreased risk of developing liver disease.
[0008] The present disclosure also includes, according to the GRCh38 / hg38 human genome assembly coordinates, 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A,14:24307474:C:T、14:24307475:A:G、14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:243 06039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G :A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24 306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109: C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:2 4306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:2430606 The present invention provides a therapeutic composition for treating or inhibiting liver disease for use in treating liver disease in a subject having a CIDEB variant nucleic acid molecule comprising 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C.
[0009] The present disclosure also provides, according to the GRCh38 / hg38 human genome assembly coordinates, 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A,14:24307474:C:T、14:24307475:A:G、14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039 :G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:2430 7418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14: 24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A , 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:2430642 0:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:243 The present invention provides a composition comprising a CIDEB inhibitor, a PNPLA3 inhibitor, or an HSD17B13 inhibitor, or any combination thereof, for use in treating liver disease in a subject having a CIDEB variant nucleic acid molecule comprising 06047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C.
[0010] The disclosure also provides a method of treating a subject having or at risk of developing liver disease, wherein the subject is heterozygous or homozygous for a PNPLA3 variant nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, the method comprising administering to the subject i) a CIDEB inhibitor; ii) a combination of a CIDEB inhibitor and a PNPLA3 inhibitor; iii) a combination of a CIDEB inhibitor and an HSD17B13 inhibitor; or iv) a combination of a CIDEB inhibitor, a PNPLA3 inhibitor, and an HSD17B13 inhibitor.
[0011] The disclosure also provides a method of treating a subject having or at risk of developing liver disease, where the subject is homozygous for a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide, the subject is administered i) a CIDEB inhibitor in an amount equal to or greater than the standard dosage; ii) a combination of a CIDEB inhibitor and a PNPLA3 inhibitor in an amount equal to or greater than the standard dosage; iii) a combination of a CIDEB inhibitor and an HSD17B13 inhibitor in an amount equal to or greater than the standard dosage; or iv) a CIDEB inhibitor, a PNPLA3 inhibitor, and an HSD17B13 inhibitor in an amount equal to or greater than the standard dosage. The present invention provides methods in which a combination of 17B13 inhibitors is administered; and if the subject is not homozygous for a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide (i.e., a carrier for loss-of-function HSD17B13), the subject is administered i) a CIDEB inhibitor in an amount less than the standard dosage; ii) a combination of a CIDEB inhibitor and a PNPLA3 inhibitor in an amount less than the standard dosage; iii) a combination of a CIDEB inhibitor and an HSD17B13 inhibitor in an amount less than the standard dosage; or iv) a combination of a CIDEB inhibitor, a PNPLA3 inhibitor, and an HSD17B13 inhibitor in an amount less than the standard dosage.
[0012] The disclosure also provides a method of treating a subject with a CIDEB inhibitor, the subject having or at risk of developing liver disease, the method comprising obtaining or obtaining a biological sample from the subject; and performing or performing a sequence analysis on the biological sample to determine whether the subject has a genotype that includes a PNPLA3 variant nucleic acid molecule, thereby determining whether the subject has a PNPLA3 variant nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide; and administering or continuing to administer an amount of the CIDEB inhibitor equal to or greater than a standard dosage, or in combination with an HSD17B13 inhibitor and / or a PNPLA3 inhibitor, to a subject who is heterozygous or homozygous for the PNPLA3 variant nucleic acid molecule, wherein the presence of a genotype that includes a PNPLA3 variant nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide indicates that the subject is a candidate for CIDEB inhibitor treatment.
[0013] The disclosure also provides a method of treating a subject with a CIDEB inhibitor, the subject having or at risk of developing liver disease, the method comprising obtaining or obtaining a biological sample from the subject; and performing or performing a sequence analysis on the biological sample to determine whether the subject has a genotype that includes a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide, thereby determining whether the subject has a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide; and administering or continuing to administer a CIDEB inhibitor, or in combination with an HSD17B13 inhibitor and / or a PNPLA3 inhibitor, to a subject who is heterozygous or homozygous for the reference HSD17B13 polypeptide or the nucleic acid molecule encoding a functional HSD17B13 polypeptide, wherein the presence of a genotype that includes a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide indicates that the subject is a candidate for treatment with a CIDEB inhibitor.
[0014] The disclosure also provides a method of treating a subject, wherein the subject is overweight, obese, has an increased body mass index (BMI), has a high liver fat percentage, or has hyperadiposity, the method comprising administering to the subject a CIDEB inhibitor, or a CIDEB inhibitor in combination with a PNPLA3 inhibitor and / or an HSD17B13 inhibitor.
[0015] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several aspects and, together with the description, serve to explain the principles of the present disclosure. [Brief description of the drawings]
[0016] [Figure 1]Association of rare coding variants in CIDEB with liver disease risk. The figure shows associations with liver disease across the etiology and severity spectrum for rare pLOF variants in CIDEB (top), rare coding variants in CIDEB (middle) and HSD17B13 splice variants (grey, heterozygous variant genotypes compared to reference homozygous genotypes; open circles, homozygous variant genotypes compared to reference homozygous genotypes). Abbreviations: OR; odds ratio; CI, confidence interval. [Diagram 2] Associations between rare coding variants in CIDEB and liver histopathology phenotypes in bariatric surgery patients. Panel a shows the analysis of liver histopathology categories (i.e., normal liver, simple steatosis, NASH, or fibrosis) among carriers and noncarriers of rare coding (i.e., pLOF and missense) variants in CIDEB. Panel b shows the distribution of nonalcoholic fatty liver disease activity scores on liver histopathology among carriers and noncarriers of rare coding (i.e., pLOF and missense) variants in CIDEB. Data are from perioperative liver biopsies of participants in the GHS bariatric surgery cohort. Abbreviations: pLOF, predicted loss of function; NASH, nonalcoholic steatohepatitis; NALD, nonalcoholic fatty liver disease. [Figure 3-1]Figure 1. Metabolic trait associations of rare coding variants in CIDEB. Association estimates in blue are for rare coding (pLOF and missense) variants, whereas association estimates in red are for rare pLOF variants only. Panel a shows associations with a range of traits, whereas panel b shows associations with binary outcome traits. Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index; WHRadjBMI, waist-to-hip ratio adjusted for BMI; DBP, diastolic blood pressure; SBP, systolic blood pressure; pLOF, predicted loss of function; CI, confidence interval; kg / m2, kilograms per square meter; mg / DL, milligrams per deciliter; and mmHg, millimeters of mercury. [Figure 3-2] Same as above. [Figure 4] Figure 1 shows a visualization of the interaction between the burden of rare coding variants in CIDEB and body mass index on alanine aminotransferase levels. CIDEB rare coding (pLOF and missense) variants (panel a) and only CIDEB rare pLOF variants (panel b) are associated with a greater reduction in ALT when individuals have a higher body mass index compared to individuals with a lower body mass index. The interaction p-value was used to determine if the difference in association with ALT by BMI was statistically significant. Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; pLOF, predicted loss of function; AAF, alternative allele frequency; SD, standard deviation; U / L, units per liter. [Diagram 5]Figure 1 shows visualization of interactions between rare coding variants in CIDEB and body mass index. Panel a shows the interaction of CIDEB genotype (i.e., rare pLOF variants) and body mass index on alanine aminotransferase levels. Panel b shows the interaction of CIDEB genotype (i.e., rare pLOF and missense variants) and body mass index on alanine aminotransferase levels. Abbreviations: pLOF, predicted loss of function; SD, standard deviation; P, p-value; ALT, alanine aminotransferase; BMI, body mass index; U / L, units per liter. [Figure 6] Figure 1 shows the proportion of non-alcoholic liver disease in carriers and non-carriers of CIDEB rare coding variants across body mass index categories. The percentage of non-alcoholic liver disease for carriers vs. non-carriers of rare coding CIDEB variants stratified by body mass index is shown. Panel a shows carriers of pLOF variants only, and panel b shows carriers of pLOF and missense variants. Abbreviations: BMI, body mass index; pLOF, predicted loss of function; AAF, alternative allele frequency. Numbers above each bar represent the observed sample size within the group represented by the bar. [Figure 7] Figure 1 shows visualization of the interaction between rare coding variants in CIDEB and PNPLA3 Ile148Met. Panel a shows the interaction of CIDEB genotype (i.e., rare pLOF variants) and Ile148Met on alanine aminotransferase levels. Panel b shows the interaction of CIDEB genotype (i.e., rare pLOF and missense variants) and Ile148Met on alanine aminotransferase levels. Abbreviations: pLOF, predicted loss of function; SD, standard deviation; P, p-value; ALT, alanine aminotransferase; BMI, body mass index; U / L, units per liter. [Figure 8-1]CIDEB expression patterns across tissues (panel a) and liver cell types (panel b). Panel a shows normalized mRNA expression per tissue for CIDEB in counts per million for each individual using data from the Genotype Tissue Expression (GTEx) Consortium (GTEx Portal 2021. Accessed via the World Wide Web on June 1, 2021 at gtexportal.org / ). Panel b shows normalized cell type-specific expression levels within the liver in transcripts per million protein-coding genes (pTPM) obtained from the Human Protein Atlas (HPA) (Nat. Biotechnol., 2010, 28, 1248-50). Box plots show median (thick black vertical bars), interquartile range, and minimum and maximum CPM values across individuals per tissue. [Figure 8-2] Same as above. [Figure 9-1]We show that a rare pLOF variant in CIDEB confers loss of function via defective mRNA processing in the liver. Panel a shows the levels of mRNA expression of CIDEB in the liver of a bariatric surgery patient from GHS (left), two Lys153* heterozygote carriers (middle), and two c.336+1G>A heterozygote carriers (right). Panel b shows allele-specific expression results for two Lys153* heterozygote carriers in RNA-seq reads mapped to variant sites (left; dashed red lines indicate variant sites and arrows indicate rare instances where reads harbor the variant allele) and in comparison of read counts with or without the variant allele (right). Panel c shows allele-specific expression results for two c.336+1G>A heterozygote carriers. The left panel shows RNA-seq reads that mapped to variant sites (dashed red lines indicate variant sites and arrows indicate rare instances where a read harbors a variant allele). The middle panel shows the number of spliced and unspliced reads in the two carriers, with unspliced reads occurring less frequently. The right panel shows allele-specific expression in unspliced reads that disproportionately harbored the variant allele. Abbreviations: pLOF, predicted loss of function; CPM, counts per million; P, p-value; mRNA, mature messenger RNA. [Figure 9-2] Same as above. [Figure 10-1]Figure 1 shows that siRNA-mediated knockdown of CIDEB prevents lipid droplet assembly in HepG2 cells. Panel A shows the subcellular localization of endogenous CIDEB to the interface of lipid droplets via immunofluorescence staining under basal conditions (no oleic acid) or in the presence of 400 μM oleic acid. Panel B shows that CIDEB protein staining is detectable in cells treated with control siRNA (top) but not with CIDEB siRNA (bottom), demonstrating the specificity of the CIDEB antibody used in both basal conditions (left) and oleic acid treatment (right). Purple, antibody staining for CIDEB; green, neutral lipids stained by BODIPY; blue, nuclei stained by DAPI; scale bar, 10 μm. Panel C shows Western blot analysis of CIDEB protein expression (left and center) and Taqman analysis of CIDEB mRNA expression (right) in HepG2 cells treated with control or CIDEB siRNA. Data are presented as the mean ± sd of independent wells, and Welch's t-test was performed to determine statistical significance (* denotes p<0.05). Panel D shows representative images of the effect of oleic acid treatment and CIDEB siRNA on lipid droplet size and distribution. Red, neutral lipids stained by AdipoRed; blue, nuclei stained by DAPI; scale bar, 20 μm. Panels E, F, and H show quantification of lipid droplet features derived from imaging, with bar plots showing the mean ± sd of four independent wells shown as individual points per condition. Panel E shows the average number of lipid droplets per cell; Panel F shows the average lipid droplet size (quantified from the three-dimensional volume of individual lipid droplets); Panel H shows the average cellular lipid droplet staining (quantified as the total area of lipid droplet staining in each cell). Panel G shows the average triglyceride concentration per cell quantified using an enzymatic assay; data show the mean ± sd of nine independent wells shown as individual points per condition. Panel I shows the concentration of the pro-inflammatory cytokine IL-8 secreted into the cell culture medium as quantified by immunoassay; data are means ± sd.Differences in EI were assessed using two-way ANOVA; pairwise comparisons of CIDEB siRNA or oleic acid treatments were available using Tukey's multiple comparisons with Sidak correction (ns, non-significant; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). Panel J shows AdipoRed staining of neutral lipids, demonstrating that increasing concentrations of oleic acid result in a dose-dependent increase in lipid droplet size and cellular lipid droplet staining (left). CIDEB siRNA pretreatment reduces lipid droplet size compared to control siRNA pretreatment (right). Red, neutral lipids stained by AdipoRed; blue, nuclei stained by 4′,6-diamidino-2-phenylindole (DAPI); scale bar, 20 μm. Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; OA, oleic acid; LD, lipid droplets. [Figure 10-2] Same as above. [Figure 10-3] Same as above. [Figure 10-4] Same as above. [Figure 10-5] Same as above. [Figure 10-6] Same as above. [Figure 10-7] Same as above. [Figure 10-8] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] Various terms relating to aspects of the present disclosure are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art unless otherwise indicated. Other specifically defined terms are to be interpreted in a manner consistent with the definitions provided herein.
[0018] Unless expressly stated otherwise, it is not intended that any method or aspect described herein be interpreted as requiring that its steps be performed in a particular order. Thus, unless a method claim specifically states in the claims or description that the steps are to be limited to a particular order, no order is intended to be implied in any respect. This is true for all potentially unclear criteria for interpretation, including questions of logic regarding the arrangement of steps or operational flow, the plain meaning derived from grammatical construction or punctuation, or the number or type of aspects described herein.
[0019] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. As used herein, the term "about" means that the recited numerical values are approximate and that small variations will not significantly affect the practice of the disclosed embodiments. When numerical values are used, unless otherwise indicated by the context, the term "about" means that the numerical values can vary by ±10% and remain within the scope of the disclosed embodiments.
[0020] As used herein, the term "comprising" may in certain embodiments be replaced with "consisting of" or "consisting essentially of," as desired.
[0021] As used herein, the terms "nucleic acid," "nucleic acid molecule," "nucleic acid sequence," "polynucleotide," or "oligonucleotide" include polymeric forms of nucleotides of any length, including DNA and / or RNA, and can be single-stranded, double-stranded, or multistranded. A strand of a nucleic acid also refers to its complement.
[0022] As used herein, the term "subject" includes any animal, including mammals. Mammals include, but are not limited to, farm animals (e.g., horses, cows, pigs, etc.), pet animals (e.g., dogs, cats, etc.), laboratory animals (e.g., mice, rats, rabbits, etc.), and non-human primates (e.g., apes and monkeys, etc.). In some embodiments, the subject is a human. In some embodiments, the subject is a patient under the care of a physician.
[0023] According to the present disclosure, it has been observed that the genetic burden of certain CIDEB variations (i.e., CIDEB variant nucleic acid molecules) is associated with a reduced risk of developing liver disease.It is believed that variants in CIDEB genes or proteins are not significantly associated with markers of liver disease or liver damage in previous exome sequencing association studies.Therefore, it is believed that people who have liver disease or are at risk of developing liver disease can be treated with CIDEB inhibitors.Therefore, the present disclosure provides a method for utilizing the identification of subjects who do not have such protective CIDEB variant nucleic acid molecules and are therefore at risk of developing liver disease, and for stratifying the risk of developing liver disease in such subjects, so that subjects at risk or subjects with active disease can be treated with CIDEB inhibitors.
[0024] In any of the embodiments described herein, the CIDEB variant nucleic acid molecule can be any CIDEB nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, cDNA molecule, etc.) that encodes a CIDEB polypeptide with partial loss of function, complete loss of function, predicted partial loss of function, or predicted complete loss of function, or that encodes a missense polypeptide, or that results in the absence of the encoded polypeptide, or that has an effect on CIDEB mRNA sequence or expression. For example, the CIDEB variant nucleic acid molecule can be any of the CIDEB variant nucleic acid molecules described herein. The CIDEB variant nucleic acid molecule can be a variant that is predicted to result in premature truncation of the CIDEB polypeptide (including, but not limited to, frameshift mutations, insertions or deletions, stop-gain, stop-lost, start-lost, splice site variants, or large chromosomal or subchromosomal rearrangements that affect the CIDEB gene). The CIDEB variant nucleic acid molecule can include, but is not limited to, an in-frame insertion or deletion in the CIDEB gene, or a variant in the untranslated region of the CIDEB gene. Missense variants are variants that are predicted to result in an alteration in the amino acid sequence of the CIDEB polypeptide.
[0025] For the purposes of this disclosure, any particular subject, e.g., a human, can be categorized as having one of three CIDEB genotypes: i) CIDEB reference; ii) heterozygous for CIDEB variant nucleic acid molecule, and iii) homozygous for CIDEB variant nucleic acid molecule. If the subject does not have a copy of the CIDEB variant nucleic acid molecule, the subject is CIDEB reference. If the subject has a single copy of the CIDEB variant nucleic acid molecule, the subject is heterozygous for the CIDEB variant nucleic acid molecule. A CIDEB variant nucleic acid molecule is any CIDEB nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) that encodes a CIDEB polypeptide with partial loss of function, complete loss of function, predicted partial loss of function, or predicted complete loss of function, or that encodes a missense polypeptide, or that has an effect on the CIDEB mRNA sequence. A subject having a CIDEB polypeptide with partial loss of function (or predicted partial loss of function, or missense) is hypomorphic for CIDEB (low gene abundance or function compared to the reference sequence version). The CIDEB variant nucleic acid molecule can be any variant nucleic acid molecule described herein. A subject is homozygous for a CIDEB variant nucleic acid molecule if the subject has either of two copies of the CIDEB variant nucleic acid molecule.
[0026] For subjects who are genotyped or determined to be heterozygous or homozygous for CIDEB variant nucleic acid molecules, such subjects have a reduced risk of developing liver disease compared to CIDEB reference subjects. For subjects who are genotyped or determined to be CIDEB reference, such subjects have an increased risk of developing liver disease compared to carriers of the above-mentioned CIDEB variants. For subjects who are genotyped or determined to be CIDEB reference or heterozygous for CIDEB variant nucleic acid molecules, such subjects can be treated with one or more CIDEB inhibitors. Such subjects can also be treated with therapeutic agents used to treat liver disease. For subjects who are genotyped or determined to be CIDEB reference or heterozygous for CIDEB variant nucleic acid molecules, such subjects can also be treated with a combination of CIDEB inhibitors and PNPLA3 inhibitors and / or HSD17B13 inhibitors.
[0027] For subjects who are genotyped or determined to be CIDEB reference and are carriers of PNPLA3 variant nucleic acid molecules encoding PNPLA3 Ile148Met or Ile144Met, such subjects have an increased risk of developing liver disease compared to subjects who are either CIDEB reference or carriers of the above CIDEB variant types, but do not carry PNPLA3 variant nucleic acid molecules encoding PNPLA3 Ile148Met or Ile144Met (PNPLA3 reference).For subjects who are genotyped or determined to be CIDEB reference or are heterozygous for CIDEB variant nucleic acid molecules and are carriers of PNPLA3 variant nucleic acid molecules encoding PNPLA3 Ile148Met or Ile144Met, such subjects can be treated with a combination of one or more CIDEB inhibitors and / or one or more PNPLA3 inhibitors.Such subjects can also be treated with therapeutic agents used to treat liver disease. Such subjects may also be treated with an HSD17B13 inhibitor.
[0028] For subjects who are genotyped or determined to be CIDEB reference and are carriers of reference HSD17B13 polypeptide or nucleic acid molecule encoding functional HSD17B13 polypeptide, such subjects have an increased risk of developing liver disease compared to subjects who are heterozygous carriers of CIDEB reference or CIDEB variants described above, but do not carry reference HSD17B13 polypeptide or nucleic acid molecule encoding functional HSD17B13 polypeptide.For subjects who are genotyped or determined to be CIDEB reference or are heterozygous for CIDEB variant nucleic acid molecule and are carriers of reference HSD17B13 polypeptide or nucleic acid molecule encoding functional HSD17B13 polypeptide, such subjects can be treated with a combination of one or more CIDEB inhibitors and / or one or more HSD17B13 inhibitors in combination.Such subjects can also be treated with therapeutic agents used to treat liver disease.Such subjects can also be treated with PNPLA3 inhibitors.
[0029] In any of the embodiments described herein, the CIDEB variant nucleic acid molecule can be any nucleic acid molecule (e.g., a genomic nucleic acid molecule, an mRNA molecule, a cDNA molecule, etc.) that encodes a CIDEB polypeptide having partial loss of function, complete loss of function, predicted partial loss of function, or predicted complete loss of function, or that encodes a missense polypeptide, or that has an effect on the CIDEB mRNA sequence. In some embodiments, the CIDEB variant nucleic acid molecule is a variant that causes or is predicted to cause a nonsynonymous amino acid substitution in CIDEB, the allele frequency of which is less than 1 / 100 in the population from which the subject is selected. In some embodiments, the CIDEB variant nucleic acid molecule is any rare missense variant (allele frequency <1%; or 1 in 100 alleles) or any missense variant, regardless of frequency, predicted or demonstrated to result in an alteration in CIDEB polypeptide sequence, folding, structure, abundance or function, or any splice site, stop gain, start loss, stop loss, frameshift, or in-frame indel, or other frameshift CIDEB variant or any other variant predicted or demonstrated to result in an alteration in the amino acid sequence of a CIDEB polypeptide. In some embodiments, the subject has the following CIDEB variant nucleic acid molecules: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T , 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C: T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G,14:24306044:G:A、14:24306047:G:A、14:24306051:T:G、14:24306064:T:C、14:24306074:A:G、14:24306077:G:C、14:24306082:A:G、14:24306083:T:A、14:24306095:G:A、14:24306122:A:G、14:24306134:C:G、14:24306373:C:G、14:24306379:T:C、14:24306382:G:A、14:24306383:G:T、14:24306426:T:G、14:24306437:C:G、14:24306439:G:C、14:24306442:A:G、14:24306444:A:G、14:24306457:C:T、14:24306463:C:T、14:24306469:C:T、14:24306480:A:G、14:24306486:A:C、14:24306504:A:G、14:24306519:A:G、14:24307382:G:C、14:24307405:A:G、14:24307417:A:T、14:24307421:T:A、14:24307441:C:A、14:24307444:A:C、14:24307444:A:G、14:24307450:C:CGCTG、14:24307461:TG:T、14:24307469:AG:A、14:24307474:C:T、14:24307475:A:G、14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG、14:24307411:T:C、14:24306121:T:C、14:24307516:C:T、14:24306424:C:T、14:24306039:G:C、14:24307853:C:A、14:24306388:A:G、14:24305990:T:C、14:24307822:G:GT、14:24305640:G:A、14:24307418:T:C、14:24305758:G:C、14:24306131:C:T、14:24305953:A:G、14:24305730:C:A、14:24306418:A:G、14:24306059:AC:A、14:24307842:G:A、14:24307837:T:G、14:24306095:G:T、14:24306109:C:T、14:24307822:G:A、14:24306077:G:A、14:24307824:A:T、14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14 :24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24 306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to the GRCh38 / hg38 human genome assembly coordinates).
[0030] In any of the embodiments described herein, the CIDEB variant nucleic acid molecule has one or more variations at the indicated positions on chromosome 14 using the nucleotide sequence of the CIDEB reference genome nucleic acid molecule (SEQ ID NO:1; ENSG00000136305.11 in the GRCh38 / hg38 human genome assembly, position 24,311,422 on chromosome 14 is the first nucleotide in SEQ ID NO:1).
[0031] In any of the embodiments described herein, the CIDEB variant nucleic acid molecules can be mRNA and cDNA molecules having corresponding variant positions with reference to a reference genome sequence as a reference sequence.
[0032] The nucleotide sequences of the CIDEB reference mRNA molecules generated via alternative splicing are shown in SEQ ID NOs: 2-12. The variant nucleotides at their respective variant positions for the variant genomic nucleic acid molecules described herein also have corresponding variant nucleotides at their respective variant positions for variant mRNA molecules based on the CIDEB reference mRNA sequences according to SEQ ID NOs: 2-12. Any of these CIDEB variant mRNA molecules can be detected in any of the methods described herein.
[0033] The nucleotide sequences of the CIDEB reference cDNA molecules generated via alternative splicing are shown in SEQ ID NOs: 13-23. The variant nucleotides at their respective variant positions for the variant genomic nucleic acid molecules described herein also have corresponding variant nucleotides at their respective variant positions for variant cDNA molecules based on the CIDEB reference cDNA sequences according to SEQ ID NOs: 13-23. Any of these CIDEB variant cDNA molecules can be detected in any of the methods described herein.
[0034] The amino acid sequence of the CIDEB reference polypeptide is shown in SEQ ID NO: 24. Using the translated nucleotide sequence of either the CIDEB mRNA or cDNA molecule, the CIDEB variant polypeptide has a corresponding translated variant amino acid at the variant position. Any of these predicted loss-of-function polypeptides of CIDEB can be detected in any of the methods described herein.
[0035] The nucleotide and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for the nucleotide bases and three-letter code for the amino acids. The nucleotide sequences follow the standard convention of starting at the 5'-end of the sequence and proceeding forward to the 3'-end (i.e., left to right on each line). Only one strand of each nucleotide sequence is shown, but the complementary strand is understood to be encompassed by any reference to the presented strand. The amino acid sequences follow the standard convention of starting at the amino terminus of the sequence and proceeding forward to the carboxy terminus (i.e., left to right on each line).
[0036] As used herein, the phrase "corresponding to" or grammatical variations thereof, when used in the context of the numbering of a specific nucleotide or sequence of nucleotides or positions, refers to the numbering of a specified reference sequence when comparing the specific nucleotide or nucleotide sequence to a reference sequence. In other words, the number of residues (e.g., nucleotides or amino acids, etc.) of a specific polymer or the position of a residue (e.g., nucleotides or amino acids, etc.) is specified with respect to a reference sequence, not by the actual number of the residues in a specific nucleotide or nucleotide sequence. For example, a specific nucleotide sequence can be aligned to a reference sequence by introducing gaps to optimize the matching of residues between the two sequences. In these cases, although gaps exist, the numbering of residues in a specific nucleotide or nucleotide sequence is performed with respect to the reference sequence to which it is aligned. There are a variety of computer algorithms that can be used to perform sequence alignment to identify nucleotide or amino acid positions in one polymeric molecule that correspond to nucleotide or amino acid positions in another polymeric molecule. For example, sequence alignment can be performed using the NCBI BLAST algorithm (Altschul et al., Nucleic Acids Res., 1997, 25, 3389-3402) or the CLUSTALW software (Sievers and Higgins, Methods Mol. Biol., 2014, 1079, 105-116). However, sequences can also be aligned manually.
[0037] Any one or more of the variants described herein (i.e., any combination) can be used in any of the methods described herein to determine whether a subject has an increased or decreased risk of developing liver disease.A particular combination of variants can form a genetic burden or "mask" that is used for statistical analysis of a particular correlation between CIDEB and a higher or lower risk of developing liver disease or liver damage (e.g., as quantified by liver biomarkers or imaging-related variables).
[0038] In any of the embodiments described herein, the predicted loss-of-function polypeptide of CIDEB can be any CIDEB polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function, or a missense polypeptide.
[0039] In any of the embodiments described herein, the liver disease is any of fatty liver disease (e.g., alcoholic fatty liver disease (AFLD), nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH)), cirrhosis, liver fibrosis, increased liver enzymes (e.g., alanine transaminase (ALT) or aspartate transaminase (AST)), simple fatty liver, steatohepatitis, parenchymal liver disease, viral hepatitis, or hepatocellular carcinoma, or complications of such conditions (including, but not limited to, cardiac or metabolic disease associated with NASH or NAFLD, portal hypertension or thrombosis, esophageal or gastric varices or bleeding from such varices, and other liver disease-related co-morbidities). In some embodiments, the liver disease is fatty liver disease. In some embodiments, the liver disease is AFLD. In some embodiments, the liver disease is NAFLD. In some embodiments, the liver disease is NASH. In some embodiments, the liver disease is cirrhosis. In some embodiments, the liver disease is liver fibrosis. In some embodiments, the liver disease is increased liver enzymes. In some embodiments, the liver disease is increased ALT. In some embodiments, the liver disease is increased AST. In some embodiments, the liver disease is simple fatty liver. In some embodiments, the liver disease is steatohepatitis. In some embodiments, the liver disease is parenchymal liver disease. In some embodiments, the liver disease is viral hepatitis. In some embodiments, the liver disease is hepatocellular carcinoma. In some embodiments, the liver disease is liver damage quantified by liver biomarkers (e.g., liver transaminases), changes in liver biomarkers, or by liver imaging, or by liver histology.
[0040] Symptoms of liver disease include, but are not limited to, liver enlargement, fatigue, pain in the upper right abdomen, abdominal distension (ascites), enlargement of blood vessels just below the surface of the skin, chest enlargement in men, spleen enlargement, palmar erythema, yellowing of the skin and eyes (jaundice), itching, dark urine, light-colored stool, nausea or vomiting, loss of appetite, and tendency to bruise easily.Testing for liver disease can involve blood tests, liver imaging, and liver biopsy.If a subject has at least one known risk factor (e.g., genetic factor such as pathogenic mutation), the individual is at increased risk of liver disease, and individuals with this risk factor are ranked as those who are at a statistically significant higher risk of developing the disease than individuals without risk factors. Risk factors for liver disease are also well known and may include, for example, excessive alcohol consumption, obesity, high cholesterol, high levels of blood triglycerides, polycystic ovary syndrome, sleep apnea, type 2 diabetes, an underactive thyroid gland (hypothyroidism), an underactive pituitary gland (hypopituitarism), and metabolic syndrome (including elevated blood lipids).
[0041] The present disclosure provides a method of treating a subject having or at risk of developing liver disease, the method comprising administering a CIDEB inhibitor to the subject. The disclosure also provides methods of treating a subject having or at risk of developing liver disease, wherein the subject is heterozygous or homozygous for a nucleic acid molecule encoding PNPLA3 Ile148Met or Ile144Met, the method comprising administering i) a CIDEB inhibitor in an amount equal to or greater than a standard dosage; ii) a combination of a CIDEB inhibitor and a PNPLA3 inhibitor in an amount equal to or greater than a standard dosage; iii) a combination of a CIDEB inhibitor and an HSD17B13 inhibitor in an amount equal to or greater than a standard dosage; or iv) a combination of a CIDEB inhibitor, a PNPLA3 inhibitor, and an HSD17B13 inhibitor in an amount equal to or greater than a standard dosage.
[0042] The disclosure also provides a method of treating a subject having or at risk of developing liver disease, where if the subject is homozygous for a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide, the subject is administered i) a CIDEB inhibitor in an amount equal to or greater than the standard dosage; ii) a combination of a CIDEB inhibitor and a PNPLA3 inhibitor in an amount equal to or greater than the standard dosage; iii) a combination of a CIDEB inhibitor and an HSD17B13 inhibitor in an amount equal to or greater than the standard dosage; or iv) a CIDEB inhibitor, a PNPLA3 inhibitor, and an HSD17B13 inhibitor in an amount equal to or greater than the standard dosage. and a combination of a HSD17B13 inhibitor is administered; and if the subject is not homozygous for a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide (i.e., a carrier for loss-of-function HSD17B13), the subject is administered i) a CIDEB inhibitor in an amount less than the standard dosage; ii) a combination of a CIDEB inhibitor and a PNPLA3 inhibitor in an amount less than the standard dosage; iii) a combination of a CIDEB inhibitor and an HSD17B13 inhibitor in an amount less than the standard dosage; or iv) a combination of a CIDEB inhibitor, a PNPLA3 inhibitor, and an HSD17B13 inhibitor in an amount less than the standard dosage.
[0043] The disclosure also provides a method of treating a subject having or at risk of developing liver disease, wherein the subject is heterozygous or homozygous for a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, and is heterozygous or homozygous for a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide, the method comprising administering to the subject a combination of a CIDEB inhibitor, a PNPLA3 inhibitor, and / or an HSD17B13 inhibitor.
[0044] In these methods, the subject may have any one or more of the liver diseases disclosed herein. In some embodiments, the liver disease is fatty liver disease. In some embodiments, the liver disease is NAFLD or NASH. In some embodiments, the liver disease is NAFLD. In some embodiments, the liver disease is NASH. In some embodiments, the liver disease is cirrhosis. In some embodiments, the liver disease is fibrosis. In some embodiments, the liver disease is increased liver enzymes. In some embodiments, the liver enzyme is ALT. In some embodiments, the liver enzyme is AST.
[0045] The present disclosure also provides a method of treating a subject having or at risk of developing liver disease, the method comprising determining a non-alcoholic fatty liver disease (NAFLD) activity score (or NASH-CRN non-alcoholic fatty liver disease activity score or NAS (NASH-CRN non-alcoholic fatty liver disease activity score)), and if the NAFLD activity score exceeds a pre-defined score, administering to the subject a CIDEB inhibitor, a PNPLA3 inhibitor, or an HSD17B13 inhibitor, or any combination thereof, as described herein. The NAFLD activity score is defined by histological examination from a liver biopsy and is reported in accordance with the NASH Clinical Research The lesions are scored according to the Network system: steatosis grade 0 (<5% parenchymal involvement), steatosis grade 1 (5 to <34%), steatosis grade 2 (34 to <67%), and steatosis grade 3 (>67%); lobular inflammation grade 0 (no lesions), lobular inflammation grade 1 (mild, <2 lesions per 200X field), lobular inflammation grade 2 (moderate, 2 to 4 lesions per 200X field), lobular inflammation grade 3 (severe, >4 lesions per 200X field); expansion grade 0 (none), expansion grade fibrosis stage 0 (none), fibrosis stage 1 (perisinusoidal or periportal fibrosis), fibrosis stage 2 (perisinusoidal and periportal fibrosis), fibrosis stage 3 (bridging fibrosis), and fibrosis stage 4 (cirrhosis); fibrosis stage 5) a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) defined as the unweighted sum (hence a range of 0-8) of the scores for steatosis (0-3), lobular inflammation (0-3), and expansion (0-2). In some embodiments, the pre-defined NAFLD activity score is greater than 0. In some embodiments, the pre-defined NAFLD activity score is greater than 1. In some embodiments, the pre-defined NAFLD activity score is greater than 2. In some embodiments, the pre-defined NAFLD activity score is greater than 3. In some embodiments, the pre-defined NAFLD activity score is greater than 4. In some embodiments, the pre-defined NAFLD activity score is greater than 5.
[0046] In some embodiments, the CIDEB inhibitor comprises an inhibitory nucleic acid molecule. Examples of inhibitory nucleic acid molecules include, but are not limited to, antisense nucleic acid molecules, small interfering RNA (siRNA), and short hairpin RNA (shRNA). Such inhibitory nucleic acid molecules can be designed to target any region of CIDEB mRNA. In some embodiments, the antisense RNA, siRNA, or shRNA hybridizes to a sequence in a CIDEB genomic nucleic acid molecule or mRNA molecule and reduces the expression of CIDEB polypeptide in cells in a subject. In some embodiments, the CIDEB inhibitor comprises an antisense RNA that hybridizes to a CIDEB genomic nucleic acid molecule or mRNA molecule and reduces the expression of CIDEB polypeptide in cells in a subject. In some embodiments, the CIDEB inhibitor comprises an siRNA that hybridizes to a CIDEB genomic nucleic acid molecule or mRNA molecule and reduces the expression of CIDEB polypeptide in cells in a subject. In some embodiments, the CIDEB inhibitor comprises an shRNA that hybridizes to a CIDEB genomic nucleic acid molecule or mRNA molecule and reduces the expression of CIDEB polypeptide in cells in a subject.
[0047] The inhibitory nucleic acid molecules described herein can be targeted to various CIDEB transcripts. For example, the inhibitory nucleic acid molecules described herein can be targeted to the CIDEB transcripts in Table 1 (from chromosome 14; Ensembl gene ID=ENSG00000136305; hgnc symbol=CIDEB; from top to bottom=transcript A, transcript B, transcript C, transcript D, transcript E, and transcript F).
[0048] [Table 1]
[0049] Additional CIDEB transcripts include, but are not limited to, those with the following Ensembl gene IDs: ENST00000555471, ENST00000555817, ENST00000556756, ENST00000258807, ENST00000336557, and ENST00000554411.
[0050] In some embodiments, an antisense nucleic acid molecule targeted to transcript A comprises or consists of the nucleotides shown in Table 2.
[0051] [Table 2-1]
[0052] [Table 2-2]
[0053] [Table 2-3]
[0054] [Table 2-4]
[0055] [Table 2-5]
[0056] [Table 2-6]
[0057] [Table 2-7]
[0058] [Table 2-8]
[0059] [Table 2-9]
[0060] [Table 2-10]
[0061] [Table 2-11]
[0062] [Table 2-12]
[0063] [Table 2-13]
[0064] In some embodiments, an antisense nucleic acid molecule targeted to transcript B comprises or consists of the nucleotides set forth in Table 3.
[0065] [Table 3-1]
[0066] [Table 3-2]
[0067] [Table 3-3]
[0068] [Table 3-4]
[0069] [Table 3-5]
[0070] [Table 3-6]
[0071] [Table 3-7]
[0072] [Table 3-8]
[0073] [Table 3-9]
[0074] [Table 3-10]
[0075] [Table 3-11]
[0076] [Table 3-12]
[0077] In some embodiments, an antisense nucleic acid molecule targeted to transcript C comprises or consists of the nucleotides set forth in Table 4.
[0078] [Table 4-1]
[0079] [Table 4-2]
[0080] [Table 4-3]
[0081] [Table 4-4]
[0082] [Table 4-5]
[0083] [Table 4-6]
[0084] [Table 4-7]
[0085] In some embodiments, an antisense nucleic acid molecule targeted to transcript D comprises or consists of the nucleotides set forth in Table 5.
[0086] [Table 5-1]
[0087] [Table 5-2]
[0088] In some embodiments, an antisense nucleic acid molecule targeted to transcript E comprises or consists of the nucleotides set forth in Table 6.
[0089] [Table 6-1]
[0090] [Table 6-2]
[0091] In some embodiments, an antisense nucleic acid molecule targeted to transcript F comprises or consists of the nucleotides set forth in Table 7.
[0092] [Table 7-1]
[0093] [Table 7-2]
[0094] [Table 7-3]
[0095] In some embodiments, the siRNA targeted to transcript A comprises or consists of the nucleotide sequence shown in Table 8 (sense and antisense strands).
[0096] [Table 8-1]
[0097] [Table 8-2]
[0098] [Table 8-3]
[0099]
Table 8-4
[0100]
Table 8-5
[0101]
Table 8-6
[0102]
Table 8-7
[0103]
Table 8-8
[0104]
Table 8-9
[0105]
Table 8-10
[0106]
Table 8-11
[0107]
Table 8-12
[0108]
Table 8-13
[0109]
Table 8-14
[0110]
Table 8-15
[0111]
Table 8-16
[0112]
Table 8-17
[0113]
Table 8-18
[0114]
Table 8-19
[0115]
Table 8-20
[0116]
Table 8-21
[0117]
Table 8-22
[0118]
Table 8-23
[0119]
Table 8-24
[0120] [Table 8-25]
[0121] [Table 8-26]
[0122] [Table 8-27]
[0123] In some embodiments, the siRNA targeted to transcript B comprises or consists of the nucleotide sequence shown in Table 9 (sense and antisense strands).
[0124] [Table 9-1]
[0125] [Table 9-2]
[0126] [Table 9-3]
[0127] [Table 9-4]
[0128] [Table 9-5]
[0129] [Table 9-6]
[0130]
Table 9-7
[0131]
Table 9-8
[0132]
Table 9-9
[0133]
Table 9-10
[0134]
Table 9-11
[0135]
Table 9-12
[0136]
Table 9-13
[0137]
Table 9-14
[0138]
Table 9-15
[0139]
Table 9-16
[0140]
Table 9-17
[0141]
Table 9-18
[0142]
Table 9-19
[0143]
Table 9-20
[0144]
Table 9-21
[0145]
Table 9-22
[0146]
Table 9-23
[0147]
Table 9-24
[0148]
Table 9-25
[0149]
Table 9-26
[0150] [Table 9-27]
[0151] In some embodiments, the siRNA targeted to transcript C comprises or consists of the nucleotide sequence shown in Table 10 (sense and antisense strands).
[0152] [Table 10-1]
[0153] [Table 10-2]
[0154] [Table 10-3]
[0155] [Table 10-4]
[0156] [Table 10-5]
[0157] [Table 10-6]
[0158] [Table 10-7]
[0159] [Table 10-8]
[0160] [Table 10-9]
[0161] [Table 10-10]
[0162] [Table 10-11]
[0163] [Table 10-12]
[0164] [Table 10-13]
[0165] [Table 10-14]
[0166] [Table 10-15]
[0167] In some embodiments, the siRNA targeted to transcript D comprises or consists of the nucleotide sequence shown in Table 11 (sense and antisense strands).
[0168] [Table 11-1]
[0169] [Table 11-2]
[0170] [Table 11-3]
[0171] [Table 11-4]
[0172] In some embodiments, the siRNA targeted to transcript E comprises or consists of the nucleotide sequence shown in Table 12 (sense and antisense strands).
[0173] [Table 12-1]
[0174] [Table 12-2]
[0175] In some embodiments, the siRNA targeted to transcript F comprises or consists of the nucleotide sequence (sense and antisense strands) shown in Table 13.
[0176] [Table 13-1]
[0177] [Table 13-2]
[0178] [Table 13-3]
[0179] [Table 13-4]
[0180] [Table 13-5]
[0181] In some embodiments, the PNPLA3 inhibitor comprises an inhibitory nucleic acid molecule. Examples of inhibitory nucleic acid molecules include, but are not limited to, antisense nucleic acid molecules, siRNAs, and shRNAs. Such inhibitory nucleic acid molecules can be designed to target any region of PNPLA3 mRNA. In some embodiments, the antisense RNA, siRNA, or shRNA hybridizes to a sequence in a PNPLA3 genomic nucleic acid molecule or mRNA molecule, and reduces the expression of PNPLA3 polypeptide in cells in a subject. In some embodiments, the PNPLA3 inhibitor comprises an antisense RNA that hybridizes to a PNPLA3 genomic nucleic acid molecule or mRNA molecule, and reduces the expression of PNPLA3 polypeptide in cells in a subject. In some embodiments, the PNPLA3 inhibitor comprises an siRNA that hybridizes to a PNPLA3 genomic nucleic acid molecule or mRNA molecule, and reduces the expression of PNPLA3 polypeptide in cells in a subject. In some embodiments, the PNPLA3 inhibitor comprises an shRNA that hybridizes to a PNPLA3 genomic nucleic acid molecule or mRNA molecule, and reduces the expression of PNPLA3 polypeptide in cells in a subject.
[0182] The inhibitory nucleic acid molecules described herein can be targeted to various PNPLA3 transcripts.For example, the inhibitory nucleic acid molecules described herein can be targeted to PNPLA3 transcripts (derived from chromosome 22; Ensembl gene ID=ENSG00000100344.11; hgnc symbol=PNPLA3).
[0183] In some embodiments, the HSD17B13 inhibitor comprises an inhibitory nucleic acid molecule. Examples of inhibitory nucleic acid molecules include, but are not limited to, antisense nucleic acid molecules, siRNAs, and shRNAs. Such inhibitory nucleic acid molecules can be designed to target any region of HSD17B13 mRNA. In some embodiments, the antisense RNA, siRNA, or shRNA hybridizes to a sequence in a HSD17B13 genomic nucleic acid molecule or mRNA molecule, and reduces the expression of HSD17B13 polypeptide in cells in a subject. In some embodiments, the HSD17B13 inhibitor comprises an antisense RNA that hybridizes to a HSD17B13 genomic nucleic acid molecule or mRNA molecule, and reduces the expression of HSD17B13 polypeptide in cells in a subject. In some embodiments, the HSD17B13 inhibitor comprises an siRNA that hybridizes to a HSD17B13 genomic nucleic acid molecule or mRNA molecule, and reduces the expression of HSD17B13 polypeptide in cells in a subject. In some embodiments, the HSD17B13 inhibitor comprises an shRNA that hybridizes to an HSD17B13 genomic nucleic acid molecule or mRNA molecule and reduces expression of an HSD17B13 polypeptide in cells in a subject.
[0184] The inhibitory nucleic acid molecules described herein can be targeted to various HSD17B13 transcripts.For example, the inhibitory nucleic acid molecules described herein can be targeted to HSD17B13 transcripts (derived from chromosome 4; Ensembl gene ID=ENSG00000170509.8; hgnc symbol=HSD17B13).
[0185] The inhibitory nucleic acid molecules disclosed herein may comprise RNA, DNA, or both RNA and DNA. The inhibitory nucleic acid molecules may also be linked or fused to a heterologous nucleic acid sequence (such as in a vector) or a heterologous label. For example, the inhibitory nucleic acid molecules disclosed herein may be in a vector that contains the inhibitory nucleic acid molecule and a heterologous nucleic acid sequence, or as an exogenous donor sequence that contains the inhibitory nucleic acid molecule and a heterologous nucleic acid sequence. The inhibitory nucleic acid molecules may also be linked or fused to a heterologous label. The label may be directly detectable (such as a fluorophore) or indirectly detectable (such as a hapten, enzyme, or fluorophore quencher). Such labels may be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Such labels include, for example, radioisotope labels, dyes, dyes, chromogens, spin labels, and fluorescent labels. The label may also be, for example, a chemiluminescent substance; a metal-containing substance; or an enzyme (where enzyme-dependent secondary signal generation occurs). The term "label" may also refer to a "tag" or hapten that can selectively bind to the conjugated molecule such that the conjugated molecule is subsequently added with a substrate and used to generate a detectable signal. For example, biotin can be used as a tag to bind to the tag with an avidin or streptavidin conjugate of horseradish peroxidase (HRP), and a colorimetric substrate (such as tetramethylbenzidine (TMB)) or a fluorogenic substrate can be used to detect the presence of HRP. Exemplary labels that can be used as tags to facilitate purification include, but are not limited to, myc, HA, FLAG or 3xFLAG, 6xHis (SEQ ID NO: 10045) or polyhistidine, glutathione-S-transferase (GST), maltose binding protein, epitope tags, or the Fc portion of an immunoglobulin. Numerous labels include, for example, particles, fluorophores, haptens, enzymes, and their colorimetric, fluorogenic, and chemiluminescent substrates, as well as other labels.
[0186] The inhibitory nucleic acid molecules disclosed herein may include, for example, nucleotides, or non-natural or modified nucleotides, such as nucleotide analogs or nucleotide substitutes. Such nucleotides include nucleotides that contain modified bases, sugars, or phosphate groups, or nucleotides that incorporate non-natural moieties into their structure. Examples of non-natural nucleotides include, but are not limited to, dideoxynucleotides, biotinylated nucleotides, aminated nucleotides, deaminated nucleotides, alkylated nucleotides, benzylated nucleotides, and fluorophore-labeled nucleotides.
[0187] The inhibitory nucleic acid molecules disclosed herein may also include one or more nucleotide analogs or substitutions. A nucleotide analog is a nucleotide that contains a modification to either the base, sugar, or phosphate moiety. Modifications to the base moiety include, but are not limited to, natural and synthetic modifications of A, C, G, and T / U, and different purine or pyrimidine bases, such as pseudouridine, uracil-5-yl, hypoxanthin-9-yl (I), and 2-aminoadenin-9-yl. Modified bases include 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine, and 2-thiocytosine, 5-halouracil and 5-halocytosine, 5-propynyluracil and 5-propynylcytosine, 6-azouracil, 6-azocytosine, and 6-azothymine, These include, but are not limited to, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted adenines and guanines, 5-halo (such as 5-bromo), 5-trifluoromethyl, and other 5-substituted uracils and cytosines, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.
[0188] Nucleotide analogs can also include modifications to the sugar moiety, including, but not limited to, natural and synthetic modifications of ribose and deoxyribose. Sugar modifications include the following modifications at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl-O-alkyl, where alkyl, alkenyl, and alkynyl are substituted or unsubstituted C 1-10 Alkyl or C 2-10 Alkenyl, and C 2-10Exemplary 2' sugar modifications include, but are not limited to, -O[(CH2) n O] m CH3, -O(CH2) n OCH3, -O(CH2) n NH2, -O(CH2) n CH3, -O(CH2) n -ONH2 and -O(CH2) n ON [(CH2) n Other modifications at the 2' position include, but are not limited to, C 1-10 These include, but are not limited to, alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, RNA cleaving groups, reporter groups, intercalators, groups for improving the pharmacokinetic properties of oligonucleotides, or groups for improving the pharmacodynamic properties of oligonucleotides, and other substituents with similar properties. Similar modifications can also be made at other positions on the sugar, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides, and the 5' position of the 5' terminal nucleotide. Modified sugars can also include those containing modifications at the bridging ring oxygen (such as CH2 and S). Nucleotide sugar analogs can also have sugar mimetics (such as cyclobutyl moieties) in place of the pentofuranosyl sugar.
[0189] Nucleotide analogs can also be modified at the phosphate moiety. Modified phosphate moieties include, but are not limited to, those in which the linkage between two nucleotides can be modified to contain phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl phosphotriesters, methyl phosphonates and other alkyl phosphonates (including 3'-alkylene phosphonates and chiral phosphonates), phosphinates, phosphoramidates (including 3'-amino phosphoramidates and aminoalkyl phosphoramidates), thionophosphoramidates, thionoalkyl phosphonates, thionoalkyl phosphotriesters, and boranophosphates. These phosphate linkages or modified phosphate linkages between two nucleotides can be via 3'-5' linkages or 2'-5' linkages, and the linkages can contain reverse polarity (such as 3'-5' to 5'-3' or 2'-5' to 5'-2'). Various salts, mixed salts, and free acid forms are also included. Nucleotide alternatives also include peptide nucleic acids (PNAs).
[0190] In some embodiments, the antisense nucleic acid molecule is a gapmer in which the first 1-7 nucleotides at the 5' and 3' ends, respectively, have a 2'-methoxyethyl (2'-MOE) modification. In some embodiments, the first 5 nucleotides at the 5' and 3' ends, respectively, have a 2'-MOE modification. In some embodiments, the first 1-7 nucleotides at the 5' and 3' ends are RNA nucleotides. In some embodiments, the first 5 nucleotides at the 5' and 3' ends are RNA nucleotides. In some embodiments, each of the internucleotide backbone linkages is a phosphorothioate linkage.
[0191] In some embodiments, the siRNA molecule has terminal modification.In some embodiments, the 5'-end of the antisense strand is phosphorylated.In some embodiments, a 5'-phosphate analog that cannot be hydrolyzed, such as 5'-(E)-vinyl-phosphonate, is used.
[0192] In some embodiments, the siRNA molecule has a backbone modification. In some embodiments, modified phosphodiester groups linking consecutive ribose nucleosides have been shown to improve the stability and in vivo bioavailability of siRNA. The non-ester group (-OH, =O) of the phosphodiester bond can be replaced with sulfur, boron, or acetate to provide phosphorothioate, boranophosphate, and phosphonoacetate linkages. Replacing the phosphodiester group with a phosphotriester can also facilitate cellular uptake of siRNA and retention on serum components by eliminating their negative charge. In some embodiments, the siRNA molecule has a sugar modification. In some embodiments, the sugar is deprotonated (a reaction catalyzed by exonucleases and endonucleases), in which case the 2'-hydroxyl can act as a nucleophile and attack the adjacent phosphorus in the phosphodiester bond. Such alternatives include 2'-O-methyl, 2'-O-methoxyethyl, and 2'-fluoro modifications.
[0193] In some embodiments, the siRNA molecule has base modifications, in some embodiments, the bases can be replaced with modified bases, such as pseudouridine, 5'-methylcytidine, N6-methyladenosine, inosine, and N7-methylguanosine.
[0194] In some embodiments, siRNA molecule is conjugated to lipid.Lipid can be conjugated to 5' or 3' end of siRNA to improve their in vivo bioavailability by enabling them to associate with serum lipoprotein.Representative lipid includes, but is not limited to, cholesterol and vitamin E, and fatty acid such as palmitate and tocopherol.
[0195] In some embodiments, an exemplary siRNA has the following formula: Sense: mN*mN* / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / *mN* / 32FN / Antisense: / 52FN / * / i2FN / *mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN*N*N where "N" is a base; "2F" is a 2'-F modification; "m" is a 2'-O-methyl modification; "I" is an internal base; and "*" is a phosphorothioate backbone linkage. has.
[0196] The present disclosure also provides a vector comprising any one or more of the inhibitory nucleic acid molecules disclosed herein. In some embodiments, the vector comprises any one or more of the inhibitory nucleic acid molecules disclosed herein and a heterologous nucleic acid. The vector can be a viral vector or a non-viral vector capable of transporting a nucleic acid molecule. In some embodiments, the vector is a plasmid or a cosmid (such as a circular double-stranded DNA into which additional DNA segments can be ligated). In some embodiments, the vector is a viral vector into which additional DNA segments can be ligated into the viral genome. Expression vectors include, but are not limited to, plasmids, cosmids, retroviruses, adenoviruses, adeno-associated viruses (AAV), plant viruses (such as cauliflower mosaic virus and tobacco mosaic virus), yeast artificial chromosomes (YACs), Epstein-Barr (EBV) derived episomes, and other expression vectors known in the art.
[0197] The present disclosure also provides a composition comprising any one or more of the inhibitory nucleic acid molecules disclosed herein. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition comprises a carrier and / or excipient. Examples of carriers include, but are not limited to, poly(lactic acid) (PLA) microspheres, poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres, liposomes, micelles, reverse micelles, lipid cochleates, and lipid microtubules. Carriers may include buffered salt solutions, PBS, HBSS, and the like.
[0198] In some embodiments, the CIDEB inhibitor comprises a nuclease agent that induces one or more nicks or double-strand breaks in the recognition sequence(s), or a DNA binding protein that binds to the recognition sequence in the CIDEB genomic nucleic acid molecule. The recognition sequence can be located in the coding region of the CIDEB gene, or in the control region that affects the expression of the gene. The recognition sequence of the DNA binding protein or nuclease agent can be located in an intron, exon, promoter, enhancer, regulatory region, or any non-protein coding region. The recognition sequence can include or be close to the start codon of the CIDEB gene. For example, the recognition sequence can be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon.
[0199] In some embodiments, the PNPLA3 inhibitor comprises a nuclease agent that induces one or more nicks or double-strand breaks in the recognition sequence(s), or a DNA binding protein that binds to the recognition sequence in the PNPLA3 genomic nucleic acid molecule. The recognition sequence can be located in the coding region of the PNPLA3 gene, or in the control region that affects the expression of the gene. The recognition sequence of the DNA binding protein or nuclease agent can be located in an intron, exon, promoter, enhancer, regulatory region, or any non-protein coding region. The recognition sequence can include or be close to the start codon of the PNPLA3 gene. For example, the recognition sequence can be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon.
[0200] In some embodiments, the HSD17B13 inhibitor comprises a nuclease agent that induces one or more nicks or double-strand breaks in the recognition sequence(s), or a DNA binding protein that binds to the recognition sequence in the HSD17B13 genomic nucleic acid molecule. The recognition sequence can be located in the coding region of the HSD17B13 gene, or in the control region that affects the expression of the gene. The recognition sequence of the DNA binding protein or nuclease agent can be located in an intron, exon, promoter, enhancer, regulatory region, or any non-protein coding region. The recognition sequence can include or be close to the start codon of the HSD17B13 gene. For example, the recognition sequence can be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon.
[0201] As another example, two or more nuclease agents can be used, each targeting a nuclease recognition sequence that includes or is adjacent to the start codon. As another example, two nuclease agents can be used, one targeting a nuclease recognition sequence that includes or is adjacent to the start codon, and one targeting a nuclease recognition sequence that includes or is adjacent to the stop codon, and cleavage by the nuclease agent can result in the deletion of the coding region between the two nuclease recognition sequences. Any nuclease agent that induces a nick or double-strand break in the desired recognition sequence can be used in the methods and compositions disclosed herein. Any DNA binding protein that binds to the desired recognition sequence can be used in the methods and compositions disclosed herein.
[0202] Suitable nuclease agents and DNA binding proteins for use herein include, but are not limited to, zinc finger proteins or zinc finger nucleases (ZFN) pairs, transcription activator-like effector (TALE) proteins or transcription activator-like effector nucleases (TALEN), or clustered regularly interspersed short palindromic repeats (CRISPR) / CRISPR-associated (Cas) systems. The length of the recognition sequence can vary, including, for example, recognition sequences that are about 30-36 bp for zinc finger proteins or ZFN pairs, about 15-18 bp for each ZFN, about 36 bp for TALE proteins or TALEN, and about 20 bp for CRISPR / Cas guide RNA.
[0203] In some embodiments, the CRISPR / Cas system can be used to modify a CIDEB genomic nucleic acid molecule, a PNPLA3 genomic nucleic acid molecule, or a HSD17B13 genomic nucleic acid molecule in a cell. The methods and compositions disclosed herein can use the CRISPR-Cas system by utilizing a CRISPR complex (including a guide RNA (gRNA) complexed with a Cas protein) for site-directed cleavage of a CIDEB nucleic acid molecule, a PNPLA3 nucleic acid molecule, or a HSD17B13 nucleic acid molecule.
[0204] Cas proteins generally contain at least one RNA recognition or binding domain that can interact with gRNA. Cas proteins may also contain nuclease domains (such as DNase or RNase domains), DNA binding domains, helicase domains, protein-protein interaction domains, dimerization domains, and other domains. Suitable Cas proteins include, for example, wild-type Cas9 proteins and wild-type Cpf1 proteins (such as FnCpf1). Cas proteins may have full cleavage activity to generate double-stranded breaks in CIDEB genomic nucleic acid molecules, PNPLA3 genomic nucleic acid molecules, or HSD17B13 genomic nucleic acid molecules, or may be nickases that generate single-stranded breaks in CIDEB genomic nucleic acid molecules, PNPLA3 genomic nucleic acid molecules, or HSD17B13 genomic nucleic acid molecules. Additional examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12), Cas10, Cas10d, Cas12a, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (CasA), Cse2 (CasB), and Cse3 (CasE). , Cse4 (CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966, as well as homologs or modified versions thereof. In some embodiments, a Cas system, such as Cas12a, may have multiple gRNAs encoded by a single crRNA. Cas proteins may also be operably linked to heterologous polypeptides as fusion proteins. For example, the Cas protein can be fused to a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. The Cas protein can be provided in any form.For example, the Cas protein may be provided in the form of a protein, such as a Cas protein complexed with a gRNA. Alternatively, the Cas protein may be provided in the form of a nucleic acid molecule, such as RNA or DNA, that encodes the Cas protein.
[0205] In some embodiments, targeted genetic modifications of the CIDEB genomic nucleic acid molecule can be generated by contacting a cell with a Cas protein and one or more gRNAs that hybridize to one or more gRNA recognition sequences within a target genomic locus in the CIDEB genomic nucleic acid molecule. For example, the gRNA recognition sequence can be located within the region of SEQ ID NO:1. For example, gRNA recognition sequences are located at positions: 14:24305635, 14:24305641, 14:24305650, 14:24305657, 14:24305662, 14:24305667, 14:24305671, 14:24305701, 14:24305709, 14:24305718, 14:24305721, 14:24305728, 14:24305743, 14:24305948, 14:24305966, 14:24305974 ,14:24305980,14:24305988,14:24306014,14:24306034,14:24306041,14:24306044,14:24306047,14:24306051,14:24306064,14:24306074,14:24306077,14:24306082,14:24306083,14:24306095,14:24306122,14:24306134,14:24306373,14: 24306379, 14:24306382, 14:24306383, 14:24306426, 14:24306437, 14:24306439, 14:24306442, 14:24306444, 14:24306457, 14:24306463, 14:24306469, 14:24306480, 14:24306486, 14:24306504, 14:24306519, 14:24307382, 14:24307405, 14:2430 7417, 14:24307421, 14:24307441, 14:24307444, 14:24307444, 14:24307450, 14:24307461, 14:24307469, 14:24307474, 14:24307475, 14:24307833, 14:24307851, 14:24306426, 14:24307849, 14:24307448, 14:24305671, 14:24305663, 14:24305686,14:24307829、14:24307818、14:24307856、14:24306423、14:24306061、14:24307390、14:24306382、14:24306373、14:24305733、14:24307858、14:24306387、14:24305637、14:24306062、14:24307853、14:24307450、14:24306052、14:24305673、14:24306043、14:24307834、14:24306417、14:24307451、14:24307436、14:24305953、14:24306489、14:24307441、14:24306375、14:24305657、14:24306427、14:24306524、14:24307516、14:24307840、14:24307501、14:24305968、14:24305986、14:24307441、14:24307459、14:24306017、14:24307424、14:24306072、14:24307423、14:24307450、14:24306420、14:24307454、14:24305653、14:24307442、14:24306002、14:24306076、14:24305664、14:24305961、14:24305706、14:24305946、14:24306455、14:24307468、14:24307825、14:24306110、14:24305710、14:24307483、14:24306459、14:24305754、14:24305650、14:24305691、14:24306508、14:24306039、14:24306139、14:24306391、14:24306373、14:24307498、14:24307415、14:24306138、14:24307453、14:24305692、14:24305683、14:24307484、14:24307385、14:24306519、14:24307839、14:24305965、14:24305988、14:24306087、14:24307439、14:24307477、14:24306436、14:24306507、14:24307397, 14:24307495, 14:24306034, 14:24306013, 14:24307381, 14:24306383, 14:24305638, 14:24307420, 14:24306020, 14:24306470, 14:24307435, 14:24306469, 14:24306451, 14:24306403, 14:24307515, 14:24307489, 14:24307414, 14:24306483, 14:24305755, 14:24305766, 14:24306064, 14:24307516, 14:24305766, 14:24306489, 14:24306097, 14:24305763, 14:24307447, 14:24307402, 14:24305972, 14:24306423, 14:24305974, 14:24307411, 14:24306121, 14:24307516, 14:24306424, 14:24306039, 14:24307853, 14:24306388, 14:24305990, 14:24307822, 1 4:24305640, 14:24307418, 14:24305758, 14:24306131, 14:24305953, 14:24305730, 14:24306418, 14:24306059, 14:24307842, 14:24307837, 14:24306095, 14:24306109, 14:24307822, 14:24306077, 14:24307824, 14:24306080, 14:24305649, 14:24306433, 14:24306420, 14:24305658, 14 14:24306472, 14:24307412, 14:24306062, 14:24306044, 14:24306047, 14:24306126, 14:24306449, 14:24307391, or 14:24307857 (according to the GRCh38 / hg38 human genome assembly coordinates).The gRNA recognition sequence may include or be adjacent to the start codon of the CIDEB genomic nucleic acid molecule or the stop codon of the CIDEB genomic nucleic acid molecule. For example, the gRNA recognition sequence may be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon or the stop codon.
[0206] The gRNA recognition sequence in the target genomic locus in the CIDEB genomic nucleic acid molecule can be located near a protospacer adjacent motif (PAM) sequence, which is a 2-6 base pair DNA sequence that immediately follows the DNA sequence targeted by the Cas9 nuclease. A canonical PAM is the sequence 5'-NGG-3', where "N" is any nucleobase and is followed by two guanine ("G") nucleobases. The gRNA can transport Cas9 to any location in the genome for gene editing, but editing cannot occur at any site other than the site where Cas9 recognizes the PAM. In addition, 5'-NGA-3' can be a highly efficient non-canonical PAM for human cells. In general, the PAM is about 2-6 nucleotides downstream of the DNA sequence targeted by the gRNA. The PAM can be adjacent to the gRNA recognition sequence. In some embodiments, the gRNA recognition sequence can be adjacent to the PAM on the 3' end. In some embodiments, the gRNA recognition sequence may be flanked by a PAM on the 5' end. For example, the cleavage site of the Cas protein may be about 1 to about 10, about 2 to about 5, or 3 base pairs upstream or downstream of the PAM sequence. In some embodiments (such as when Cas9 from S. pyogenes or a closely related Cas9 is used), the PAM sequence of the non-complementary strand may be 5'-NGG-3', where N is any DNA nucleotide, immediately 3' to the gRNA recognition sequence of the non-complementary strand of the target DNA. Thus, the PAM sequence of the complementary strand will be 5'-CCN-3', where N is any DNA nucleotide, immediately 5' to the gRNA recognition sequence of the non-complementary strand of the target DNA.
[0207] A gRNA is an RNA molecule that binds to a Cas protein and targets the Cas protein to a specific location within a CIDEB genomic nucleic acid molecule. Exemplary gRNAs are gRNAs that are effective to direct a Cas enzyme to bind to or cleave a CIDEB genomic nucleic acid molecule, and the gRNAs are located at the following locations: 14:24305635, 14:24305641, 14:24305650, 14:24305657, 14:24305662, 14:24305667, 14:24305671, 14:24305701, 14:24305709, 14:24305718, 14:24305721, 14:24305728, 14:24305743, 14:24305751, 14:24305761, 14:24305772, 14:24305781, 14:24305792, 14:24305716, 14:24305718, 14:24305721, 14:24305728, 14:24305743, 14:24305751, 14:24305761, 14:24305772, 14:24305773, 14:24305774, 14:24305775, 14:24305776, 14:24305777, 14:24305777, 14:2430577 305948, 14:24305966, 14:24305974, 14:24305980, 14:24305988, 14:24306014, 14:24306034, 14:24306041, 14:24306044, 14:24306047, 14:24306051, 14:24306064, 14:24306074, 14:24306077, 14:24306082, 14:24306083, 14:24306095, 14:24306122, 14:24306134, 14:24306373 ,14:24306379,14:24306382,14:24306383,14:24306426,14:24306437,14:24306439,14:24306442,14:24306444,14:24306457,14:24306463,14:24306469,14:24306480,14:24306486,14:24306504,14:24306519,14:24307382,14:24307405,14:24307417,14:24307421,14:24 307441, 14:24307444, 14:24307444, 14:24307450, 14:24307461, 14:24307469, 14:24307474, 14:24307475, 14:24307833, 14:24307851, 14:24306426, 14:24307849, 14:24307448, 14:24305663, 14:24305686, 14:24307829, 14:24307818, 14:24307856, 14:24306423, 14:24306061,14:24307390、14:24306382、14:24306373、14:24305733、14:24307858、14:24306387、14:24305637、14:24306062、14:24307853、14:24307450、14:24306052、14:24305673、14:24306043、14:24307834、14:24306417、14:24307451、14:24307436、14:24305953、14:24306489、14:24307441、14:24306375、14:24305657、14:24306427、14:24306524、14:24307516、14:24307840、14:24307501、14:24305968、14:24305986、14:24307441、14:24307459、14:24306017、14:24307424、14:24306072、14:24307423、14:24307450、14:24306420、14:24307454、14:24305653、14:24307442、14:24306002、14:24306076、14:24305664、14:24305961、14:24305706、14:24305946、14:24306455、14:24307468、14:24307825、14:24306110、14:24305710、14:24307483、14:24306459、14:24305754、14:24305650、14:24305691、14:24306508、14:24306039、14:24306139、14:24306391、14:24306373、14:24307498、14:24307415、14:24306138、14:24307453、14:24305692、14:24305683、14:24307484、14:24307385、14:24306519、14:24307839、14:24305965、14:24305988、14:24306087、14:24307439、14:24307477、14:24306436、14:24306507、14:24307397、14:24307495、14:24306034、14:24306013、14:24307381、14:24306383, 14:24305638, 14:24307420, 14:24306020, 14:24306470, 14:24307435, 14:24306469, 14:24306451, 14:24306403, 14:24307515, 14:24307489, 14:24307414, 14:24306483, 14:24305755, 14:24305766, 14:24306064, 14:24307516, 14:24305766, 14:24306489, 14:24306097, 14:24305763, 14:24307447, 14:24307402, 14:24305972, 14:24306423, 14:24305974, 14:24307411, 14:24306121, 14:24307516, 14:24306424, 14:24306039, 14:24307853, 14:24306388, 14:24305990, 14:24307822, 14:24305640, 1 4:24307418, 14:24305758, 14:24306131, 14:24305953, 14:24305730, 14:24306418, 14:24306059, 14:24307842, 14:24307837, 14:24306095, 14:24306109, 14:24307822, 14:24306077, 14:24307824, 14:24306080, 14:24305649, 14:24306433, 14:24306420, 1 comprising a DNA targeting segment that hybridizes to a gRNA recognition sequence within a CIDEB genomic nucleic acid molecule that includes or is adjacent to a position corresponding to 4:24305658, 14:24306472, 14:24307412, 14:24306062, 14:24306044, 14:24306047, 14:24306126, 14:24306449, 14:24307391, or 14:24307857 (according to the GRCh38 / hg38 human genome assembly coordinates). For example, gRNA can be used to identify the following: 14:24305635, 14:24305641, 14:24305650, 14:24305657, 14:24305662, 14:24305667, 14:24305671, 14:24305701, 14:24305709, 14:24305718,14:24305721、14:24305728、14:24305743、14:24305948、14:24305966、14:24305974、14:24305980、14:24305988、14:24306014、14:24306034、14:24306041、14:24306044、14:24306047、14:24306051、14:24306064、14:24306074、14:24306077、14:24306082、14:24306083、14:24306095、14:24306122、14:24306134、14:24306373、14:24306379、14:24306382、14:24306383、14:24306426、14:24306437、14:24306439、14:24306442、14:24306444、14:24306457、14:24306463、14:24306469、14:24306480、14:24306486、14:24306504、14:24306519、14:24307382、14:24307405、14:24307417、14:24307421、14:24307441、14:24307444、14:24307444、14:24307450、14:24307461、14:24307469、14:24307474、14:24307475、14:24307833、14:24307851、14:24306426、14:24307849、14:24307448、14:24305663、14:24305686、14:24307829、14:24307818、14:24307856、14:24306423、14:24306061、14:24307390、14:24306382、14:24306373、14:24305733、14:24307858、14:24306387、14:24305637、14:24306062、14:24307853、14:24307450、14:24306052、14:24305673、14:24306043、14:24307834、14:24306417、14:24307451、14:24307436、14:24305953、14:24306489、14:24307441、14:24306375、14:24305657、14:24306427、14:24306524、14:24307516、14:24307840、14:24307501、14:24305968、14:24305986、14:24307441、14:24307459、14:24306017、14:24307424、14:24306072、14:24307423、14:24307450、14:24306420、14:24307454、14:24305653、14:24307442、14:24306002、14:24306076、14:24305664、14:24305961、14:24305706、14:24305946、14:24306455、14:24307468、14:24307825、14:24306110、14:24305710、14:24307483、14:24306459、14:24305754、14:24305650、14:24305691、14:24306508、14:24306039、14:24306139、14:24306391、14:24306373、14:24307498、14:24307415、14:24306138、14:24307453、14:24305692、14:24305683、14:24307484、14:24307385、14:24306519、14:24307839、14:24305965、14:24305988、14:24306087、14:24307439、14:24307477、14:24306436、14:24306507、14:24307397、14:24307495、14:24306034、14:24306013、14:24307381、14:24306383、14:24305638、14:24307420、14:24306020、14:24306470、14:24307435、14:24306469、14:24306451、14:24306403、14:24307515、14:24307489、14:24307414、14:24306483、14:24305755、14:24305766、14:24306064、14:24307516、14:24305766、14:24306489、14:24306097、14:24305763、14:24307447、14:24307402、14:24305972、14:24306423、14:24305974、14:24307411、14:24306121、14:24307516、14:24306424、14:24306039、14:24307853、14、 :24306388, 14:24305990, 14:24307822, 14:24305640, 14:24307418, 14:24305758, 14:24306131, 14:24305953, 14:24305730, 14:24306418, 14:24306059, 14: 24307842, 14:24307837, 14:24306095, 14:24306109, 14:24307822, 14:24306077, 14:24307824, 14:24306080, 14:24305649, 14:24306433, 14:24306420, 14:2 In some embodiments, the gRNA recognition sequence may be selected to hybridize to a gRNA recognition sequence located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from a position corresponding to 4305658, 14:24306472, 14:24307412, 14:24306062, 14:24306044, 14:24306047, 14:24306126, 14:24306449, 14:24307391, or 14:24307857 (according to the GRCh38 / hg38 human genome assembly coordinates). Other exemplary gRNA comprises a DNA targeting segment that hybridizes to the gRNA recognition sequence present in the CIDEB genomic nucleic acid molecule that includes or is adjacent to the start codon or stop codon.For example, gRNA can be selected so that it hybridizes to the gRNA recognition sequence that is located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon, or about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the stop codon. A suitable gRNA may comprise from about 17 to about 25 nucleotides, from about 17 to about 23 nucleotides, from about 18 to about 22 nucleotides, or from about 19 to about 21 nucleotides. In some embodiments, the gRNA may comprise 20 nucleotides.
[0208] Examples of suitable gRNA recognition sequences located within the human CIDEB reference gene are shown in Table 14 as SEQ ID NOs: 25-37.
[0209] [Table 14]
[0210] The Cas protein and gRNA form a complex, and the Cas protein cleaves the target CIDEB genome nucleic acid molecule. The Cas protein can cleave the nucleic acid molecule at a site within or outside the nucleic acid sequence present in the target CIDEB genome nucleic acid molecule to which the DNA targeting segment of the gRNA binds. For example, the formation of a CRISPR complex (including the gRNA hybridized to the gRNA recognition sequence and complexed with the Cas protein) can result in the cleavage of one or both strands in or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the nucleic acid sequence present in the CIDEB genome nucleic acid molecule to which the DNA targeting segment of the gRNA will bind.
[0211] Such a method may result in a CIDEB genomic nucleic acid molecule in which, for example, the region of SEQ ID NO:1 is destroyed, the start codon is destroyed, the stop codon is destroyed, or the coding sequence is destroyed or deleted. Optionally, the cell may be further contacted with one or more additional gRNAs that hybridize to additional gRNA recognition sequences in the target genomic locus in the CIDEB genomic nucleic acid molecule. By contacting the cell with one or more additional gRNAs (such as a second gRNA that hybridizes to a second gRNA recognition sequence), the cleavage by the Cas protein may generate two or more double-strand breaks or two or more single-strand breaks.
[0212] In some embodiments, targeted genetic modification of a PNPLA3 genomic nucleic acid molecule can be generated by contacting a cell with a Cas protein and one or more gRNAs that hybridize to one or more gRNA recognition sequences in a target genomic locus in a PHPLA3 genomic nucleic acid molecule. For example, the gRNA recognition sequence can be located within a region of SEQ ID NO: 43. For example, the gRNA recognition sequence can be located at about 1000, about 500, about 400, about 300, about 200, about 100, about 50, about 45, about 40, about 35, about 30, about 25, about 20, about 15, about 10, or about 5 nucleotides from a position corresponding to position 5109 according to SEQ ID NO: 43. Other exemplary gRNAs include a DNA targeting segment that hybridizes to a gRNA recognition sequence present in a PNPLA3 genomic nucleic acid molecule that includes or is adjacent to a start codon or a stop codon. For example, a gRNA can be selected to hybridize to a gRNA recognition sequence located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon, or about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the stop codon. Suitable gRNAs can include about 17 to about 25 nucleotides, about 17 to about 23 nucleotides, about 18 to about 22 nucleotides, or about 19 to about 21 nucleotides. In some embodiments, the gRNA includes 20 nucleotides.
[0213] Examples of suitable gRNA recognition sequences located within the PNPLA3 reference gene are shown in Table 15 as SEQ ID NOs: 75-94.
[0214] [Table 15]
[0215] The Cas protein and gRNA form a complex, and the Cas protein cuts the target PNPLA3 genomic nucleic acid molecule. The Cas protein can cut the nucleic acid molecule at a site within or outside the nucleic acid sequence present in the target PNPLA3 genomic nucleic acid molecule to which the DNA targeting segment of the gRNA binds. For example, the formation of a CRISPR complex (comprising a gRNA hybridized to a gRNA recognition sequence and complexed with a Cas protein) can result in the cleavage of one or both strands in or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs from) the nucleic acid sequence present in the PNPLA3 genomic nucleic acid molecule to which the DNA targeting segment of the gRNA will bind.
[0216] Such a method may result in a PNPLA3 genomic nucleic acid molecule in which, for example, the region of SEQ ID NO:43 is destroyed, the start codon is destroyed, the stop codon is destroyed, or the coding sequence is destroyed or deleted. Optionally, the cell may be further contacted with one or more additional gRNAs that hybridize with additional gRNA recognition sequences in the target genomic locus in the PNPLA3 genomic nucleic acid molecule. By contacting the cell with one or more additional gRNAs (such as a second gRNA that hybridizes with a second gRNA recognition sequence), the cleavage by Cas protein may generate two or more double-strand breaks or two or more single-strand breaks.
[0217] In some embodiments, targeted genetic modification of HSD17B13 genomic nucleic acid molecule can be generated by contacting cells with Cas protein and one or more gRNAs that hybridize to one or more gRNA recognition sequences in the target genomic locus in PHPLA3 genomic nucleic acid molecule.For example, the gRNA recognition sequence can be a DNA targeting segment that hybridizes to the gRNA recognition sequence present in the HSD17B13 genomic nucleic acid molecule that includes or is adjacent to the start codon or stop codon. For example, a gRNA can be selected to hybridize to a gRNA recognition sequence located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon or about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the stop codon. Suitable gRNAs can include about 17 to about 25 nucleotides, about 17 to about 23 nucleotides, about 18 to about 22 nucleotides, or about 19 to about 21 nucleotides. In some embodiments, the gRNA includes 20 nucleotides.
[0218] Examples of suitable gRNA recognition sequences located within the HSD17B13 reference gene are shown in Table 16 as SEQ ID NOs: 95-114.
[0219] [Table 16]
[0220] The Cas protein and gRNA form a complex, and the Cas protein cleaves the target HSD17B13 genomic nucleic acid molecule. The Cas protein can cleave the nucleic acid molecule at a site within or outside the nucleic acid sequence present in the target HSD17B13 genomic nucleic acid molecule to which the DNA targeting segment of the gRNA binds. For example, the formation of a CRISPR complex (comprising a gRNA hybridized to a gRNA recognition sequence and complexed with a Cas protein) can result in the cleavage of one or both strands in or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the nucleic acid sequence present in the HSD17B13 genomic nucleic acid molecule to which the DNA targeting segment of the gRNA will bind.
[0221] Such a method may result in a HSD17B13 genomic nucleic acid molecule in which, for example, the region of SEQ ID NO:52 is destroyed, the start codon is destroyed, the stop codon is destroyed, or the coding sequence is destroyed or deleted. Optionally, the cell may be further contacted with one or more additional gRNAs that hybridize with additional gRNA recognition sequences in the target genomic locus in the HSD17B13 genomic nucleic acid molecule. By contacting the cell with one or more additional gRNAs (such as a second gRNA that hybridizes with a second gRNA recognition sequence), the cleavage by the Cas protein may generate two or more double-strand breaks or two or more single-strand breaks.
[0222] In some embodiments, the CIDEB inhibitor is a small molecule. In some embodiments, the CIDEB inhibitor is an antibody. In some embodiments, the CIDEB inhibitor comprises an inhibitory nucleic acid molecule, such as an antisense nucleic acid molecule, an siRNA, or an shRNA.
[0223] In some embodiments, the PNPLA3 inhibitor is a small molecule. In some embodiments, the PNPLA3 inhibitor is an antibody. In some embodiments, the PNPLA3 inhibitor comprises an inhibitory nucleic acid molecule, such as an antisense nucleic acid molecule, an siRNA, or an shRNA. An exemplary PNPLA3 inhibitor is AZD2693.
[0224] In some embodiments, the HSD17B13 inhibitor is a small molecule. Numerous HSD17B13 inhibitors are described, for example, in PCT Publications WO2019 / 183329, WO2019 / 183164, and WO2020 / 061177. In some embodiments, the HSD17B13 inhibitor is an antibody. In some embodiments, the HSD17B13 inhibitor comprises an inhibitory nucleic acid molecule, such as an antisense nucleic acid molecule, siRNA, or shRNA. Additional examples of HSD17B13 inhibitors include, but are not limited to, ARO-HSD or ALN-HSD.
[0225] In some embodiments, the dose of the CIDEB inhibitor may be reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% for a subject who is a heterozygote for one or more CIDEB variant nucleic acid molecules compared to a subject who is a CIDEB reference (which may receive a standard dosage). In some embodiments, the dose of the CIDEB inhibitor may be reduced by about 10%, about 20%, about 30%, about 40%, or about 50%. Also, the dose of the CIDEB inhibitor in a subject who is a heterozygote for one or more CIDEB variant nucleic acid molecules may be administered less frequently compared to a subject who is a CIDEB reference. The dose may also be modified based on BMI, liver fat %, liver span, age, sex, etc.
[0226] In some embodiments, the dose of PNPLA3 inhibitor can be increased by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% for a subject who is heterozygous for one or more PNPLA3 variant nucleic acid molecules compared to a subject who is a PNPLA3 reference (which can receive standard dosage).In some embodiments, the dose of PNPLA3 inhibitor can be increased by about 10%, about 20%, about 30%, about 40%, or about 50%.Also, the dose of PNPLA3 inhibitor in a subject who is heterozygous for one or more PNPLA3 variant nucleic acid molecules can be administered more frequently compared to a subject who is a PNPLA3 reference.
[0227] In some embodiments, the dose of HSD17B13 inhibitors can be reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% for subjects who are heterozygous for one or more HSD17B13 variant nucleic acid molecules compared to subjects who are HSD17B13 references (who can receive standard dosages). In some embodiments, the dose of HSD17B13 inhibitors can be reduced by about 10%, about 20%, about 30%, about 40%, or about 50%. Also, the dose of HSD17B13 inhibitors in subjects who are heterozygous for one or more HSD17B13 variant nucleic acid molecules can be administered less frequently compared to subjects who are HSD17B13 references.
[0228] In some embodiments, the method further comprises detecting the presence or absence of a CIDEB variant nucleic acid molecule and / or a predicted loss-of-function polypeptide of CIDEB in a biological sample from the subject. In some embodiments, the CIDEB variant nucleic acid molecule is a genomic nucleic acid molecule. In some embodiments, the CIDEB variant nucleic acid molecule is an mRNA molecule. In some embodiments, the CIDEB variant nucleic acid molecule is a cDNA molecule generated from an mRNA molecule. In some embodiments, the CIDEB variant nucleic acid molecule is a missense variant, a splice site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant encoding a truncated or mutated CIDEB polypeptide. In some embodiments, the CIDEB variant nucleic acid molecule is selected from the group consisting of 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305681:G:T, 14:24305682:G:T, 14:24305683:G:T, 14:24305684:G:T, 14:24305685:G:T, 14:24305686:G:T, 14:24305687:G:T, 14:24305688:G:T, 14:24305689:G:T, 14:24305690:G:A, 14:24305691:G:T, 14:24305692:G:T, 14:24305694:G:T, 14:24305695:G:T, 14:24305696:G:T, 14:24305697:G:T, 14:24305698:G:T, 14:24305699:G:T, 14:24305600:G:T, 14:24305601:G:T, 14:24305602:G:T, 14:24305603:G 4305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C , 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24 305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A: C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:243060 64:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:2 4306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C,14:24306382:G:A、14:24306383:G:T、14:24306426:T:G、14:24306437:C:G、14:24306439:G:C、14:24306442:A:G、14:24306444:A:G、14:24306457:C:T、14:24306463:C:T、14:24306469:C:T、14:24306480:A:G、14:24306486:A:C、14:24306504:A:G、14:24306519:A:G、14:24307382:G:C、14:24307405:A:G、14:24307417:A:T、14:24307421:T:A、14:24307441:C:A、14:24307444:A:C、14:24307444:A:G、14:24307450:C:CGCTG、14:24307461:TG:T、14:24307469:AG:A、14:24307474:C:T、14:24307475:A:G、14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG、14:24307411:T:C、14:24306121:T:C、14:24307516:C:T、14:24306424:C:T、14:24306039:G:C、14:24307853:C:A、14:24306388:A:G、14:24305990:T:C、14:24307822:G:GT、14:24305640:G:A、14:24307418:T:C、14:24305758:G:C、14:24306131:C:T、14:24305953:A:G、14:24305730:C:A、14:24306418:A:G、14:24306059:AC:A、14:24307842:G:A、14:24307837:T:G、14:24306095:G:T、14:24306109:C:T、14:24307822:G:A、14:24306077:G:A、14:24307824:A:T、14:24306080:C:T、14:24305649:C:T、14:24306433:G:GA、14:24306420:G:C、14:24305658:T:G、14:24306472:C:T、14:24307412:TC:T、14:24306062:C:A、14:24306044:G:C、14:24306047:G:T、14:24306126:CAG:C、14:24306449:C:G、14:24307391:G:A、or 14:24307857:A:C (according to the GRCh38 / hg38 human genome assembly coordinates).
[0229] Detecting the presence or absence of a CIDEB variant nucleic acid molecule in a biological sample from a subject and / or determining whether a subject has a CIDEB variant nucleic acid molecule may be performed by any of the methods described herein. In some embodiments, these methods may be performed in vitro. In some embodiments, these methods may be performed in situ. In some embodiments, these methods may be performed in vivo. In any of these embodiments, the nucleic acid molecule may be present in a cell obtained from the subject.
[0230] In some embodiments, the detecting step comprises obtaining or having obtained a biological sample from the subject and performing or having performed an assay on the biological sample to determine whether the subject has a CIDEB variant nucleic acid molecule and / or a predicted loss-of-function polypeptide of CIDEB. In some embodiments, the assay is a sequence analysis comprising sequencing at least a portion of the nucleotide sequence of a CIDEB genomic nucleic acid molecule in the biological sample. In some embodiments, the assay is a sequence analysis comprising sequencing at least a portion of the nucleotide sequence of a CIDEB mRNA molecule in the biological sample. In some embodiments, the assay is a sequence analysis comprising sequencing at least a portion of the nucleotide sequence of a CIDEB cDNA molecule generated from an mRNA molecule in the biological sample.
[0231] In some embodiments, sequence analysis comprises: a) contacting the biological sample with a primer that hybridizes to a portion of the nucleotide sequence of the CIDEB nucleic acid molecule adjacent to the CIDEB variant nucleic acid molecule location; b) extending the primer through at least the CIDEB variant nucleic acid molecule location; and c) determining whether an extension product of the primer comprises a CIDEB variant nucleotide at the variant nucleic acid molecule location. In some embodiments, sequence analysis comprises sequencing the entire nucleic acid molecule in the biological sample.
[0232] In some embodiments, the assay is a sequence analysis comprising: a) amplifying at least a portion of a CIDEB nucleic acid molecule in a biological sample, the portion comprising a CIDEB variant nucleic acid molecule location; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising a mutation-specific probe, the mutation-specific probe comprising a nucleotide sequence that hybridizes to the CIDEB variant nucleic acid molecule location under stringent conditions; and d) detecting the detectable label. In some embodiments, the CIDEB nucleic acid molecule in the biological sample is mRNA, and the mRNA is reverse transcribed into cDNA prior to the amplification step.
[0233] In some embodiments, the assay is a sequence analysis comprising contacting a CIDEB nucleic acid molecule in a biological sample with a mutation-specific probe comprising a detectable label, the mutation-specific probe comprising a nucleotide sequence that hybridizes to a CIDEB variant nucleic acid molecule location under stringent conditions, and detecting the detectable label.
[0234] In some embodiments, the assay is an immunoassay for detecting the presence of a predicted loss-of-function polypeptide of CIDEB. In some embodiments, mass spectrometry is used to detect the presence of a predicted loss-of-function polypeptide of CIDEB.
[0235] In some embodiments, the method further comprises determining the genetic burden of the subject having a CIDEB variant nucleic acid molecule and / or a predicted loss-of-function polypeptide of CIDEB. If the subject has a lower genetic burden, the subject is administered or continues to be administered a standard dosage of the CIDEB inhibitor. If the subject has a higher genetic burden, the subject is administered or continues to be administered an amount of the CIDEB inhibitor equal to or less than the standard dosage. In some embodiments, the genetic burden of the subject represents the weighted sum of multiple genetic variants associated with protection against the development of liver disease. In some embodiments, the genetic burden is calculated using at least about 2, at least about 3, at least about 4, at least about 5, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 100, at least about 120, at least about 150, at least about 200, at least about 250, at least about 300, at least about 400, at least about 500, or at least about 1,000 genetic variants associated with liver disease. In some embodiments, the genetic burden can be divided into quintiles, e.g., top quintile, middle quintile, and bottom quintile, with the top quintile of genetic burden corresponding to the lowest risk group and the bottom quintile of genetic burden corresponding to the highest risk group.
[0236] Sequence analysis to determine whether a subject has a CIDEB variant nucleic acid molecule can be performed by any of the methods described herein. In some embodiments, the methods can be performed in vitro. In some embodiments, the methods can be performed in situ. In some embodiments, the methods can be performed in vivo. In any of these embodiments, the nucleic acid molecule can be present in a cell obtained from the subject.
[0237] In some embodiments, the method further comprises detecting the presence or absence of a PNPLA3 variant nucleic acid molecule encoding a PNPLA3 Ile148Met or PNPLA3 Ile144Met polypeptide and / or a PNPLA3 Ile148Met or PNPLA3 Ile144Met polypeptide in a biological sample from the subject. In some embodiments, the PNPLA3 variant nucleic acid molecule is a genomic DNA molecule that comprises a guanine at a position corresponding to position 5109 according to SEQ ID NO: 43; an mRNA molecule that comprises a guanine at a position corresponding to position 444 according to SEQ ID NO: 46, or a guanine at a position corresponding to position 432 according to SEQ ID NO: 47; a cDNA molecule generated from the mRNA molecule, the cDNA molecule having a nucleotide sequence that comprises a guanine at a position corresponding to position 444 according to SEQ ID NO: 50, or a guanine at a position corresponding to position 432 according to SEQ ID NO: 51.
[0238] Detecting the presence or absence of a PNPLA3 variant nucleic acid molecule encoding a PNPLA3 Ile148Met or PNPLA3 Ile144Met polypeptide in a biological sample from a subject and / or determining whether a subject has a PNPLA3 variant nucleic acid molecule encoding a PNPLA3 Ile148Met or PNPLA3 Ile144Met polypeptide may be performed by any of the methods described herein. In some embodiments, these methods may be performed in vitro. In some embodiments, these methods may be performed in situ. In some embodiments, these methods may be performed in vivo. In any of these embodiments, the nucleic acid molecule may be present in a cell obtained from the subject.
[0239] In some embodiments, the detecting step includes obtaining or having obtained a biological sample from the subject, and performing or having performed an assay on the biological sample to determine whether the subject has i) a PNPLA3 genomic nucleic acid molecule that comprises a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; ii) a PNPLA3 mRNA molecule that comprises a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or a complement thereof; or iii) a PNPLA3 cDNA molecule that comprises a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or a complement thereof.
[0240] In some embodiments, sequence analysis may involve a) contacting the biological sample with a primer that hybridizes to i) a portion of the nucleotide sequence of a PNPLA3 genomic nucleic acid molecule adjacent to a position corresponding to position 5109 according to SEQ ID NO: 43, or a complement thereof; ii) a portion of the nucleotide sequence of a PNPLA3 mRNA molecule adjacent to a position corresponding to position 444 according to SEQ ID NO: 46, or a position corresponding to position 432 according to SEQ ID NO: 47, or a complement thereof; or iii) a portion of the nucleotide sequence of a PNPLA3 cDNA molecule adjacent to a position corresponding to position 444 according to SEQ ID NO: 50, or a position corresponding to position 432 according to SEQ ID NO: 51, or a complement thereof; b) contacting the biological sample with a primer that hybridizes to at least i) a portion of the nucleotide sequence of a PNPLA3 genomic nucleic acid molecule corresponding to a position corresponding to position 5109 according to SEQ ID NO: 43, or a complement thereof; ii) a portion of the nucleotide sequence of a PNPLA3 mRNA molecule corresponding to a position corresponding to position 444 according to SEQ ID NO: 46, or a position corresponding to position 432 according to SEQ ID NO: 47, or a complement thereof; and c) determining whether the extension product of the primer comprises a guanine at a position corresponding to position 5109 according to SEQ ID NO:43; a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or its complement, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47; or a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or its complement, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or its complement.
[0241] In some embodiments, the assay comprises: a) i) a PNPLA3 genomic nucleic acid molecule comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; ii) a PNPLA3 mRNA molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or a complement thereof; or iii) a PNPLA3 mRNA molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51. a) amplifying at least a portion of the cDNA molecule; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising a mutation-specific probe, the mutation-specific probe comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence of the amplified nucleic acid molecule comprising: i) a guanine at a position corresponding to position 5109 according to SEQ ID NO: 43, or a complement thereof; ii) a guanine at a position corresponding to position 444 according to SEQ ID NO: 46, or a guanine at a position corresponding to position 432 according to SEQ ID NO: 47, or a complement thereof; or iii) a guanine at a position corresponding to position 444 according to SEQ ID NO: 50, or a guanine at a position corresponding to position 432 according to SEQ ID NO: 51, or a complement thereof; and d) detecting the detectable label.
[0242] In some embodiments, the assay is a sequence analysis comprising contacting a PNPLA3 nucleic acid molecule in a biological sample with a mutation-specific probe comprising a detectable label, the mutation-specific probe comprising a nucleotide sequence that hybridizes under stringent conditions to: i) a PNPLA3 genomic nucleic acid molecule comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; ii) a PNPLA3 mRNA molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or a complement thereof; or iii) a PNPLA3 cDNA molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51; and detecting the detectable label.
[0243] Sequence analysis to determine whether a subject has a PNPLA3 variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of PNPLA3 can be performed by any of the methods described herein. In some embodiments, these methods can be performed in vitro. In some embodiments, these methods can be performed in situ. In some embodiments, these methods can be performed in vivo. In any of these embodiments, the nucleic acid molecule can be present in a cell obtained from the subject.
[0244] In some embodiments, the assay is an immunoassay for detecting the presence of PNPLA3 Ile148Met or Ile144Met variant polypeptides. In some embodiments, mass spectrometry is used to detect the presence of PNPLA3 Ile148Met or Ile144Met variant polypeptides.
[0245] In some embodiments, the method further comprises detecting the presence or absence of a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide and / or a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide in a biological sample from the subject. In some embodiments, the nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide comprises a genomic nucleic acid molecule comprising a nucleotide sequence according to SEQ ID NO:52, or a nucleotide sequence having at least 90% sequence identity with SEQ ID NO:52 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; an mRNA molecule comprising a nucleotide sequence according to any one of SEQ ID NOs:53-62, or a nucleotide sequence having at least 90% sequence identity with SEQ ID NOs:53-62 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; or a cDNA molecule comprising a nucleotide sequence according to any one of SEQ ID NOs:63-72, or a nucleotide sequence having at least 90% sequence identity with SEQ ID NOs:63-72 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide.
[0246] Detecting the presence or absence of a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide and / or determining whether a subject has a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide may be performed by any of the methods described herein. In some embodiments, these methods may be performed in vitro. In some embodiments, these methods may be performed in situ. In some embodiments, these methods may be performed in vivo. In any of these embodiments, the nucleic acid molecule may be present in a cell obtained from the subject.
[0247] In some embodiments, the detecting step comprises obtaining or having obtained a biological sample from the subject; and performing or having performed an assay on the biological sample to determine whether the subject has i) an HSD17B13 genomic nucleic acid molecule comprising SEQ ID NO:52, or a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:52 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; ii) an HSD17B13 mRNA molecule comprising any one of SEQ ID NOs:53-62, or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:53-62 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; or iii) an HSD17B13 cDNA molecule comprising any one of SEQ ID NOs:63-72, or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:63-72 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide.
[0248] In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of an HSD17B13 genomic nucleic acid molecule, an mRNA molecule, or a cDNA molecule generated from an mRNA molecule in a biological sample.
[0249] In some embodiments, the assay is an immunoassay for detecting the presence of HSD17B13 wild-type or reference polypeptide. In some embodiments, mass spectrometry is used to detect the presence of HSD17B13 wild-type or reference polypeptide.
[0250] In any of the embodiments described herein, if the subject is a CIDEB reference, the subject can be administered a standard dosage of CIDEB inhibitor.If the subject is heterozygous for the CIDEB variant nucleic acid molecule that encodes the predicted loss-of-function polypeptide of CIDEB, the subject can be administered a dosage of CIDEB inhibitor that is equal to or less than the standard dosage.CIDEB inhibitor can also be administered in combination with one or more PNPLA3 inhibitors and / or one or more HSD17B13 inhibitors.
[0251] In any of the embodiments described herein, if a subject is a CIDEB reference or heterozygous for a CIDEB variant nucleic acid molecule and is also a carrier for a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, such subject may be treated with a combination of one or more CIDEB inhibitors, one or more PNPLA3 inhibitors and / or one or more HSD17B13 inhibitors.
[0252] In any of the embodiments described herein, if the subject is homozygous for the reference HSD17B13 polypeptide or the nucleic acid molecule encoding a functional HSD17B13 polypeptide, the subject is administered a CIDEB inhibitor in an amount equal to or greater than the standard dosage, or a combination of a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor in an amount equal to or greater than the standard dosage.If the subject is not homozygous for the reference HSD17B13 polypeptide or the nucleic acid molecule encoding a functional HSD17B13 polypeptide (i.e., a carrier for loss-of-function HSD17B13), the subject is administered a CIDEB inhibitor in an amount less than the standard dosage, or a combination of a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor in an amount less than the standard dosage.
[0253] In some embodiments, if the subject is a CIDEB reference, the subject is also administered a standard dosage of a therapeutic agent that treats or inhibits liver disease. In some embodiments, if the subject is heterozygous for a CIDEB variant nucleic acid molecule, the subject is also administered a standard dosage of a therapeutic agent that treats or inhibits liver disease.
[0254] In some embodiments, the treatment method further comprises detecting the presence or absence of predicted loss-of-function polypeptide of CIDEB in a biological sample from the subject.In some embodiments, if the subject does not have predicted loss-of-function or polypeptide of CIDEB, the subject is also administered a standard dosage of a therapeutic agent for treating or inhibiting liver disease.In some embodiments, if the subject has predicted loss-of-function polypeptide of CIDEB, the subject is also administered a dosage of a therapeutic agent for treating or inhibiting liver disease that is the same or less than the standard dosage.
[0255] In some embodiments, the method of treatment further comprises detecting the presence or absence of a PNPLA3 Ile148Met or Ile144Met polypeptide in a biological sample from the subject. In some embodiments, if the subject has a predicted loss-of-function CIDEB polypeptide and a PNPLA3 Ile148Met or Ile144Met polypeptide, the subject is also administered a standard dosage or greater of a therapeutic agent that treats or inhibits liver disease.
[0256] In some embodiments, the treatment method further comprises detecting the presence or absence of a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide in a biological sample from the subject.In some embodiments, if the subject is homozygous for the reference HSD17B13 polypeptide or the nucleic acid molecule encoding the functional HSD17B13 polypeptide, the subject is administered a CIDEB inhibitor in an amount equal to or greater than the standard dosage, or a combination of a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor in an amount equal to or greater than the standard dosage.If the subject is not homozygous for the reference HSD17B13 polypeptide or the nucleic acid molecule encoding the functional HSD17B13 polypeptide (i.e., a carrier for loss-of-function HSD17B13), the subject is administered a CIDEB inhibitor in an amount less than the standard dosage, or a combination of a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor in an amount less than the standard dosage.
[0257] The present disclosure also provides a method of treating a subject with a CIDEB inhibitor, the subject having or at risk of developing liver disease. The method includes obtaining or obtaining a biological sample from the subject, and determining whether the subject has a CIDEB variant nucleic acid molecule by performing or performing sequence analysis on the biological sample to determine whether the subject has a genotype that includes a CIDEB variant nucleic acid molecule. If the subject is a CIDEB reference, the method further includes administering or continuing to administer a standard dosage of the CIDEB inhibitor to the subject. If the subject is heterozygous for the CIDEB variant nucleic acid molecule, the method further includes administering or continuing to administer a dosage of the CIDEB inhibitor to the subject that is equal to or less than the standard dosage. The presence of a genotype that includes a CIDEB variant nucleic acid molecule indicates that the subject has a reduced risk of developing liver disease or has a reduced risk of developing a more severe form of liver disease. Determining whether the subject has a genotype that includes a CIDEB variant nucleic acid molecule can be performed as described herein.
[0258] In some embodiments, the subject is a CIDEB reference and the subject is administered or continues to be administered a standard dosage of a CIDEB inhibitor. In some embodiments, the subject is heterozygous for a CIDEB variant nucleic acid molecule and the subject is administered or continues to be administered a CIDEB inhibitor at a dosage equal to or less than the standard dosage.
[0259] In some embodiments, the subject is a CIDEB reference or heterozygous for a CIDEB variant nucleic acid molecule, the subject is a carrier of a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, and the subject is administered or continues to be administered a CIDEB inhibitor and is administered a PNPLA3 inhibitor and / or an HSD17B13 inhibitor.
[0260] In some embodiments, the subject is a CIDEB reference or heterozygous for a CIDEB variant nucleic acid molecule, the subject is a carrier of a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide, and the subject is administered or continues to be administered a CIDEB inhibitor and is administered an HSD17B13 inhibitor and / or a PNPLA3 inhibitor.
[0261] In any of the embodiments described herein, the method may further include administering to the subject a therapeutic agent for treating liver disease. In some embodiments, the subject being treated with a CIDEB inhibitor, a PNPLA3 inhibitor, or an HSD17B13 inhibitor, or any combination thereof, has excess weight, has an elevated BMI, is obese, has elevated body fat mass, has elevated liver fat percentage, has elevated body fat percentage, has elevated body fat volume, and / or has excess food intake. In some embodiments, the subject is obese. In some embodiments, the subject has excess weight. In some embodiments, the subject has an elevated BMI. In some embodiments, the subject has elevated body fat mass. In some embodiments, the subject has elevated body fat percentage. In some embodiments, the subject has elevated liver fat percentage. In some embodiments, the subject has elevated body fat volume. In some embodiments, the subject has excess food intake. In such a subject, a CIDEB inhibitor, a PNPLA3 inhibitor, or an HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, cirrhosis, or co-morbidities thereof. In some embodiments, CIDEB inhibitor, PNPLA3 inhibitor, or HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent liver injury, liver fat accumulation, liver inflammation, fibrosis, liver cirrhosis, or any combination thereof.In some embodiments, CIDEB inhibitor, PNPLA3 inhibitor, HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent liver injury complications.In some embodiments, CIDEB inhibitor, PNPLA3 inhibitor, or HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent liver fat accumulation complications.In some embodiments, CIDEB inhibitor, PNPLA3 inhibitor, or HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent liver inflammation complications.In some embodiments, CIDEB inhibitor, PNPLA3 inhibitor, or HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent fibrosis complications. In some embodiments, CIDEB inhibitor, PNPLA3 inhibitor, or HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent cirrhosis or its co-morbidity complications. In some embodiments, BMI is measured, body fat is determined, or fat distribution is determined to determine whether CIDEB inhibitor, PNPLA3 inhibitor, or HSD17B13 inhibitor, or any combination thereof, should be used, or whether different doses or patterns of administration should be used. In some embodiments, BMI is measured. In some embodiments, body fat is determined. In some embodiments, fat distribution is determined. In some embodiments, the dosage of a CIDEB inhibitor, a PNPLA3 inhibitor, or an HSD17B13 inhibitor, or any combination thereof, may be increased upon increase in any one or more of body weight, BMI, obesity, body fat mass, liver fat percentage, body fat percentage, body fat volume, and / or food intake.
[0262] In some embodiments, the subject being treated with a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor is heterozygous or homozygous for a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide. In some embodiments, the subject being treated and having a PNPLA3 Ile148Met or Ile144Met polypeptide is administered a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor to treat or prevent complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, cirrhosis, or co-morbidities thereof. In some embodiments, the CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor is administered to treat or prevent complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, cirrhosis, or co-morbidities thereof. In some embodiments, the CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor is administered to treat or prevent complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, cirrhosis, or co-morbidities thereof. In some embodiments, the CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor is administered to treat or prevent complications of liver injury. In some embodiments, the CIDEB inhibitor, HSD17B13 inhibitor, and / or PNPLA3 inhibitor is administered to treat or prevent complications of liver fat accumulation. In some embodiments, the CIDEB inhibitor, HSD17B13 inhibitor, and / or PNPLA3 inhibitor is administered to treat or prevent complications of liver inflammation. In some embodiments, the CIDEB inhibitor, HSD17B13 inhibitor, and / or PNPLA3 inhibitor is administered to treat or prevent complications of fibrosis. In some embodiments, the CIDEB inhibitor, HSD17B13 inhibitor, and / or PNPLA3 inhibitor is administered to treat or prevent complications of cirrhosis or its co-morbidities. In some embodiments, the method further comprises genetic testing for PNPLA3 Ile148Met or Ile144Met polypeptide to determine whether a PNPLA3 inhibitor should be used or whether a different dose or pattern of administration should be used.
[0263] The present disclosure also provides a method of treating a subject having or at risk of developing liver disease and who is heterozygous or homozygous for a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, the method comprising administering to the subject a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor.
[0264] The amino acid sequences for two reference PNPLA3 polypeptides are set forth in SEQ ID NO:38 and SEQ ID NO:39. The reference PNPLA3 polypeptide having SEQ ID NO:38 is 481 amino acids in length, while the reference PNPLA3 polypeptide having SEQ ID NO:39 is 477 amino acids in length. The reference PNPLA3 polypeptide having SEQ ID NO:38 has an isoleucine at position 148. The reference PNPLA3 polypeptide having SEQ ID NO:39 has an isoleucine at position 144.
[0265] The PNPLA3 Ile148Met polypeptide comprises the amino acid sequence set forth in SEQ ID NO:40, wherein the isoleucine at position 148 is replaced with methionine. The PNPLA3 Ile144Met polypeptide comprises the amino acid sequence set forth in SEQ ID NO:41, wherein the isoleucine at position 144 is replaced with methionine.
[0266] The nucleotide sequence of a PNPLA3 genomic nucleic acid molecule encoding a reference PNPLA3 polypeptide is set forth in SEQ ID NO: 42. The reference PNPLA3 genomic nucleic acid molecule having SEQ ID NO: 42 comprises a cytosine at position 5109. The reference PNPLA3 genomic nucleic acid molecule having SEQ ID NO: 42 comprises an ATC codon at positions 5107-5109.
[0267] The nucleotide sequence of the genomic nucleic acid molecule PNPLA3 variant encoding the PNPLA3 Ile148Met and Ile144Met polypeptides is set forth in SEQ ID NO:43, in which the cytosine at a position corresponding to position 5109 (according to SEQ ID NO:42) of the reference PNPLA3 genomic nucleic acid molecule has been replaced with a guanine, and the ATC codon at positions corresponding to positions 5107-5109 (according to SEQ ID NO:42) of the reference PNPLA3 genomic DNA molecule has been replaced by an ATG codon.
[0268] The nucleotide sequence of a PNPLA3 mRNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:38 is set forth in SEQ ID NO:44. The mRNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:38 contains a cytosine at position 444. The mRNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:38 contains an AUC codon at positions 442-444. The nucleotide sequence of a PNPLA3 mRNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:39 is set forth in SEQ ID NO:45. The mRNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:39 contains a cytosine at position 432. The mRNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:39 contains an AUC codon at positions 430-432.
[0269] The nucleotide sequence of a PNPLA3 mRNA molecule encoding a PNPLA3 Ile148Met polypeptide is set forth in SEQ ID NO: 46, in which the cytosine at the position corresponding to position 444 (according to SEQ ID NO: 44) of the PNPLA3 reference mRNA molecule has been replaced with a guanine and the AUC codon at the position corresponding to positions 442-444 (according to SEQ ID NO: 44) of the PNPLA3 reference mRNA molecule has been replaced by an AUG codon. The nucleotide sequence of a PNPLA3 mRNA molecule encoding a PNPLA3 Ile144Met polypeptide is set forth in SEQ ID NO: 47, in which the cytosine at the position corresponding to position 432 (according to SEQ ID NO: 45) of the PNPLA3 reference mRNA molecule has been replaced with a guanine and the AUC codon at the position corresponding to positions 430-432 (according to SEQ ID NO: 45) of the PNPLA3 reference mRNA molecule has been replaced by an AUG codon.
[0270] The nucleotide sequence of a PNPLA3 cDNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:38 is set forth in SEQ ID NO:48. The cDNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:38 contains a cytosine at position 444. The cDNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:38 contains an ATC codon at positions 442-444. The nucleotide sequence of a PNPLA3 cDNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:39 is set forth in SEQ ID NO:49. The cDNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:39 contains a cytosine at position 432. The cDNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:39 contains an ATC codon at positions 430-432.
[0271] The nucleotide sequence of a PNPLA3 cDNA molecule encoding a PNPLA3 Ile148Met polypeptide is set forth in SEQ ID NO:50, in which the cytosine at the position corresponding to position 444 (according to SEQ ID NO:48) of the PNPLA3 reference cDNA molecule has been replaced with a guanine, and the ATC codon at the position corresponding to positions 442-444 (according to SEQ ID NO:48) of the PNPLA3 reference cDNA molecule has been replaced by an ATG codon. The nucleotide sequence of a PNPLA3 cDNA molecule encoding a PNPLA3 Ile144Met polypeptide is set forth in SEQ ID NO:51, in which the cytosine at the position corresponding to position 432 (according to SEQ ID NO:49) of the PNPLA3 reference cDNA molecule has been replaced with a guanine, and the ATC codon at the position corresponding to positions 430-432 (according to SEQ ID NO:49) of the PNPLA3 reference cDNA molecule has been replaced by an ATG codon.
[0272] The disclosure also provides a method of treating a subject with a CIDEB inhibitor and / or a PNPLA3 inhibitor and / or an HSD17B13 inhibitor, wherein the subject has or is at risk for developing liver disease, the method comprising obtaining or obtaining a biological sample from the subject; and determining whether the subject has a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide by performing or performing a sequence analysis on the biological sample to determine whether the subject has a genotype that includes a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide; and The method includes administering or continuing to administer a CIDEB inhibitor and / or a PNPLA3 inhibitor and / or an HSD17B13 inhibitor to a subject who is heterozygous or homozygous for a nucleic acid molecule encoding an Ile148Met or Ile144Met polypeptide; the presence of a genotype having a PNPLA3 nucleic acid molecule encoding an Ile148Met or Ile144Met polypeptide indicates that the subject is a candidate for treatment with a CIDEB inhibitor and / or an HSD17B13 inhibitor and / or a PNPLA3 inhibitor. In some embodiments, the PNPLA3 nucleic acid molecule encodes PNPLA3 Ile148Met. In some embodiments, the PNPLA3 nucleic acid molecule encodes PNPLA3 Ile144Met. In some embodiments, the subject is also administered a therapeutic agent that treats or inhibits liver disease.
[0273] In some embodiments, a PNPLA3 nucleic acid molecule encoding an Ile148Met or Ile144Met polypeptide is a genomic nucleic acid molecule having a nucleotide sequence that includes a guanine at a position corresponding to position 5109 according to SEQ ID NO:43; an mRNA molecule having a nucleotide sequence that includes a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47; or a cDNA molecule generated from the mRNA molecule, wherein the cDNA molecule has a nucleotide sequence that includes a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51.
[0274] Methods for detecting either the PNPLA3 genomic nucleic acid molecule, mRNA molecule, cDNA molecule, or polypeptide can be carried out by gene chip assay, bead assay, sequencing, or immunoassay.
[0275] In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of a PNPLA3 genomic nucleic acid molecule in the biological sample, the sequenced portion includes a position corresponding to position 5109 according to SEQ ID NO: 43, or a complement thereof. In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of a PNPLA3 mRNA molecule in the biological sample, the sequenced portion includes a position corresponding to position 444 according to SEQ ID NO: 46, or a complement thereof; or position 432 according to SEQ ID NO: 47, or a complement thereof. In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of a PNPLA3 cDNA molecule in the biological sample, the sequenced portion includes a position corresponding to position 444 according to SEQ ID NO: 50, or a complement thereof; or position 432 according to SEQ ID NO: 51, or a complement thereof.
[0276] In some embodiments, sequence analysis includes: a) contacting the biological sample with a primer that hybridizes to a portion of the nucleotide sequence of the PNPLA3 genomic nucleic acid molecule proximate to a position corresponding to position 5109 according to SEQ ID NO:43; b) extending the primer through at least the position in the nucleotide sequence of the PNPLA3 genomic nucleic acid molecule that corresponds to position 5109 according to SEQ ID NO:43; and c) determining whether the extension product of the primer comprises a guanine at the position corresponding to position 5109 according to SEQ ID NO:43.
[0277] In some embodiments, sequence analysis includes: a) contacting the biological sample with a primer that hybridizes to a portion of the nucleotide sequence of a PNPLA3 mRNA molecule proximate to a position corresponding to position 444 according to SEQ ID NO: 46 or position 432 according to SEQ ID NO: 47; b) extending the primer through at least a position in the nucleotide sequence of a PNPLA3 mRNA molecule corresponding to position 444 according to SEQ ID NO: 46 or position 432 according to SEQ ID NO: 47; and c) determining whether an extension product of the primer comprises a guanine at the position corresponding to position 444 according to SEQ ID NO: 46 or a guanine at the position corresponding to position 432 according to SEQ ID NO: 47.
[0278] In some embodiments, sequence analysis includes: a) contacting the biological sample with a primer that hybridizes to a portion of the nucleotide sequence of a PNPLA3 cDNA molecule proximate to a position corresponding to position 444 according to SEQ ID NO:50 or position 432 according to SEQ ID NO:51; b) extending the primer through at least a position in the nucleotide sequence of a PNPLA3 cDNA molecule corresponding to position 444 according to SEQ ID NO:50 or position 432 according to SEQ ID NO:51; and c) determining whether an extension product of the primer contains a guanine at the position corresponding to position 444 according to SEQ ID NO:50 or a guanine at the position corresponding to position 432 according to SEQ ID NO:51.
[0279] In some embodiments, the sequence analysis involves sequencing the entire nucleic acid molecule. In some embodiments, sequence analysis comprises: a) amplifying at least a portion of a nucleic acid molecule encoding a PNPLA3 polypeptide, the portion comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising a mutation-specific probe, the mutation-specific probe comprising a nucleotide sequence that hybridizes under stringent conditions to the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; and d) detecting the detectable label.
[0280] In some embodiments, sequence analysis comprises: a) amplifying at least a portion of a nucleic acid molecule encoding a PNPLA3 polypeptide, the portion comprising a guanine at a position corresponding to position 444 according to SEQ ID NO: 46, or a complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO: 47, or a complement thereof; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising a mutation-specific probe, the mutation-specific probe comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO: 46, or a complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO: 47, or a complement thereof; and d) detecting the detectable label.
[0281] In some embodiments, the sequence analysis comprises: a) amplifying at least a portion of a nucleic acid molecule encoding a PNPLA3 polypeptide, the portion comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or a complement thereof; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising a mutation-specific probe, the mutation-specific probe comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or a complement thereof; and d) detecting the detectable label. In some embodiments, the nucleic acid molecule in the sample is mRNA, and the mRNA is reverse transcribed into cDNA prior to the amplification step.
[0282] In some embodiments, the sequence analysis comprises contacting a nucleic acid molecule in the biological sample with a mutation-specific probe comprising a detectable label, the mutation-specific probe comprising a nucleotide sequence that hybridizes under stringent conditions to an amplified nucleic acid molecule comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO: 43, or a complement thereof; and detecting the detectable label. In some embodiments, the sequence analysis comprises contacting a nucleic acid molecule in the biological sample with a mutation-specific probe comprising a detectable label, the mutation-specific probe comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence of an amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO: 46, or a complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO: 47, or a complement thereof; and detecting the detectable label. In some embodiments, sequence analysis comprises contacting a nucleic acid molecule in a biological sample with a mutation-specific probe comprising a detectable label, wherein the mutation-specific probe comprises a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or a complement thereof; and detecting the detectable label.
[0283] In some embodiments, the subject being treated with a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor is heterozygous or homozygous for a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide. In some embodiments, the subject being treated and having a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide is administered a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor to treat or prevent complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, liver cirrhosis, or co-morbidities thereof. In some embodiments, the CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor is administered to treat or prevent complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, liver cirrhosis, or co-morbidities thereof. In some embodiments, the CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor is administered to treat or prevent complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, liver cirrhosis, or co-morbidities thereof. In some embodiments, the CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor is administered to treat or prevent complications of liver injury. In some embodiments, the CIDEB inhibitor, HSD17B13 inhibitor, and / or PNPLA3 inhibitor are administered to treat or prevent complications of hepatic fat accumulation. In some embodiments, the CIDEB inhibitor, HSD17B13 inhibitor, and / or PNPLA3 inhibitor are administered to treat or prevent complications of hepatic inflammation. In some embodiments, the CIDEB inhibitor, HSD17B13 inhibitor, and / or PNPLA3 inhibitor are administered to treat or prevent complications of fibrosis. In some embodiments, the CIDEB inhibitor, HSD17B13 inhibitor, and / or PNPLA3 inhibitor are administered to treat or prevent complications of cirrhosis or its co-morbidities. In some embodiments, the method further comprises genetic testing for a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide to determine whether the CIDEB inhibitor, HSD17B13 inhibitor, and / or PNPLA3 inhibitor should be used or whether a different dose or pattern of administration should be used.
[0284] The present disclosure also provides a method of treating a subject having or at risk of developing liver disease and who is heterozygous or homozygous for a reference HSD17B13 polypeptide or a nucleic acid encoding a functional HSD17B13 polypeptide, the method comprising administering to the subject a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor.
[0285] The amino acid sequences of two reference HSD17B13 polypeptides are shown in SEQ ID NO: 73 and SEQ ID NO: 74. The reference HSD17B13 polypeptide having SEQ ID NO: 73 is 264 amino acids in length, while the reference HSD17B13 polypeptide having SEQ ID NO: 74 is 300 amino acids in length.
[0286] The nucleotide sequence of a genomic nucleic acid molecule encoding the reference HSD17B13 polypeptide is set forth in SEQ ID NO:52 (corresponding to ENSG00000170509.8, located at chr4:87,303,789-87,322,906 according to the GRCh38 / hg38 human genome assembly).
[0287] The nucleotide sequence of an mRNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 53. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 54. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 55. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 56. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 57. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 58. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 59. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 60. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 61. The nucleotide sequence of another mRNA molecule encoding the reference HSD17B13 polypeptide is shown in SEQ ID NO:62.
[0288] The nucleotide sequence of a cDNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 63. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 64. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 65. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 66. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 67. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 68. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 69. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 70. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is shown in SEQ ID NO: 71. The nucleotide sequence of another cDNA molecule encoding the reference HSD17B13 polypeptide is shown in SEQ ID NO:72.
[0289] The disclosure also provides a method of treating a subject with a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor, wherein the subject has or is at risk for developing liver disease, the method comprising obtaining or obtaining a biological sample from the subject; and the subject receiving or receiving a biological sample from the subject comprising: i) an HSD17B13 genomic nucleic acid molecule comprising SEQ ID NO:52, or a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:52 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; ii) an HSD17B13 mRNA molecule comprising any one of SEQ ID NOs:53-62, or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:53-62 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; iii) an HSD17B13 genomic nucleic acid molecule comprising any one of SEQ ID NOs:63-72. The method includes determining whether the subject has a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide by performing or performing an assay on the biological sample to determine whether the subject has a cDNA molecule or a nucleotide sequence having at least 90% sequence identity with any one of SEQ ID NOs: 63-72 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, the presence of a genotype having a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide indicating that the subject is a candidate for treatment with a CIDEB inhibitor, an HSD17B13 inhibitor, and / or a PNPLA3 inhibitor. In some embodiments, the subject is also administered a therapeutic agent that treats or inhibits liver disease.
[0290] In some embodiments, the nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide is a genomic nucleic acid molecule comprising a nucleotide sequence according to SEQ ID NO: 52, or a nucleotide sequence having at least 90% sequence identity with SEQ ID NO: 52 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; an mRNA comprising a nucleotide sequence according to any one of SEQ ID NOs: 53-62, or a nucleotide sequence having at least 90% sequence identity with any one of SEQ ID NOs: 53-62 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; or a cDNA comprising a nucleotide sequence according to any one of SEQ ID NOs: 63-72, or a nucleotide sequence having at least 90% sequence identity with any one of SEQ ID NOs: 63-72 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide.
[0291] Methods for detecting any of the HSD17B13 genomic nucleic acid molecules, mRNA molecules, cDNA molecules, or polypeptides may be carried out by gene chip assays, bead assays, sequencing, or immunoassays.
[0292] In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of HSD17B13 genomic DNA, mRNA, or cDNA generated from an mRNA molecule in a biological sample.
[0293] In some embodiments, the sequence analysis involves sequencing the entire nucleic acid molecule. In some embodiments, the nucleic acid molecule is present in a cell obtained from the subject.
[0294] In some embodiments, the CIDEB inhibitor comprises an inhibitory nucleic acid molecule. In some embodiments, the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, an siRNA, or an shRNA that hybridizes to a CIDEB nucleic acid molecule.
[0295] Examples of therapeutic agents that treat or inhibit liver disease include, but are not limited to, disulfiram, naltrexone, acamprosate, prednisone, azathioprine, penicillamine, trientine, deferoxamine, ciprofloxacin, norfloxacin, ceftriaxone, ofloxacin, amoxicillin-clavulanate, phytonadione, bumetanide, furosemide, hydrochlorothiazide, chlorothiazide, amiloride, triamterene, spironolactone, octreotide, atenolol, metoprolol, nadolol, propranolol, timolol, and carvedilol, or any combination thereof.
[0296] Additional examples of liver disease therapeutics (e.g., for use in treating chronic hepatitis C) include, but are not limited to, ribavirin, paritaprevir, OLYSIO® (simeprevir), grazoprevir, ledipasvir, ombitasvir, elbasvir, DAKLINZA® (daclatasvir), dasabuvir, ritonavir, sovosbuvir, velpatasvir, voxilaprevir, glecaprevir, pibrentasvir, peginterferon alfa-2a, peginterferon alfa-2b, and interferon alfa-2b, or any combination thereof.
[0297] Additional examples of liver disease therapeutic agents (e.g., for use in non-alcoholic fatty liver disease) include, but are not limited to, weight loss inducers, such as orlistat or sibutramine; insulin sensitizers, such as thiazolidinediones (TZDs), metformin, and meglitinides; lipid lowering agents, such as statins, fibrates, and omega-3 fatty acids; antioxidants, such as vitamin E, betaine, N-acetyl-cysteine, lecithin, silymarin, and beta-carotene; anti-TNF agents, such as pentoxifylline; probiotics, such as VSL#3; and cytoprotectants, such as ursodeoxycholic acid (UDCA), or any combination thereof.Other suitable treatments include ACE inhibitors / ARBs, oligofructose, and incretin analogs.
[0298] Additional examples of liver disease therapeutics (e.g., for use in NASH) include OCALIVA® (obeticholic acid), selonsertib, elafibranor, cenicriviroc, GR_MD_02, MGL_3196, IMM124E, ARAMCHOL™ (arachidylamide cholanoic acid), GS0976, emricasan, vorixibat, NGM282, GS9674, tropifexor, MN_001, LMB763, BI_1467335, MSDC_0602, PF_05221304, DF102, saroglitazar, BMS986036, lanifibranor, semaglutide, nitazoxanide, GRI_0621, EYP001, VK2809, nalmefene, LIK066, MT_3995, elobixibat, namodenoside , foralumab, SAR425899, sotagliflozin, EDP_305, isosabutate, gemcabene, TERN_101, KBP_042, PF_06865571, DUR928, PF_06835919, NGM313, BMS_986171, namacizumab, CER_209, ND_L02_s0201, RTU_1096, DRX_065, IONIS_DG These include, but are not limited to, AT2Rx, INT_767, NC_001, Seradepal, PXL770, TERN_201, NV556, AZD2693, SP_1373, VK0214, Hepastem, TGFTX4, RLBN1127, GKT_137831, RYI_018, CB4209-CB4211, and JH_0920, or any combination thereof.
[0299] Administration of CIDEB inhibitor, PNPLA3 inhibitor, or HSD17B13 inhibitor, or any combination thereof, and / or therapeutic agent for treating or inhibiting liver disease can be repeated, for example, after 1 day, 2 days, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 2 months, or 3 months. Repeated administration can be the same dose or different dose. Administration can be repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times. For example, according to a certain dosing regimen, subject can receive therapy for a long period of time (for example, 6 months, 1 year, or more).
[0300] Administration of the CIDEB inhibitor, PNPLA3 inhibitor, or HSD17B13 inhibitor, or any combination thereof, and / or therapeutic agent for treating or inhibiting liver disease may be by any suitable route, including, but not limited to, parenteral, intravenous, oral, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, topical, intranasal, or intramuscular. Pharmaceutical compositions for administration are desirably sterile, substantially isotonic, and manufactured under GMP conditions. Pharmaceutical compositions may be provided in unit dosage form (i.e., dosage for single administration). Pharmaceutical compositions may be formulated using one or more physiologically and pharmacologic acceptable carriers, diluents, excipients, or adjuvants. The formulation depends on the route of administration chosen. The term "pharmaceutical acceptable" means that the carrier, diluent, excipient, or adjuvant is compatible with the other ingredients of the formulation and is not substantially deleterious to the recipient thereof.
[0301] In any of the embodiments described herein, the subject may have or be at risk of developing any one or more of the liver diseases described herein.In some embodiments, the subject is CIDEB reference.In some embodiments, the subject is heterozygous for CIDEB variant nucleic acid molecule.In some embodiments, the subject is homozygous for CIDEB variant nucleic acid molecule.
[0302] The present disclosure also provides a method of treating a subject, the subject being overweight, obese, having an increased body mass index (BMI), having a high liver fat percentage, or having hyperadiposity, the method comprising administering to the subject an amount of a CIDEB inhibitor, or a CIDEB inhibitor in combination with a PNPLA3 inhibitor and / or an HSD17B13 inhibitor, that is equal to or exceeds a standard dosage. In some embodiments, the subject is obese. In some embodiments, the subject is overweight. In some embodiments, the subject has an increased BMI. In some embodiments, the subject is hyperadiposity.
[0303] The terms "treat", "treating", and "treatment" as well as "prevent", "preventing", and "prevention", as used herein, refer to eliciting a desired biological response (such as a therapeutic effect and a prophylactic effect, respectively). In some embodiments, the therapeutic effect includes one or more of: a decrease and / or reduction in liver disease, a decrease and / or reduction in the severity of liver disease, a decrease and / or reduction in symptoms and liver disease related effects, a delay in the onset of symptoms and liver disease related effects, a decrease in the severity of symptoms of liver disease related effects, a decrease in the number of symptoms and liver disease related effects, a decrease in the latency of symptoms and liver disease related effects, an improvement in symptoms and liver disease related effects, a decrease in secondary symptoms, a decrease in secondary infections, prevention of relapse to liver disease, a decrease in the number or frequency of relapse occurrences, an increase in the latency between symptom occurrences, an increase in the time to sustained progression, an accelerated recovery, or an increase in the effectiveness of or a decrease in resistance to alternative therapeutic agents, and / or an increased survival time of an affected host animal following administration of an agent or a composition comprising an agent. A prophylactic effect can include complete or partial avoidance and / or inhibition or delay (e.g., complete or partial avoidance / inhibition or delay, etc.) of liver disease onset and / or progression following administration of a therapeutic protocol, and increased survival time of an affected host animal. Treatment of liver disease encompasses treatment of a subject already diagnosed as having any form of liver disease at any clinical stage or symptom, delaying the onset or progression or progression or worsening of symptoms or signs of liver disease, and / or preventing and / or reducing the severity of liver disease.
[0304] The present disclosure also provides a method for identifying a subject with an increased risk of developing liver disease. In some embodiments, the method includes determining or having determined the presence or absence of a CIDEB variant nucleic acid molecule (e.g., a genomic nucleic acid molecule, an mRNA molecule, and / or a cDNA molecule) in a biological sample obtained from a subject. If a subject lacks a CIDEB variant nucleic acid molecule (i.e., the subject is genotypically categorized as a CIDEB reference), then the subject has an increased risk of developing liver disease. If a subject has a CIDEB variant nucleic acid molecule (i.e., the subject is heterozygous or homozygous for a CIDEB variant nucleic acid molecule), then the subject has a reduced risk of developing liver disease compared to a subject who is a CIDEB reference.
[0305] Having a single copy of a CIDEB variant nucleic acid molecule protects a subject from developing liver disease more than not having a copy of the CIDEB variant nucleic acid molecule. Without intending to be limited to any particular theory or mechanism of action, it is believed that a subject is protected from developing liver disease by a single copy of a CIDEB variant nucleic acid molecule (i.e., heterozygous for the CIDEB variant nucleic acid molecule), and it is also believed that a subject can be further protected from developing liver disease by having two copies of a CIDEB variant nucleic acid molecule (i.e., homozygous for the CIDEB variant nucleic acid molecule) compared to a subject with a single copy. Thus, in some embodiments, a single copy of a CIDEB variant nucleic acid molecule may not completely protect a subject from developing liver disease, but may instead be partially or incompletely protected. Without wishing to be bound by any particular theory, it is possible that there are additional factors or molecules involved in the development of liver disease that are still present in a subject with a single copy of a CIDEB variant nucleic acid molecule, resulting in less than complete protection from developing liver disease.
[0306] Determining whether a subject has a CIDEB variant nucleic acid molecule and / or determining whether a subject has a CIDEB variant nucleic acid molecule in a biological sample from the subject may be performed by any of the methods described herein. In some embodiments, these methods may be performed in vitro. In some embodiments, these methods may be performed in situ. In some embodiments, these methods may be performed in vivo. In any of these embodiments, the nucleic acid molecule may be present in a cell obtained from the subject.
[0307] The present disclosure also provides a method for identifying a subject with an increased risk of developing liver disease, such as fatty liver disease, liver parenchymal disease, liver cirrhosis, and / or fibrosis, comprising determining or having determined the genetic burden of a subject with one or more CIDEB variant genomic nucleic acid molecules described herein, one or more CIDEB variant mRNA molecules described herein, or one or more variant cDNA molecules described herein, and / or one or more predicted loss-of-function or missense polypeptides of CIDEB described herein.The higher the genetic burden, the lower the risk of the subject developing liver disease.The lower the genetic burden, the higher the risk of the subject developing liver disease.
[0308] In some embodiments, the genetic burden of a subject having a plurality (or all) of CIDEB variant nucleic acid molecules represents the weighted sum of a plurality of genetic variants associated with protection against the development of liver disease. In some embodiments, the genetic burden is calculated using at least about 2, at least about 3, at least about 4, at least about 5, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 100, at least about 120, at least about 150, at least about 200, at least about 250, at least about 300, at least about 400, at least about 500, or at least about 1,000 genetic variants associated with liver disease. In some embodiments, if a subject has a genetic burden higher than a threshold score, the subject has a reduced risk of developing liver disease. In some embodiments, if a subject has a genetic burden lower than a threshold score, the subject has an increased risk of developing liver disease.
[0309] In some embodiments, the genetic burden is the following variants: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T: C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:2430603 4:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306 051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:243 06082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:2 4306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14 :24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C: T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504: A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:2430741 7:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307 444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A,14:24307474:C:T、14:24307475:A:G、14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24 306039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:2430564 0:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:243 06109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649: C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to the GRCh38 / hg38 human genome assembly coordinates), or one or more of these, as determined by each consideration.
[0310] In some embodiments, the genetic weights can be divided into quintiles, e.g., top, middle, and bottom quintiles, with the top quintile of genetic weights corresponding to the lowest risk group and the bottom quintile of genetic weights corresponding to the highest risk group.
[0311] In some embodiments, if a subject is identified as having an increased risk of developing liver disease, the subject is further treated with a therapeutic agent that treats or inhibits liver disease and / or a CIDEB inhibitor as described herein. For example, if a subject is a CIDEB reference and therefore has an increased risk of developing liver disease, the subject may be administered a standard dosage of a CIDEB inhibitor. In some embodiments, such a subject is also administered a therapeutic agent that treats or inhibits liver disease. In some embodiments, if a subject is heterozygous for a CIDEB variant nucleic acid molecule, the subject may be administered a CIDEB inhibitor at a dosage equal to or less than the standard dosage, and may also be administered a therapeutic agent that treats or inhibits liver disease. In some embodiments, the subject is a CIDEB reference. In some embodiments, the subject is heterozygous for a CIDEB variant nucleic acid molecule.
[0312] The present disclosure also provides for the detection or determination of the presence of CIDEB variant genomic nucleic acid molecules, CIDEB variant mRNA molecules, and / or CIDEB variant cDNA molecules generated from mRNA molecules in a biological sample from a subject in any of the methods described herein. It is understood that gene sequences within a population and the mRNA molecules encoded by such genes may vary due to polymorphisms (such as single nucleotide polymorphisms). The sequences provided herein for the CIDEB variant nucleic acid molecules disclosed herein are only exemplary sequences. Other sequences for the CIDEB variant nucleic acid molecules are also possible.
[0313] The present disclosure also provides for detecting or determining the presence of a genomic nucleic acid molecule encoding a PNPLA3 Ile148Met polypeptide or a PNPLA3 Ile144Met polypeptide, an mRNA molecule encoding a PNPLA3 Ile148Met polypeptide or a PNPLA3 Ile144Met polypeptide, a cDNA molecule encoding a PNPLA3 Ile148Met polypeptide or a PNPLA3 Ile144Met polypeptide, and / or a PNPLA3 Ile148Met polypeptide or a PNPLA3 Ile144Met polypeptide in a biological sample from a subject in any of the methods described herein. It is understood that gene sequences within a population and mRNA molecules encoded by such genes may vary due to polymorphisms (such as single nucleotide polymorphisms). The sequences provided herein for the PNPLA3 variant nucleic acid molecules disclosed herein are only exemplary sequences. Other sequences for the PNPLA3 variant nucleic acid molecules are also possible. Detecting or determining the presence of a PNPLA3 variant nucleic acid molecule is described, for example, in U.S. Patent No. 10,961,583.
[0314] The present disclosure also provides for detection or determination of the presence of a reference HSD17B13 polypeptide or a genomic nucleic acid molecule encoding a functional HSD17B13 polypeptide, a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, a mRNA molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, a cDNA molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, and / or a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide in a biological sample from a subject in any of the methods described herein. It is understood that gene sequences within a population and the mRNA molecules encoded by such genes may vary due to polymorphisms (such as single nucleotide polymorphisms). The sequences provided herein for the HSD17B13 variant nucleic acid molecules disclosed herein are only exemplary sequences. Other sequences for HSD17B13 nucleic acid molecules are also possible. Detection or determination of the presence of HSD17B13 nucleic acid molecules is described, for example, in U.S. Patent No. 10,961,583.
[0315] The biological sample may be derived from any cell, tissue, or biological fluid from a subject. The sample may include any clinically relevant tissue, such as bone marrow sample, tumor biopsy, fine needle aspirate, or a sample of bodily fluid, such as blood, gingival crevicular fluid, plasma, serum, lymph, ascites, cyst fluid, or urine. In some cases, the sample includes a buccal swab. The sample used in the methods disclosed herein may vary based on the assay format, the nature of the detection method, and the tissue, cell, or extract used as the sample. Depending on the assay being used, the biological sample may be processed differently. For example, when detecting any of the nucleic acid molecules, a preliminary processing designed to isolate or enrich the sample for genomic DNA may be used. A variety of techniques may be used for this purpose. When detecting the presence or level of any CIDEB, PNPLA3, and / or HSD17B13 mRNA molecule, different techniques may be used to enrich the biological sample with mRNA. A variety of methods may be used to detect the presence or level of mRNA or the presence of specific variant genomic DNA loci.
[0316] In some embodiments, detecting a CIDEB variant nucleic acid molecule in a subject comprises assaying or performing sequence analysis on a biological sample obtained from the subject to determine whether a CIDEB genomic nucleic acid molecule, a CIDEB mRNA molecule, or a CIDEB cDNA molecule generated from an mRNA molecule in the biological sample is a CIDEB variant nucleic acid molecule.
[0317] In some embodiments, a method for detecting the presence or absence of a CIDEB variant nucleic acid molecule (e.g., a genomic nucleic acid molecule, an mRNA molecule, and / or a cDNA molecule, etc.) in a subject includes performing an assay on a biological sample obtained from the subject, where the assay determines whether a nucleic acid molecule in the biological sample comprises a particular nucleotide sequence.
[0318] In some embodiments, detecting a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide in a subject comprises assaying or performing sequence analysis on a biological sample obtained from the subject to determine whether a PNPLA3 genomic nucleic acid molecule, a PNPLA3 mRNA molecule, or a PNPLA3 cDNA molecule generated from an mRNA molecule in the biological sample encodes an Ile148Met or Ile144Met polypeptide.
[0319] In some embodiments, a method for detecting the presence or absence of a nucleic acid molecule (e.g., a genomic nucleic acid molecule, an mRNA molecule, and / or a cDNA molecule, etc.) encoding a PNPLA3 Ile148Met or Ile144Met polypeptide in a subject includes performing an assay on a biological sample obtained from the subject, where the assay determines whether a nucleic acid molecule in the biological sample comprises a particular nucleotide sequence.
[0320] In some embodiments, detecting a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide comprises assaying or performing sequence analysis on a biological sample obtained from a subject to determine whether an HSD17B13 genomic nucleic acid molecule, an HSD17B13 mRNA molecule, or an HSD17B13 cDNA molecule generated from an mRNA molecule in the biological sample encodes a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide.
[0321] In some embodiments, a method for detecting the presence or absence in a subject of a nucleic acid molecule (e.g., a genomic nucleic acid molecule, an mRNA molecule, and / or a cDNA molecule, etc.) encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide comprises performing an assay on a biological sample obtained from the subject, wherein the assay determines whether a nucleic acid molecule in the biological sample comprises a particular nucleotide sequence.
[0322] In some embodiments, the biological sample comprises cells or cell lysates. Such methods may further comprise, for example, obtaining biological samples from subjects that comprise CIDEB, PNPLA3, and / or HSD17B13 genomic nucleic acid molecules or mRNA molecules, and optionally reverse transcribing the mRNA into cDNA if it is mRNA. Such assays may comprise, for example, determining the identity of these positions of a particular CIDEB, PNPLA3, and / or HSD17B13 nucleic acid molecule. In some embodiments, the methods are in vitro methods.
[0323] In some embodiments, the determining step, detecting step, or sequence analysis comprises sequencing at least a portion of the nucleotide sequence of a CIDEB, PNPLA3, and / or HSD17B13 genomic nucleic acid molecule, a CIDEB, PNPLA3, and / or HSD17B13 mRNA molecule, or a CIDEB, PNPLA3, and / or HSD17B13 cDNA molecule generated from the mRNA molecule in a biological sample, wherein the sequenced portion contains one or more variations that cause or are predicted to cause a loss of function or missense (partial or complete), e.g., any one or more of the CIDEB, PNPLA3, and / or HSD17B13 nucleic acid molecules described herein.
[0324] In any of the methods described herein, the determining step, detecting step, or sequence analysis includes sequencing at least a portion of the nucleotide sequence of a CIDEB or PNPLA3 nucleic acid molecule in a biological sample, wherein the sequenced portion includes a position corresponding to a variant nucleic acid molecule position, and if a variant nucleotide is detected at the variant nucleic acid molecule position, then the CIDEB or PNPLA3 nucleic acid molecule in the biological sample comprises a CIDEB or PNPLA3 variant nucleic acid molecule.
[0325] In some embodiments, the determining step, detecting step, or sequence analysis comprises: a) contacting the biological sample with a primer that hybridizes to a portion of the nucleotide sequence of the CIDEB nucleic acid molecule adjacent to the variant nucleic acid molecule location; b) extending the primer through at least the variant nucleic acid molecule location; and c) determining whether an extension product of the primer comprises a variant nucleotide at the variant nucleic acid molecule location.
[0326] In some embodiments, the assay comprises sequencing the entire nucleic acid molecule. In some embodiments, only the CIDEB genomic nucleic acid molecule is analyzed. In some embodiments, only the CIDEB mRNA is analyzed. In some embodiments, only the CIDEB cDNA derived from the CIDEB mRNA is analyzed.
[0327] In some embodiments, the determining step, detecting step, or sequence analysis comprises: a) amplifying at least a portion of a CIDEB nucleic acid molecule encoding a CIDEB polypeptide, the portion comprising a variant nucleic acid molecule location; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising a mutation-specific probe, the mutation-specific probe comprising a nucleotide sequence that hybridizes to the variant nucleic acid molecule location under stringent conditions; and d) detecting the detectable label.
[0328] In any of the methods described herein, the determining step, detecting step, or sequence analysis comprises sequencing at least a portion of the nucleotide sequence of a PNPLA3 genomic nucleic acid molecule in a biological sample, the sequenced portion comprising a position corresponding to position 5109 (i.e., variant nucleic acid molecule position) according to SEQ ID NO: 43, or a complement thereof. In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of a PNPLA3 mRNA molecule in a biological sample, the sequenced portion comprising a position corresponding to position 444 (i.e., variant nucleic acid molecule position) according to SEQ ID NO: 46, or a complement thereof; or position 432 (i.e., variant nucleic acid molecule position) according to SEQ ID NO: 47, or a complement thereof. In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of a PNPLA3 cDNA molecule in a biological sample, the sequenced portion comprising a position corresponding to position 444 (i.e., variant nucleic acid molecule position) according to SEQ ID NO: 50, or a complement thereof; or position 432 (i.e., variant nucleic acid molecule position) according to SEQ ID NO: 51, or a complement thereof.
[0329] In some embodiments, sequence analysis includes: a) contacting the biological sample with a primer that hybridizes to a portion of the nucleotide sequence of the PNPLA3 genomic nucleic acid molecule proximate to a position corresponding to position 5109 according to SEQ ID NO:43; b) extending the primer through at least the position in the nucleotide sequence of the PNPLA3 genomic nucleic acid molecule that corresponds to position 5109 according to SEQ ID NO:43; and c) determining whether the extension product of the primer comprises a guanine at the position corresponding to position 5109 according to SEQ ID NO:43.
[0330] In some embodiments, sequence analysis includes: a) contacting the biological sample with a primer that hybridizes to a portion of the nucleotide sequence of a PNPLA3 mRNA molecule proximate to a position corresponding to position 444 according to SEQ ID NO: 46 or position 432 according to SEQ ID NO: 47; b) extending the primer through at least a position in the nucleotide sequence of a PNPLA3 mRNA molecule corresponding to position 444 according to SEQ ID NO: 46 or position 432 according to SEQ ID NO: 47; and c) determining whether an extension product of the primer comprises a guanine at the position corresponding to position 444 according to SEQ ID NO: 46 or a guanine at the position corresponding to position 432 according to SEQ ID NO: 47.
[0331] In some embodiments, sequence analysis includes: a) contacting the biological sample with a primer that hybridizes to a portion of the nucleotide sequence of a PNPLA3 cDNA molecule proximate to a position corresponding to position 444 according to SEQ ID NO:50 or position 432 according to SEQ ID NO:51; b) extending the primer through at least a position in the nucleotide sequence of a PNPLA3 cDNA molecule corresponding to position 444 according to SEQ ID NO:50 or position 432 according to SEQ ID NO:51; and c) determining whether an extension product of the primer contains a guanine at the position corresponding to position 444 according to SEQ ID NO:50 or a guanine at the position corresponding to position 432 according to SEQ ID NO:51.
[0332] In some embodiments, the assay comprises sequencing the entire nucleic acid molecule. In some embodiments, only the PNPLA3 genomic nucleic acid molecule is analyzed. In some embodiments, only the PNPLA3 mRNA is analyzed. In some embodiments, only the PNPLA3 cDNA derived from the PNPLA3 mRNA is analyzed.
[0333] In some embodiments, sequence analysis comprises: a) amplifying at least a portion of a nucleic acid molecule encoding a PNPLA3 polypeptide, the portion comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising a mutation-specific probe, the mutation-specific probe comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; and d) detecting the detectable label.
[0334] In some embodiments, sequence analysis comprises: a) amplifying at least a portion of a nucleic acid molecule encoding a PNPLA3 polypeptide, the portion comprising a guanine at a position corresponding to position 444 according to SEQ ID NO: 46, or a complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO: 47, or a complement thereof; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising a mutation-specific probe, the mutation-specific probe comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO: 46, or a complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO: 47, or a complement thereof; and d) detecting the detectable label.
[0335] In some embodiments, sequence analysis includes a) amplifying at least a portion of a nucleic acid molecule encoding a PNPLA3 polypeptide, the portion comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or a complement thereof; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising a mutation-specific probe, the mutation-specific probe comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or a complement thereof; and d) detecting the detectable label.
[0336] In any of the methods described herein, the determining, detecting, or sequence analysis comprises obtaining or having obtained a biological sample from a subject; and performing or having performed an assay on the biological sample to determine whether the subject has i) HSD17B13 genomic DNA comprising SEQ ID NO:52; or a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:52 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; ii) HSD17B13 mRNA comprising any one of SEQ ID NOs:53-62, or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:53-62 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; or iii) HSD17B13 cDNA comprising any one of SEQ ID NOs:63-72, or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:63-72 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide.
[0337] In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of HSD17B13 genomic DNA, mRNA, or cDNA generated from an mRNA molecule in a biological sample.
[0338] In some embodiments, the nucleic acid molecule is mRNA and the determining step further comprises reverse transcribing the mRNA into cDNA prior to the amplifying step. In some embodiments, the determining step, detecting step, or sequence analysis comprises contacting a nucleic acid molecule in a biological sample with a mutation-specific probe comprising a detectable label, the mutation-specific probe comprising a nucleotide sequence that hybridizes to the variant nucleic acid molecule location under stringent conditions; and detecting the detectable label.
[0339] The mutation-specific probe or mutation-specific primer described herein comprises a nucleic acid sequence that is complementary to, hybridizes to, or specifically hybridizes to a CIDEB variant nucleic acid molecule, or its complement. In some embodiments, the mutation-specific probe or mutation-specific primer comprises or consists of at least about 1, at least about 5, at least about 8, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, or at least about 50 nucleotides. In some embodiments, the mutation-specific probe or mutation-specific primer comprises or consists of at least 15 nucleotides to at least about 35 nucleotides. In some embodiments, the mutation-specific probe or mutation-specific primer hybridizes under stringent conditions to a CIDEB variant genomic nucleic acid molecule, a CIDEB variant mRNA molecule, and / or a CIDEB variant cDNA molecule.
[0340] The mutation-specific probe or mutation-specific primer described herein comprises a nucleic acid sequence that is complementary to, hybridizes to, or specifically hybridizes to a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, or its complement. In some embodiments, the mutation-specific probe or mutation-specific primer comprises or consists of at least about 1, at least about 5, at least about 8, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, or at least about 50 nucleotides. In some embodiments, the mutation-specific probe or mutation-specific primer comprises or consists of at least 15 nucleotides. In some embodiments, the mutation-specific probe or primer comprises or consists of at least 15 nucleotides to at least about 35 nucleotides. In some embodiments, the mutation-specific probe or primer hybridizes under stringent conditions to a genomic nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, an mRNA molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, and / or a cDNA molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide.
[0341] Mutation-specific polymerase chain reaction techniques can be used to detect mutations (such as SNPs in a nucleic acid sequence). Mutation-specific primers can be used because DNA polymerase will not extend if there is a mismatch with the template.
[0342] In some embodiments, the nucleic acid molecule in the sample is mRNA, and the mRNA is reverse transcribed into cDNA prior to the amplification step. In some embodiments, the nucleic acid molecule is present in a cell obtained from the subject.
[0343] In some embodiments, the assay involves contacting the biological sample under stringent conditions with a primer or probe, such as a mutation-specific primer or a mutation-specific probe, that specifically hybridizes to a CIDEB variant genomic sequence, variant mRNA sequence, or variant cDNA sequence, but not to the corresponding CIDEB reference sequence, and determining whether hybridization occurs.
[0344] In some embodiments, the assay involves contacting a biological sample with a primer or probe, such as a mutation-specific primer or mutation-specific probe, that specifically hybridizes under stringent conditions to a genomic nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, an mRNA molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, and / or a cDNA molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, and determining whether hybridization occurs.
[0345] In some embodiments, the assay includes RNA sequencing (RNA-Seq). In some embodiments, the assay also includes reverse transcribing mRNA into cDNA, such as by reverse transcriptase polymerase chain reaction (RT-PCR).
[0346] In some embodiments, the method utilizes probes and primers of sufficient nucleotide length to bind to target nucleotide sequences and specifically detect and / or identify polynucleotides including CIDEB variant genomic nucleic acid molecules, variant mRNA molecules, or variant cDNA molecules, and / or nucleic acid molecules encoding PNPLA3 Ile148Met or Ile144Met polypeptides, mRNA molecules encoding PNPLA3 Ile148Met or Ile144Met polypeptides, and / or cDNA molecules encoding PNPLA3 Ile148Met or Ile144Met polypeptides. The operator can determine the hybridization or reaction conditions to achieve this result. The nucleotide length can be any length sufficient for use in the selected detection method, including any assay described or exemplified herein. Such probes and primers can specifically hybridize to the target nucleotide sequence under high stringency hybridization conditions. Probes and primers may have complete nucleotide sequence identity of consecutive nucleotides within a target nucleotide sequence, but probes that differ from the target nucleotide sequence and retain the ability to specifically detect and / or identify the target nucleotide sequence may be designed by conventional methods. Probes and primers may have about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% sequence identity or complementarity with the nucleotide sequence of the target nucleic acid molecule.
[0347] Exemplary examples of nucleic acid sequencing techniques include, but are not limited to, chain terminator (Sanger) sequencing and dye terminator sequencing. Other methods include nucleic acid hybridization methods other than sequencing, including using labeled primers or probes on purified DNA, amplified DNA, and fixed cell preparations (fluorescence in situ hybridization (FISH)). In some methods, the target nucleic acid molecule can be amplified prior to or simultaneously with detection. Illustrative examples of nucleic acid amplification techniques include, but are not limited to, polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), and nucleic acid sequence-based amplification (NASBA). Other methods include, but are not limited to, ligase chain reaction, strand displacement amplification, and thermophilic SDA (tSDA).
[0348] In hybridization techniques, stringent conditions can be used so that probe or primer specifically hybridizes to its target.In some embodiments, polynucleotide primer or probe under stringent conditions will hybridize to its target sequence detectably higher than other non-target sequences (at least 2 times higher than background, at least 3 times higher than background, at least 4 times higher than background, etc., including 10 times higher than background).Stringent conditions are sequence-dependent and will be different in different situations.
[0349] Suitable stringency conditions that promote DNA hybridization (e.g., 6x sodium chloride / sodium citrate (SSC) at about 45°C, followed by a 2x SSC wash at 50°C) are known or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6. Typically, stringent conditions for hybridization and detection include conditions in which the salt concentration is less than about 1.5 M NaCl at pH 7.0-8.3. +ion, typically about 0.01 to 1.0 M Na + Stringent conditions will be conditions of ionic concentration (or other salts) and temperature of at least about 30° C. for short probes (e.g., 10-50 nucleotides, etc.) and at least about 60° C. for longer probes (e.g., more than 50 nucleotides, etc.). Stringent conditions can also be achieved by the addition of destabilizing agents (e.g., formamide). Optionally, the wash buffer may contain about 0.1% to about 1% SDS. The duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours. The duration of the wash period will be at least long enough to reach equilibrium.
[0350] In some embodiments, detecting the presence of a predicted loss-of-function or missense polypeptide comprises performing an assay on a sample obtained from a subject to determine whether CIDEB in the polypeptide contains one or more variations that cause the polypeptide to have a loss-of-function (partial or complete) or a predicted loss-of-function (partial or complete) or missense variant. In some embodiments, the assay comprises sequencing at least a portion of the CIDEB polypeptide that includes the variant position. In some embodiments, the detecting step comprises sequencing the entire polypeptide. Identification of a variant amino acid at a variant position of the CIDEB polypeptide indicates that the CIDEB polypeptide is a predicted loss-of-function or missense CIDEB polypeptide. In some embodiments, the assay is an immunoassay for detecting the presence of a polypeptide that includes a variant. Detection of a variant amino acid at a variant position of the CIDEB polypeptide indicates that the CIDEB polypeptide is a predicted loss-of-function or missense CIDEB polypeptide.
[0351] In some embodiments, detecting the presence of a PNPLA3 Ile148Met or Ile144Met polypeptide comprises performing an assay on a sample obtained from a subject to determine whether the PNPLA3 polypeptide in the subject contains an Ile148Met or Ile144Met variant. In some embodiments, the assay comprises sequencing at least a portion of the PNPLA3 polypeptide that includes the variant position. In some embodiments, the detection step comprises sequencing the entire polypeptide. In some embodiments, the assay is an immunoassay for detecting the presence of a polypeptide that includes a variant.
[0352] In some embodiments, the isolated nucleic acid molecule hybridizes under stringent conditions to a CIDEB variant nucleic acid molecule, a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, or a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide (e.g., a genomic nucleic acid molecule, an mRNA molecule, and / or a cDNA molecule). Such nucleic acid molecules can be used, for example, as probes, primers, mutation-specific probes, or mutation-specific primers as described or exemplified herein, including, but not limited to, primers, probes, antisense RNA, shRNA, and siRNA, each of which are described in more detail elsewhere herein and can be used in any of the methods described herein.
[0353] In some embodiments, the isolated nucleic acid molecule hybridizes to at least about 15 contiguous nucleotides of a nucleic acid molecule that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a CIDEB variant genomic nucleic acid molecule, a CIDEB variant mRNA molecule, and / or a CIDEB variant cDNA molecule.
[0354] In some embodiments, the isolated nucleic acid molecule hybridizes to at least about 15 contiguous nucleotides of a nucleic acid molecule that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a PNPLA3 genomic nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, a PNPLA3 mRNA molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, and / or a PNPLA3 cDNA molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide.
[0355] In some embodiments, the isolated nucleic acid molecule hybridizes to at least about 15 contiguous nucleotides of a nucleic acid molecule that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a reference HSD17B13 polypeptide or a HSD17B13 genomic nucleic acid molecule encoding a functional HSD17B13 polypeptide, a reference HSD17B13 mRNA molecule encoding a functional HSD17B13 polypeptide, and / or a reference HSD17B13 polypeptide or a HSD17B13 cDNA molecule encoding a functional HSD17B13 polypeptide. In some embodiments, the isolated nucleic acid molecule consists of or comprises about 15 to about 100 nucleotides, or about 15 to about 35 nucleotides. In some embodiments, the isolated nucleic acid molecule consists of or comprises about 15 to 100 nucleotides. In some embodiments, the isolated nucleic acid molecule consists of or comprises about 15-35 nucleotides.
[0356] In some embodiments, the mutation-specific probe and the mutation-specific primer comprise DNA. In some embodiments, the mutation-specific probe and the mutation-specific primer comprise RNA.
[0357] In some embodiments, the probes and primers described herein (including mutation-specific probes and mutation-specific primers) have nucleotide sequences that specifically hybridize to any of the nucleic acid molecules disclosed herein, or their complements. In some embodiments, the probes and primers specifically hybridize under stringent conditions to any of the nucleic acid molecules disclosed herein.
[0358] In some embodiments, the primers (including mutation-specific primers) can be used in second generation or high throughput sequencing. In some instances, the primers (including mutation-specific primers) can be modified. In particular, the primers can include various modifications used in different steps of, for example, massively parallel signature sequencing (MPSS), polony sequencing, and 454 pyrosequencing. Modified primers can be used in multiple steps of the process, including biotinylated primers in the cloning step, and fluorescently labeled primers used in the bead loading and detection steps. Polony sequencing is generally accomplished using paired-end tag libraries, where each molecule of DNA template is about 135 bp in length. Biotinylated primers are used in the bead loading and emulsion PCR steps. Fluorescently labeled degenerate nonamer oligonucleotides are used in the detection step. The adapters can contain 5'-biotin tags for immobilization of the DNA library onto streptavidin-coated beads.
[0359] The probes and primers described herein can also be used to detect nucleotide variations in any of the CIDEB variant genomic nucleic acid molecules, CIDEB variant mRNA molecules, and / or CIDEB variant cDNA molecules disclosed herein. The primers described herein can be used to amplify a CIDEB variant genomic nucleic acid molecule, a CIDEB variant mRNA molecule, or a CIDEB variant cDNA molecule, or a fragment thereof.
[0360] In some embodiments, the probe (such as a mutation-specific probe) comprises a label. In some embodiments, the label is a fluorescent label, a radioisotope label, or biotin.
[0361] The present disclosure also provides a support comprising a substrate to which any one or more of the probes disclosed herein are bound. A solid support is a solid phase substrate or support to which a molecule (such as any of the probes disclosed herein) can be associated. A form of solid support is an array. Another form of solid support is an array detector. An array detector is a solid support to which a number of different probes are coupled in an array, grid, or other organized pattern. A form for a solid-state substrate is a microtiter dish (such as a standard 96-well type). In some embodiments, a multi-well glass slide can be used, usually containing one array per well.
[0362] This disclosure also includes 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G,14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG、14:24307411:T:C、14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:2430 6388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G: C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24 307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G :A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14: 24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:2430604 The present invention provides a therapeutic composition for treating or inhibiting liver disease for use in treating liver disease in a subject having one or more CIDEB variant nucleic acid molecules including 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to the GRCh38 / hg38 human genome assembly coordinates).
[0363] This disclosure also includes 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G,14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG、14:24307411:T:C、14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:243063 88:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 1 4:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:243078 42:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14: 24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658 :T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14: A composition is provided comprising a therapeutic agent that treats or inhibits liver disease for use in the preparation of a medicament for the treatment of liver disease in a subject having one or more CIDEB variant nucleic acid molecules including 24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to the GRCh38 / hg38 human genome assembly coordinates).
[0364] This disclosure also includes 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G,14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG、14:24307411:T:C、14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388:A: G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131 :C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307 837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:2430 6080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:2 4307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, Compositions are provided that include one or more CIDEB inhibitors, one or more PNPLA3 inhibitors, or one or more HSD17B13 inhibitors, or any combination thereof, for use in treating liver disease in a subject having one or more CIDEB variant nucleic acid molecules including 14:24307391:G:A, or 14:24307857:A:C (according to the GRCh38 / hg38 human genome assembly coordinates). The CIDEB inhibitors, PNPLA3 inhibitors, and / or HSD17B13 inhibitors can be any of the CIDEB inhibitors, PNPLA3 inhibitors, and / or HSD17B13 inhibitors described herein.
[0365] This disclosure also includes 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G,14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG、14:24307411:T:C、14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388: A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306 131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:2 4307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 1 4:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C :T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:2430 Provided are one or more CIDEB inhibitors, one or more PNPLA3 inhibitors, and / or one or more HSD17B13 inhibitors for use in the preparation of a medicament for the treatment of liver disease in a subject having one or more CIDEB variant nucleic acid molecules including 6449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to the GRCh38 / hg38 human genome assembly coordinates). The CIDEB inhibitor, PNPLA3 inhibitor, and / or HSD17B13 inhibitor can be any of the CIDEB inhibitors, PNPLA3 inhibitors, and / or HSD17B13 inhibitors described herein.
[0366] The present disclosure also provides a method for treating a subject with liver disease or at risk of developing liver disease, where if the subject is homozygous for a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide, the subject is administered a CIDEB inhibitor in an amount equal to or greater than the standard dosage, or a combination of a CIDEB inhibitor and an HSD17B13 inhibitor and / or a PNPLA3 inhibitor in an amount equal to or greater than the standard dosage; if the subject is not homozygous for a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide (i.e., a carrier for loss-of-function HSD17B13), the subject is administered a CIDEB inhibitor in an amount less than the standard dosage. The CIDEB inhibitor, PNPLA3 inhibitor, and / or HSD17B13 inhibitor can be any of the CIDEB inhibitors and / or HSD17B13 inhibitors described herein.
[0367] The disclosure also provides a method of treating a subject with a CIDEB inhibitor, wherein the subject has or is at risk for developing liver disease, the method comprising obtaining or obtaining a biological sample from the subject; and determining whether the subject has a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide by performing or performing a sequence analysis on the biological sample to determine whether the subject has a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide, wherein the subject is homozygous for the reference HSD17B13 polypeptide or the nucleic acid molecule encoding the functional HSD17B13 polypeptide. If the subject is a homozygous subject, the subject is administered an amount of a CIDEB inhibitor equal to or greater than the standard dosage, or a combination of a CIDEB inhibitor and an HSD17B13 inhibitor and / or a PNPLA3 inhibitor; if the subject is not homozygous for the reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide (i.e., is a carrier for loss-of-function HSD17B13), the subject is administered an amount of a CIDEB inhibitor less than the standard dosage; and the presence of a genotype having a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide indicates that the subject is a candidate for treatment with a CIDEB inhibitor.
[0368] All patent documents, websites, other publications, accession numbers, and the like cited above or below are incorporated by reference in their entirety for all purposes to the same extent as if each individual item was specifically and individually indicated to be so incorporated by reference. If different versions of sequences are associated with accession numbers at different times, the version associated with the accession number at the effective filing date of this application is intended. By effective filing date is meant the earlier of the actual filing date or the filing date of the priority application, and the accession number is referenced if applicable. Similarly, if different versions of a publication, website, or the like are published at different times, the most recently published version at the effective filing date of this application is meant unless otherwise indicated. Any feature, step, element, embodiment, or aspect of the present disclosure may be used in combination with other features, steps, elements, embodiments, or aspects, unless otherwise specifically indicated. Although the present disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
[0369] The following examples are provided to describe the embodiments in more detail. They are intended to illustrate, not limit, the claimed embodiments. The following examples provide those skilled in the art with disclosure and description of how the compounds, compositions, articles, devices and / or methods described herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the scope of any claims. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperatures, etc.), but some error and deviation can be accounted for. Unless otherwise indicated, parts are parts by weight, temperature is °C or is ambient temperature, and pressure is at or near atmospheric pressure. EXAMPLES
[0370] Example 1: Frequency of rare coding variants in CIDEB across general methodologies and populations research participants Discovery exome-wide association analyses were performed in the UK Biobank (UKB) cohort and the Geisinger Health System's (GHS) MyCode Community Health Initiative. UKB is a population-based cohort including individuals aged 40-69 years recruited from 22 testing sites in the UK between 2006-2010. We included 411,926 participants of European ancestry, 9,830 of South Asian ancestry, 8,544 of African ancestry, 2,108 of East Asian ancestry, and 587 of American ancestry with available whole-exome sequencing and transaminase data. MyCode is a health system-based cohort of patients from rural Pennsylvania (USA) recruited between 2007-2021. We included 109,909 participants of European ancestry with available whole-exome sequencing and transaminase data. Liver disease outcome association analyses further included up to 28,948 participants from the Malmo Diet and Cancer Study (MDCS), 13,418 participants from the University of Pennsylvania PennMedicine BioBank (UPENN-PMBB), and 23,849 participants from the Mount Sinai BioMe BioBank cohort (BioMe). Liver histopathology association analyses were also performed in 3,599 bariatric surgery patients from the GHS who were not included in the primary discovery analysis.
[0371] DNA exome sequencing Exome sequences were captured using NimbleGen VCRome probes (for some of the GHS cohorts) or a modified version of the xGen design available from Integrated DNA Technologies (IDT; for the remainder of the GHS cohorts and other cohorts). After capture, balanced pools were sequenced using 75 bp paired-end reads on an Illumina v4 HiSeq 2500 instrument (for some of the GHS cohorts) or NovaSeq instrument (for the remainder of the GHS cohorts and other cohorts). Sequencing achieved 20x coverage of >85% of the target bases in 96% of the VCRome samples and >90% of the target bases in 99% of the IDT samples. After sequencing, pooled samples were demultiplexed using Illumina software, sequenced reads were aligned to the GRCh38 human genome reference sequence using BWA-mem, and cohort-level genotype files were generated using GLnexus.
[0372] Variants were annotated using snpEff software and Ensembl v85 gene definitions. Annotations were prioritized for protein-coding transcripts based on the most deleterious functional effect for each gene based on the following rank order (from most deleterious to least deleterious): frameshift, stop-gain, stop-loss, splice acceptor, splice donor, in-frame indel, missense, and other annotations. Predicted LOF gene variants included a) insertions or deletions resulting in a frameshift, b) insertions, deletions, or single nucleotide variants resulting in the introduction of a premature stop codon or loss of a transcription start or stop site, and c) variants at donor or acceptor splice sites. Missense variants were classified for their potential impact on function according to the number of in silico prediction algorithms that predicted deleteriousness using SIFT, Polyphen2_HDIV and Polyphen2_HVAR, LRT, and MutationTaster. For each gene, the alternative allele frequency (AAF) and functional annotation of each variant determined inclusion in these seven gene burden exposures: 1) pLOF variants with AAF<1%; 2) pLOF or missense variants predicted as deleterious by 5 / 5 algorithms with AAF<1%; 3) pLOF or missense variants predicted as deleterious by 5 / 5 algorithms with AAF<0.1%; 4) pLOF or missense variants predicted as deleterious by at least 1 / 5 algorithms with AAF<1%; 5) pLOF or missense variants predicted as deleterious by at least 1 / 5 algorithms with AAF<0.1%; 6) pLOF or any missense with AAF<1%; 7) pLOF or any missense variant with AAF<0.1%.
[0373] Phenotype definition Data cleaning was performed by removing non-physiological laboratory values or results arising from invalid or contaminated samples for a range of attributes. At Geisinger Health System (GHS), median transaminases for each individual were extracted from electronic health records. At UK Biobank (UKB), transaminases were measured using a Beckman Coulter AU5800 at the baseline study visit.
[0374] Cases for binary liver disease outcomes were defined based on one or more of the following criteria: i) self-reported disease obtained from a digital questionnaire or interview with a trained nurse, ii) hospitalization for disease or clinical problem list entry according to International Classification of Diseases, Ninth (ICD-9) or Tenth (ICD-10) Revision diagnosis codes, iii) medical procedure or surgery attributable to disease, iv) death attributable to disease, and v) disease diagnosis codes entered at two or more outpatient visits on separate calendar days. The specific entries used to define the different types of liver disease are detailed in Table 17. Controls were defined as individuals who did not meet any of the criteria for case status. To minimize misclassification, the following were excluded from the control group: i) non-cases diagnosed with any type of liver disease (not limited to the type of liver disease in question), ii) non-cases with only one outpatient encounter related to the type of liver disease in question, iii) non-cases diagnosed with ascites possibly related to liver failure, and iv) non-cases with elevated alanine aminotransferase (ALT) levels (>33 IU / L for men and >25 IU / L for women).
[0375] [Table 17-1]
[0376] [Table 17-2]
[0377] ICD10 refers to the 10th edition of the International Statistical Classification of Diseases and Related Health Problems; OPCS4 refers to the Office of Population Censuses and Surveys (OPCS) Classification of Interventions and Procedures version 4; NOMESCO refers to the Nordic Medico-Statistical Committee procedure codes. Participants were excluded from the control population if they i) were diagnosed with an "any liver disease" outcome code (defined in the table); ii) were diagnosed with ascites possibly related to liver failure (ICD10R18 (ascites) (excluding individuals with other potential causes of ascites); C16 (malignant neoplasm of the stomach), C17 (malignant neoplasm of the small intestine), C18 (malignant neoplasm of the colon), C20 (malignant neoplasm of the rectum), I42 (cardiomyopathy), I50 (heart failure)) or iii) had an elevated ALT >33 U / L (for men) and >25 U / L (for women).
[0378] Liver histopathology phenotype definition in the GHS bariatric surgery cohort The GHS Obesity Cohort consists of 3,599 individuals of European ancestry who underwent bariatric surgery and were enrolled in GHS's MyCode and the GHS-Regeneron Genetics Center (RGC) DiscovEHR Collaboration. Surgeons took a wedge biopsy of the liver 10 cm left of the falciform ligament before any liver retraction or gastric surgery according to a standardized protocol. Biopsies were sectioned, the main section was sent to a clinical pathologist for liver histology (fixed in 10% neutral buffered formalin and stained with hematoxylin and eosin for routine histology and with Masson's trichrome for assessment of fibrosis), and the remaining sections were deposited in the research biobank (stabilized in RNAlater tissue collection system (ThermoFisher Scientific) or frozen in liquid nitrogen). Histological examination was performed by an experienced pathologist and then reviewed by a second pathologist and scored according to the NASH Clinical Research Network system: steatosis grade 0 (<5% parenchymal involvement), grade 1 (5 to <34%), grade 2 (34 to <67%), and grade 3 (>67%); lobular inflammation grade 0 (no foci), grade 1 (mild, <2 foci per 200X field), grade 2 (moderate, 2 to 4 foci per 200X field), grade 3 (severe, >4 foci per 200X field); expansion grade 0 (none), grade 1 (few swollen cells), grade 2 (many cells / marked expansion); fibrosis stage 0 (none), stage 1 (perisinusoidal or periportal fibrosis), stage 2 (perisinusoidal and periportal fibrosis), stage 3 (bridging fibrosis), and stage 4 (cirrhosis).These histological diagnoses were used to define the following phenotypes: 1) normal liver: no evidence of steatosis, nonalcoholic steatohepatitis (NASH), or fibrosis; 2) simple steatosis: steatosis (any grade) without evidence of NASH or fibrosis; 3) NASH: any presence of lobular inflammation or hepatocyte swelling (any grade), or any presence of fibrosis (any stage); 4) fibrosis: any presence of fibrosis (any stage); 5) nonalcoholic fatty liver disease (NAFLD) activity score (NAS), defined as the unweighted sum (hence range 0-8) of the scores for steatosis (0-3), lobular inflammation (0-3), and swelling (0-2).
[0379] statistical analysis Associations between genotypes and phenotypes were estimated by fitting linear (for quantitative traits) or Firth bias-corrected logistic (for binary traits) regression models using REGENIE v2+ (10.1038 / s41588-021-00870-7) or the logistf function in R. Analyses were stratified by cohort and ancestry, age, 2 , gender, age by gender and age by gender 2 We adjusted for interaction term, experimental batch-related covariates, the first 10 common variant-derived gene principal components (PCs), the first 20 variant-derived PCs, and a polygenic score generated by REGENIE that accounts for association, population structure, and polygenicity (10.1038 / ng.257). To ensure independence between rare and common variant signals, discovery exome-wide analysis for common variant signals identified by fine mapping was additionally adjusted as previously described. Results across studies were combined by fixed-effects inverse variance-weighted meta-analysis.
[0380] Frequency of CIDEB coding variants identified by ancestry-wide exome sequencing Using exome sequencing across ancestry groups as described above, the frequencies of the homozygous reference genotype (reference-reference, RR), heterozygous alternative allele carrier genotype (reference-alternate, RA), and homozygous alternative allele carrier genotype (alternate-alternate, AA) were determined in sequenced individuals across ancestry groups. In each ancestry group, the RR genotype, which genetic analysis has associated with higher risk of liver fat, injury, and liver disease, was the most common genotype (Table 18).
[0381] [Table 18]
[0382] Abbreviations: RR, reference-reference genotype for predicted loss-of-function or missense variants in CIDEB; RA, reference-alternate genotype; AA, alternative-alternate genotype. The sum of percentages may differ from 100% due to rounding.
[0383] GTEx RNA-seq TMM-normalized gene expression matrices per tissue were obtained using the GTEx v8 raw expression matrix downloaded from the GTEx portal. Within each tissue, we subsetted samples included in the GTEx v8 analysis freeze and filtered for genes using the same quality control filters described below.
[0384] Liver RNA-seq in obese cohort samples We performed liver RNA-seq in 2,304 patients from the GHS who underwent perioperative wedge biopsy of the liver as part of bariatric surgery.
[0385] RNA concentration was determined by UV absorbance, and 500 ng of total RNA was used for processing. Samples were processed using the NEBNext Poly(A)mRNA Magnetic Isolation Module and the NEB NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs) according to the manufacturer's recommendations. Samples were amplified with 10 cycles of PCR using Kapa HiFi polymerase (Roche) and custom barcoded primers (IDT). Samples were sequenced on an Illumina NovaSeq 6000 platform on an S2 flow cell using paired-end 75 bp reads. The average number of reads per sample was 72 million, with a median of 68 million; 93% of samples had at least 50 million reads, and 99% of samples had more than 45 million reads, reflecting high coverage sequencing. Gene expression values for all samples were then normalized across samples using the trimmed mean (TMM) of m-value approach implemented in edgeR.
[0386] RNA-seq data were extensively processed according to the GTEx v8 analysis protocol (World Wide Web at gtexportal.org / home / documentationPage#staticTextAnalysisMethods). Briefly, sequenced samples were aligned to the human reference genome GRCh38 / hg38 using STAR v2.5.3a. Duplicate markings were applied to optical duplicates in Picard only using the pixel distance setting OPTICAL_DUPLICATE_PIXEL_DISTANCE=15000.
[0387] mRNA quantification was based on GENCODE Release 32 annotations (world wide web gencodegenes.org / human / release_32.html) collapsed into single transcript models for each gene. Gene-level expression quantification was performed using RNA-SeQC. Gene-level read counts and TPM values were generated using the following read-level filters: 1) reads were uniquely mapped; 2) reads were properly pairwise aligned; 3) read alignment distance was ≦6; 4) reads were well contained within exon boundaries.
[0388] Gene expression values for all samples were normalized: 1) read counts were normalized across samples using TMM; 2) genes were selected based on expression thresholds of ≧0.1 TPM in ≧20% of samples and ≧6 reads in ≧20% of samples (non-normalized).
[0389] Allele-specific counting and analysis Read counts per allele were generated by counting the number of reads that overlapped the variant position and carried the allele of interest (reference or alternative). p-values for the observed degree of imbalance in read counts per allele were based on an exact binomial test as implemented in the binomial test function in R version 4.0.5, assuming a 50% chance of success under the null.
[0390] CIDEB knockdown in HepG2 cells HepG2 (ATCC) cells were cultured in MEM with Earle's salts supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine. For siRNA knockdown, cells were transfected with CIDEB siRNA (Smartpool, Dharmacon L-004410-00-0050) or control siRNA (non-targeting pool, Dharmacon D-001810-10-50) for 48 h. For OA treatment, cells were treated with 400 μM OA for 24 h (starting 24 h after transfection).
[0391] For localization of CIDEB in lipid droplets, cells were fixed in 3% PFA for 20 min, then permeabilized in 0.1% saponin, blocked in 1% BSA, and incubated overnight with primary antibody against CIDEB (1:1000, Abnova H00027141-M01). Alexa Fluor 594 goat anti-mouse IgG (Thermo) was used during secondary antibody incubation.
[0392] BODIPY493 / 503 was incubated for 1 h during the secondary antibody incubation step, followed by a 10 min incubation with DAPI to stain the nuclei. After washing, PBS was replaced with mounting medium for fluorescence microscopy (Ibidi 50001) and then imaged using an LSM880 confocal microscope.
[0393] For Western blotting, cells were lysed in RIPA lysis buffer and protease and phosphatase inhibitors. Lysates were cleared, quantified, electrophoresed, and transferred to PVDF membranes. Membranes were blocked with Superblock T20 TBS buffer (Thermo 37536) and then incubated in primary antibodies (CIDEB: Abnova H00027141-M01 1:1000; GAPDH: HRP-conjugated Sigma G9295). For CIDEB, anti-mouse IgG, HRP secondary antibody (Cell Signaling 7076, 1:10000 dilution. Bound antibody was detected via incubation with Supersignal West Pico Plus Chemiluminescent Substrate (Thermo 4579), and Supersignal West Femto Maximum Sensitivity Substrate (Thermo 34094) was used for development of chemiluminescent signal. Relative protein expression was determined by quantification of CIDEB and GAPDH bands with ImageJ. Data were normalized using GAPDH and control cells.
[0394] RNA isolation was performed using RNeasy Mini Kit (QIAGEN 74104) with DNaseI digestion (QIAGEN 79254) according to the manufacturer's instructions. A total of 1 μg of RNA was used for cDNA synthesis using SuperScript IV VILO cDNA Synthesis Kit (Thermo 11754050). Gene expression levels were determined using Taqman gene expression assays (Applied Biosystems assay IDs: CIDEB (Hs00205339_m1), GAPDH (Hs02786624_g1)) using Taqman Fast Advanced Master Mix (Thermo 4444963) on a QuantStudio6 instrument. Data was normalized using GAPDH and control cells.
[0395] For lipid droplet visualization, cells were incubated with AdipoRed (Lonza PT-7009) for 10 min and then fixed in 4% paraformaldehyde (PFA) for 10 min. Cells were washed and then incubated with 4′,6-diamidino-2-phenylindole (DAPI) for 10 min to stain nuclei. After washing, PBS was replaced with mounting medium for fluorescence microscopy (Ibidi 50001) and then imaged using an LSM880 confocal microscope.
[0396] For lipid droplet quantification, lipid droplets were revealed in the red channel (excitation at 485 nm and emission at 572 nm) using Laplacian-of-Gaussian blob detection as implemented in the Scikit-Image Python package. To adjust the detection threshold parameters of the blob detection algorithm, lipid droplets were manually marked for six random small regions (250x250 pixels) from three images per experimental group. The number of cells in each field was estimated from the DAPI channel. For each experimental group, the following quantitative endpoints were derived: mean lipid droplet size (quantified as lipid droplet volume), mean number of lipid droplets per nucleus, and mean cellular lipid droplet staining (quantified as total lipid droplet area per nucleus).
[0397] The level of intracellular triglyceride content was measured using the Triglyceride Assay Kit (Abcam ab65336) according to the manufacturer's instructions. Triglyceride content was normalized to total protein content as determined by DC Protein assay (BioRad5000111). IL8 protein concentration in cell culture medium was measured using the Meso Scale Diagnostics Proinflammatory Panel and normalized to total protein content.
[0398] A two-way analysis of variance (ANOVA) was used to determine whether there was an interaction between the effects of oleic acid and CIDEB siRNA, and Tukey's multiple comparisons with Sidak correction were used to determine pairwise effects of: 1) 0 μM vs. 400 μM oleic acid in the presence of control siRNA; 2) 0 μM vs. 400 μM oleic acid in the presence of CIDEB siRNA; 3) control vs. CIDEB siRNA in the presence of 0 μM oleic acid; 4) control vs. CIDEB siRNA in the presence of 400 μM oleic acid. Since there was no oleic acid treatment, a Welch's t-test was used to compare the effects of control siRNA vs. CIDEB siRNA on CIDEB expression via Western blot and Taqman analysis. Statistical tests were performed using Prism9.
[0399] Example 2: Loss of function in CIDEB is associated with lower hepatic transaminases and protection against liver disease To identify genetic factors that contribute to predisposition to or protection against chronic liver disease, exome sequencing analysis of alanine aminotransferase (ALT), a widely used biomarker of liver injury, was performed in over 500,000 individuals from the UK Biobank (UKB) cohort and the MyCode Community Health Initiative at Geisinger Health System (GHS). UKB is a population-based cohort including individuals aged 40-69 years recruited from 22 testing sites in the UK between 2006-2010 (PLoS Med 2015;12:e1001779). We included 411,926 participants of European ancestry, 9,830 of South Asian ancestry, 8,544 of African ancestry, 2,108 of East Asian ancestry, and 587 of American ancestry with available whole exome sequencing and transaminase data (Table 19). MyCode is a health-system-based cohort of patients from rural Pennsylvania (USA) recruited between 2007 and 2021 (Genet Med 2016;18:906-13.) We included 109,909 participants of European ancestry with available whole-exome sequencing and transaminase data (Table 19).
[0400] [Table 19]
[0401] Abbreviations: UKB: UK Biobank, GHS: Geisinger Health System, SD: standard deviation, N: number of participants, WHO: World Health Organization, kg / m 2 : kilograms per square metre, mg / dL: milligrams per decilitre, mmHg: millimetres of mercury, IQR: interquartile range.
[0402] For each gene in the genome, the burden of rare predicted loss-of-function (pLOF) and missense variants identified by exome sequencing was estimated for association with ALT (see Methods in Example 1). Statistically significant findings of novel associations in the CIDEB gene were then evaluated for their association with 1) aspartate aminotransferase (AST), another transaminase often associated with liver damage, 2) liver disease clinical outcomes, and 3) liver histopathology (see Methods in Example 1).
[0403] In exome-wide analysis, the burden of rare (alternative allele frequency (AAF) < 1%) predicted loss-of-function (pLOF) or missense genetic variants in the CIDEB gene was strongly associated with lower ALT with statistical significance at the exome-wide level (p < 3.6 × 10 -7 , Bonferroni correction for 20,000 genes and 7 variant selection model, Table 20), this is a novel association. Rare pLOF or missense variants in CIDEB were also associated with lower AST levels (Table 20).
[0404] [Table 20]
[0405] Abbreviations: CI, confidence interval; SD, standard deviation; U / L, units per liter; AAF, alternative allele frequency; RR, reference-reference genotype; RA, reference-alternative heterozygote genotype; AA, alternative-alternative homozygote genotype; pLOF, predicted loss of function.
[0406] An association of rare CIDEB pLOF variants alone (excluding missense variants) with lower transaminases was also observed (Table 21), indicating that the association for rare pLOF and missense variants affects loss of function in CIDEB.
[0407] [Table 21]
[0408] Abbreviations: CI, confidence interval; SD, standard deviation; U / L, units per liter; AAF, alternative allele frequency; RR, reference-reference genotype; RA, reference-alternative heterozygote genotype; AA, alternative-alternative homozygote genotype; pLOF, predicted loss of function.
[0409] We estimated associations between CIDEB rare coding variants and risk of liver disease outcomes across the etiology and severity spectrum. Rare coding variants in CIDEB were associated with 1) lower risk of any-cause alcoholic and nonalcoholic liver disease, 2) lower risk of any-cause alcoholic and nonalcoholic cirrhosis, and 3) lower risk of viral hepatitis. Heterozygous carriers of rare coding variants had 29–53% lower odds of these outcomes compared to noncarriers (Figure 1). On a log-linear scale and in the same set of individuals, the protective associations for rare coding variants in CIDEB were 3–7 times higher than the rs72613567 splice LOF variant in the HSD17B13 gene (N. Engl. J. Med., 2018, 378, 1096-106), which was previously reported to be associated with protection against liver disease (Figure 1).
[0410] Associations with liver histopathology phenotypes were estimated in 3,599 bariatric surgery patients who underwent perioperative liver biopsy (see Methods in Example 1). Individuals carrying rare pLOF or missense variants in CIDEB had lower odds of biopsy-defined hepatic steatosis, NASH, or fibrosis compared to noncarriers (odds ratio (OR) per allele, 0.34; 95% confidence interval, 0.14 to 0.79; p=0.012; Figure 2, panel a). This association was driven by a lower proportion of obese patients with simple steatosis and a lower proportion of patients with NASH or fibrosis among carriers (Table 22). Rare pLOF or missense variants in CIDEB were also associated with lower NASH-CRN nonalcoholic fatty liver disease activity scores (NAS) on biopsy (beta per allele in standard deviation units of score, -0.56; 95% CI -0.88 to -0.24; beta per allele in untransformed score units, -0.98; 95% CI -1.54 to -0.41; p=7×10 -4 , Figure 2, panel b and Table 22).
[0411] [Table 22]
[0412] Abbreviations: OR, odds ratio; SD, standard deviation; CI, confidence interval; Ref, homozygous reference genotype; Het, heterozygous carriers of rare pLOF or missense variants in CIDEB; Hom, homozygous carriers of rare pLOF or missense variants in CIDEB; NASH; nonalcoholic steatohepatitis; NAFLD, nonalcoholic fatty liver disease.
[0413] Associations with lipid, glycemic, and anthropometric traits (Figure 3) were estimated for rare coding variants in CIDEB in over 500,000 individuals. No statistically significant associations were found for CIDEB pLOF or missense variants with these traits, except for a nominally significant association with a lower risk of type 2 diabetes (odds ratio per allele, 0.87; 95% CI, 0.79 to 0.97; p = 0.011).
[0414] Furthermore, we investigated whether rare pLOF or missense variants in CIDEB were associated with any of the 6,040 clinical phenotypes in the GHS, the phenome-wide analysis in UKB, or the meta-analysis of these two cohorts. In this analysis, after adjustment for the number of statistical tests performed, no statistically significant associations were observed with clinical phenotypes other than those with lower liver enzymes and the outcomes mentioned above (p<8.3x10 -6 ).
[0415] The association between CIDEB and liver phenotype was induced by multiple rare pLOF or missense variants in the CIDEB gene (Table 23).
[0416] [Table 23-1]
[0417] [Table 23-2]
[0418] [Table 23-3]
[0419] [Table 23-4]
[0420]
Table 23-5
[0421]
Table 23-6
[0422]
Table 23-7
[0423]
Table 23-8
[0424]
Table 23-9
[0425]
Table 23-10
[0426]
Table 23-11
[0427]
Table 23-12
[0428]
Table 23-13
[0429]
Table 23-14
[0430]
Table 23-15
[0431]
Table 23-16
[0432]
Table 23-17
[0433]
Table 23-18
[0434]
Table 23-19
[0435]
Table 23-20
[0436]
Table 23-21
[0437]
Table 23-22
[0438]
Table 23-23
[0439] C:P:R:A indicates the genomic coordinates of the gene variants including chromosome (C), physical genomic location in base pairs (P), reference allele (R) and alternative allele (A) relative to build 38 of the human genome sequence by the Human Genome Reference Consortium. Coding DNA and protein changes refer to three CIDEB transcripts annotated in the Ensembl database (URL: https: / / useast.ensembl.org / index.html) according to the Human Genome Variation Society nomenclature. Annotations for these three transcripts are reported in Table 23 in the following order: ENST00000258807, ENST00000554411, ENST00000336557. AAF indicates alternative allele frequency. pLOF indicates predicted loss-of-function variant.
[0440] Example 3: Interaction of CIDEB rare coding variants with body mass index It was hypothesized that rare coding variants in CIDEB may protect against liver disease by preventing the excessive assembly of hepatic fat into lipid droplets that are prone to enlargement and inflammation. If so, the protective association of rare pLOF and missense variants in CIDEB may be stronger in individuals with higher steatosis who are more exposed to hepatic steatosis and injury. Thus, interactions between rare coding variants in CIDEB and body mass index (BMI), the major epidemiological risk factor for hepatic steatosis, were estimated. The association of CIDEB rare coding variants with lower ALT was amplified in individuals with higher BMI when BMI was modeled as a continuous variable (pLOF for rare pLOF and missense variants in CIDEB). 相互作用 =4.5×10 -7 and p for pLOF variants in CIDEB 相互作用 = 0.0046, as shown in Figure 4).
[0441] We identified an interaction between rare coding variants in CIDEB and clinical categories of BMI on ALT. Specifically, CIDEB rare coding variants were not associated with ALT levels in non-overweight individuals (beta per allele (U / L), 0.1; 95% CI, -0.7 to 0.8; p=0.85), but were associated with -2.8 U / L lower ALT in obese individuals (95% CI, -3.6 to -2.1; p=1.7×10 -13 ; p with BMI category 相互作用 =2.9×10 -8 (Figure 5, panel a and Table 24). This interaction was also observed for the CIDEB pLOF variant (Figure 5, panel b and Table 24). Thus, the protective association against liver injury observed in carriers of rare pLOF variants in CIDEB is higher in individuals with a higher body mass index or categorically classified as overweight or obese.
[0442] [Table 24]
[0443] BMI indicates body mass index. BMI categories were defined according to the World Health Organization as follows: "non-overweight" (BMI < 25 kg / m 2 ), "overweight" (BMI ≥ 25 and < 30 kg / m 2 ), "obese" (BMI ≥ 30). RR indicates the number of individuals with no rare missense or pLOF variants in CIDEB (homozygote non-carriers); RA indicates the number of individuals with a rare missense or pLOF variant in a single CIDEB allele (heterozygote carriers); AA indicates the number of individuals with a rare missense or pLOF variant in both CIDEB alleles (homozygote carriers); SD indicates standard deviation units; AAF indicates alternative allele frequency; pLOF indicates predicted loss of function; CI indicates confidence interval; kg / m 2 Kilograms per square meter.
[0444] Table 24 shows the association of rare pLOF or missense variants in CIDEB with ALT levels within BMI categories in estimates from meta-analysis and linear interaction analysis of the GHS and UKB cohorts.
[0445] Considering the significant interaction between CIDEB and BMI (this example) and PNPLA3 (example 4) on ALT and the potential of CIDEB to affect liver fat by experimental evidence (example 5), it was hypothesized that rare coding variants in CIDEB would be associated with liver fat, and that the association would be more pronounced in overweight individuals. Rare coding variants in CIDEB were significantly associated with liver fat measured by MRI (Table 25): rare pLOF variants were associated with lower liver fat in overweight or obese individuals (beta per allele in % of liver fat fraction, -1.5%; 95% CI, -3.0% to -0.1%; p=0.04). Also, a significant interaction was found between rare pLOF or missense variants in CIDEB and BMI on liver fat measured by MRI (p-interaction=0.02).
[0446] [Table 25]
[0447] Linear regressions were performed separately between PDFF and CIDEB rare coding variants within non-overweight and overweight or obese individuals. Interaction estimates were calculated separately in each ancestry in the full model and meta-analyzed (same as in discovery analyses). Abbreviations: pLOF, predicted loss of function; SD, standard deviation; P, p-value; AAF, alternative allele frequency.
[0448] We also estimated the proportion of liver disease by CIDEB genotype and BMI category and found that the difference in the proportion of liver disease in CIDEB rare coding variant carriers versus noncarriers was highest in the obese category (Figure 6).
[0449] Example 4: Rare coding variants in CIDEB interact with PNPLA3 genotype and show additive association with HSD17B13 genotype. A common missense variant in the patatin-like phospholipase domain-containing 3 (PNPLA3) gene, encoding the p.Ile148Met (dbSNP rsID, rs738409; C>G substitution) missense change in the PNPLA3 protein, is one of the most common and strongest genetic risk factors for liver damage (as measured by ALT levels), alcoholic and nonalcoholic liver disease, and cirrhosis (Nat. Genet., 2008, 40, 1461-5; and Nat. Genet., 2010, 42, 21-3). In exome-sequencing datasets, the 148Met risk allele was strongly associated with higher ALT levels (beta per allele in SD units of ALT, 0.11; 95% confidence interval, 0.10, 0.11; p<1.0x10 -300 ), which is consistent with prior literature.
[0450] A statistically significant interaction between rare coding variants in CIDEB and the common PNPLA3 148Met risk allele for ALT was observed (Table 26 and Figure 7).
[0451] [Table 26]
[0452] RR indicates the number of individuals with no rare missense or pLOF variants in CIDEB (homozygous non-carriers); RA indicates the number of individuals with a rare missense or pLOF variant in a single CIDEB allele (heterozygous carriers); AA indicates the number of individuals with a rare missense or pLOF variant in both CIDEB alleles (homozygous carriers); SD indicates standard deviation units; AAF indicates alternative allele frequency; pLOF indicates expected loss of function; CI indicates confidence interval.
[0453] The first section of Table 26 describes the burden of pLOF or missense variants in CIDEB with AAF<1% as the genetic exposure; the second section describes the burden of only pLOF variants in CIDEB with AAF<1% as the genetic exposure. Table 26 shows the association of CIDEB genotypes with ALT levels within PNPLA3 rs738409 Ile148Met genotype categories in estimates from meta-analysis and linear interaction analysis of GHS and UKB cohorts.
[0454] The association of lower ALT levels for rare pLOF variants in CIDEB was strongest in homozygous carriers of the 148Met risk allele (G / G group), with an estimated effect size that was five times more protective than that observed in homozygous carriers of the PNPLA3 148Ile allele (C / C group; Table 26). Thus, the protective association against liver injury observed in carriers of rare pLOF or missense variants in CIDEB is higher in individuals carrying the common PNPLA3 148Met risk allele.
[0455] No significant interaction was found between rare coding variants in CIDEB and the loss-of-function splice variant rs72613567 in HSD17B13, which was shown to be protective against liver disease (N. Engl. J. Med., 2018, 378, 1096-106) (Table 27). These results indicate that rare coding variants in CIDEB have an additive protective association with that of rs72613567-TA in HSD17B13.
[0456] [Table 27]
[0457] Example 5: CIDEB is expressed on the surface of lipid droplets in hepatocytes, predicted loss-of-function variants in CIDEB are associated with lower gene expression in the liver, and inhibition of CIDEB expression via siRNA decreases lipid droplet size and reduces lipid accumulation in HepG2 cells We examined CIDEB mRNA expression across tissues in humans from the Genotype Tissue Expression Consortium (GTEx), and found CIDEB to be most highly expressed in liver across GTEx tissues (Figure 8). We also examined CIDEB mRNA expression across cells in data from the Human Protein Atlas (HPA), and found CIDEB to be most highly expressed in hepatocytes (Figure 8).
[0458] Given that CIDEB is expressed in the liver, the impact of predicted loss-of-function (pLOF) variants in the gene was investigated using liver RNASeq data from bariatric surgery patients from the GHS. Liver RNASeq was used to assess the impact of two pLOF variants (c.336+1G>A, and Lys153*). These were the two LOF variants that were unique in the 2,304 bariatric surgery patients in the GHS who underwent RNASeq. Two heterozygous carriers for each of the two variant sites were found, and we observed expression levels for CIDEB below the 25th percentile in each of the four carriers (Figure 9). Both carriers of the Lys153* variant expressed reads containing stop-gain mutations much less frequently than those carrying the reference allele (proportion expected under no-effect assumption, 50%; proportion of carrier 1, 9.9%; p-binomial for observed imbalance = 1.8 × 10 -89 ; proportion of career 2, 11.9%; p binomial = 5.2 × 10 -51; Figure 9), indicating that the variant is subject to nonsense-mediated decay, resulting in loss of a copy of CIDEB. In carriers of the c.336+1G>A variant, none of the RNAseq reads with splice sequences overlapping the variant position harbored the splice donor allele. However, RNAseq reads in which unspliced sequences overlapped the splice site position were enriched for the splice donor variant compared to the reference allele (proportion expected under no-effect assumption, 50%; proportion in carrier 3, 78.0%; p 二項 =4.1×10 -06 ;Percentage of career 4, 76.5%;p 二項 =2.0×10 -04 ; Figure 9 ), showing that the variant results in intron retention.
[0459] Given that protective loss-of-function variants in CIDEB were associated with lower hepatic expression of this gene, the effect of siRNA-mediated knockdown of CIDEB was studied in human hepatoma HepG2 cells with or without treatment with oleic acid, a monosaturated omega-9 fatty acid routinely used to mimic steatotic conditions in vitro. In particular, HepG2 human hepatoma cells were treated with control siRNA or siRNA targeting CIDEB. 24 hours after siRNA transfection, cells were treated with 0 μM or 400 μM oleic acid for 24 hours. Endogenous CIDEB protein was localized dotted on the surface of lipid droplets and at the interface of adjacent lipid droplets in both conditions in cells treated with a non-targeting pool of control siRNA (Figure 10, panel A); no CIDEB staining was observed in cells treated with CIDEB siRNA to inhibit CIDEB expression (Figure 10, panel B), demonstrating the specificity of the CIDEB antibody used. For each treatment, the image on the left shows the merge of all three stainings, and the image on the right shows only CIDEB staining. Further quantification showed that CIDEB siRNA inhibited CIDEB mRNA expression by 71% and CIDEB protein expression by 89% (Figure 10, Panel C). GAPDH was used as a loading and normalization control.
[0460] Silencing of CIDEB did not affect lipid droplet number or average lipid droplet size, cellular triglyceride content, or cellular lipid droplet staining in basal conditions (Figure 10, panels D, E, F, G, and H). Cells treated with CIDEB siRNA secreted less IL-8, a pro-inflammatory cytokine associated with NAFLD progression (Figure 10, panel I), consistent with genetic associations indicating reduced risk of inflammatory liver diseases, such as NASH and cirrhosis. Cells were then treated with oleic acid to induce fat accumulation. Oleic acid led to the appearance of larger lipid droplets in cells treated with control siRNA in proportion to the amount of oleic acid administered (Figure 10, panel J), with increased average lipid droplet size, cellular triglyceride content, and cellular lipid droplet staining (Figure 10, panels E, F, G, and H). A numerically non-statistically significant reduction in mean cellular triglyceride content or cellular lipid droplet staining was observed in cells treated with CIDEB siRNA (FIG. 10, panels G and H), consistent with the genetic association results for liver fat fraction. However, inhibition of CIDEB expression prior to oleic acid treatment resulted in an increased number of smaller lipid droplets compared to cells treated with control siRNA, with a significantly reduced mean lipid droplet size (p<0.0001) and an increased number of lipid droplets per cell (p<0.01) (FIG. 10, panels D, E, and F).
[0461] In addition to those described herein, various modifications of the described subject matter will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to be included within the scope of the appended claims. Each reference cited in this application (including, but not limited to, journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, gene bank accession numbers, etc.) is incorporated herein by reference in its entirety.
Claims
1. A method for identifying in vitro susceptibility to developing liver disease in a subject, the method comprising: determining or having determined the presence or absence of a cell death-inducing DFFA-like effector B (CIDEB) variant nucleic acid molecule in a biological sample obtained from said subject; the subject being a CIDEB reference indicates that the subject is at increased risk of developing the liver disease; The subject's heterozygote or homozygote for the CIDEB variant nucleic acid molecule indicates that the subject has a reduced risk of developing the liver disease.
2. The method of claim 1, wherein the CIDEB variant nucleic acid molecule is a missense variant, a splice site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant encoding a truncated CIDEB polypeptide.
3. The CIDEB variant nucleic acid molecule is represented by the following sequence according to the GRCh38 / hg38 human genome assembly coordinates: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24 305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C: T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:2430601 4:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306 047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:243 06077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14: 24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 1 4:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G , 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C :T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486 :A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:243074 05:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:2430 7444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T,14:24307469:AG:A、14:24307474:C:T、14:24307475:A:G、14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:14:2 405074:4040、14:243 41100000000121:14:243 14. 14:24307516:1 24306424:143 000000000000000000000000000000000000000000000000000006 DAMS、14:24306388:100、 14:2430599000006、14:2 30782200004、14:24305 400000、14:2430418:0 14. 14:24305758:14 243013114:14:2 55530000、14:2405730 DAMS、14:24306418:100、 14:24306059:14:2 4308420000、14:243078 37:005、14:243000500 14. 14:14:243060100:4 243078220000、14:2 00770000、14:2407824 1000000000000000000000000000000 14:243056490004、14:2 30433:14:23064 200006、14:24305658:0 14:24306472:4 24307412:14:2 000620044. 14:20004 14:24306047:14:1 14:24306126:14: 243044400000、14:24304 391:00、または14:243785 4:00:00 01:00:00 0:00:00 00:00:0
4. According to the GRCh38 / hg38 human genome assembly coordinates, 14:24305635: A: AGTAG, 14:24305641: A: C, 14:24305650: G: A, 14:24305657: C: A, 14:24305662: G: T, 14:24305667: T: C, 14:24305671: C: A, 14:24305671: C: G, 14:24305701: A: T, 14:24305709: C: T, 14:24305718: A: G, 14:24305721: T: C, 14:24305728: G: GGCC TT, 14:24305743: T: C, 14:24305948: T: C, 14:24305966: C: T, 14:24305974: T: C, 14:24305980: TCA: T, 14:24305988: C: T, 14:24306014: C: T, 14:24306034: A: C, 14:24306041: C: G, 14:24306044: G: A, 14:24306047: G: A, 14:24306051: T: G, 14:24306064: T: C, 14:24306074: A: G, 14:24306077: G: C, 14:24306082: A: G, 14:24306083: T: A, 14:24306095: G: A, 14:24306122: A: G, 14:24306134: C: G, 14:24306373: C: G, 14:24306379: T: C, 14:24306382: G: A, 14:24306383: G: T, 14:24306426: T: G, 14:24306437: C: G, 14:24306439: G: C, 14:24306442: A: G, 14:24306444: A: G, 14:24306457: C: T, 14:24306463: C: T, 14:24306469: C: T, 14:24306480: A: G, 14:24306486: A: C, 14:24306504: A: G, 14:24306519: A: G, 14:24307382: G: C, 14:24307405: A: G, 14:24307417: A: T, 14:24307421: T: A, 14:24307441: C: A, 14:24307444: A: C, 14:24307444: A: G, 14:24307450: C: CGC TG, 14:24307461: TG: T, 14:24307469: AG: A,14:24307474:C:T、14:24307475:A:G、14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:243 06039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G :A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:2 4306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109 :C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14 :24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306 Use of a therapeutic agent that treats or inhibits liver disease in the preparation of a medicament for treating liver disease in a subject having a CIDEB variant nucleic acid molecule comprising 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C.
5. According to the GRCh38 / hg38 human genome assembly coordinates, 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A,14:24307474:C:T、14:24307475:A:G、14:24307833:G:C、14:24307851:T:TAC、14:24306426:T:C、14:24307849:G:C、14:24307448:G:T、14:24305671:C:T、14:24305663:C:T、14:24305686:C:G、14:24307829:A:C、14:24307818:CTGAG:C、14:24307856:C:T、14:24306423:T:C、14:24306061:AC:A、14:24307390:C:T、14:24306382:G:T、14:24306373:C:T、14:24305733:T:C、14:24307858:T:C、14:24306387:C:T、14:24305637:T:C、14:24306062:C:T、14:24307853:C:G、14:24307450:C:G、14:24306052:TG:T、14:24305673:G:A、14:24306043:C:T、14:24307834:G:A、14:24306417:C:T、14:24307451:G:A、14:24307436:A:C、14:24305953:ACTTT:A、14:24306489:G:T、14:24307441:C:T、14:24306375:C:T、14:24305657:C:G、14:24306427:C:T、14:24306524:C:T、14:24307516:C:A、14:24307840:G:C、14:24307501:A:G、14:24305968:A:C、14:24305986:C:T、14:24307441:C:G、14:24307459:G:T、14:24306017:T:A、14:24307424:G:A、14:24306072:G:T、14:24307423:C:T、14:24307450:C:T、14:24306420:G:A、14:24307454:G:A、14:24305653:C:T、14:24307442:G:A、14:24306002:C:T、14:24306076:C:T、14:24305664:C:T、14:24305961:TG:T、14:24305706:A:G、14:24305946:C:T、14:24306455:G:C、14:24307468:G:A、14:24307825:A:C、14:24306110:G:A、14:24305710:C:T、14:24307483:C:T、14:24306459:A:G、14:24305754:C:T、14:24305650:G:C、14:24305691:C:T、14:24306508:G:C、14:24306039:G:T、14:24306139:T:C、14:24306391:T:C、14:24306373:C:A、14:24307498:C:T、14:24307415:G:A、14:24306138:CTG:C、14:24307453:T:C、14:24305692:G:A、14:24305683:C:G、14:24307484:G:A、14:24307385:C:T、14:24306519:A:T、14:24307839:A:C、14:24305965:C:T、14:24305988:CAT:C、14:24306087:C:G、14:24307439:C:T、14:24307477:A:C、14:24306436:G:T、14:24306507:A:G、14:24307397:C:T、14:24307495:G:A、14:24306034:A:T、14:24306013:G:A、14:24307381:A:G、14:24306383:G:C、14:24305638:A:G、14:24307420:G:A、14:24306020:C:T、14:24306470:A:C、14:24307435:C:T、14:24306469:C:G、14:24306451:C:T、14:24306403:G:A、14:24307515:C:G、14:24307489:A:G、14:24307414:C:T、14:24306483:A:G、14:24305755:G:A、14:24305766:C:T、14:24306064:T:G、14:24307516:C:G、14:24305766:C:G、14:24306489:G:A、14:24306097:T:C、14:24305763:T:G、14:24307447:G:A、14:24307402:G:A、14:24305972:C:G、14:24306423:T:G、14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:2 4307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305 758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842: G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 1 4:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24 307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:2430 Use of a composition comprising a cell death-inducing DFFA-like effector B (CIDEB) inhibitor, a patatin-like phospholipase domain-containing 3 (PNPLA3) inhibitor, or a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor, or any combination thereof, in the preparation of a medicament for treating liver disease in a subject having a CIDEB variant nucleic acid molecule comprising 14:24307857:A:C, or 14:24307857:A:C.
6. The use of claim 5, wherein the CIDEB inhibitor comprises an inhibitory nucleic acid molecule, the PNPLA3 inhibitor comprises an inhibitory nucleic acid molecule, and / or the HSD17B13 inhibitor comprises an inhibitory nucleic acid molecule.
7. The use of claim 6, wherein the CIDEB inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to CIDEB mRNA, the PNPLA3 inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to PNPLA3 mRNA, and / or the HSD17B13 inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to HSD17B13 mRNA.
8. The use of claim 5, wherein the CIDEB inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence in a CIDEB genomic nucleic acid molecule, the PNPLA3 inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence in a PNPLA3 genomic nucleic acid molecule, and / or the HSD17B13 inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence in a HSD17B13 genomic nucleic acid molecule.
9. The use according to claim 8, wherein the Cas protein is Cas9 or Cpf1.
10. Use of a cell death-inducing DFFA-like effector B (CIDEB) inhibitor in the preparation of a medicament for treating liver disease in a subject who is heterozygous or homozygous for a patatin-like phospholipase domain-containing 3 (PNPLA3) variant nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide.
11. The use of claim 10, wherein the PNPLA3 variant nucleic acid molecule encodes PNPLA3 Ile148Met.
12. The use according to claim 10 or claim 11, wherein the CIDEB inhibitor comprises an inhibitory nucleic acid molecule.
13. The use according to claim 12, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to a CIDEB nucleic acid molecule.
14. The use according to any one of claims 10 to 13 in combination with a patatin-like phospholipase domain-containing 3 (PNPLA3) inhibitor.
15. The use of claim 14 , wherein the PNPLA3 inhibitor comprises an inhibitory nucleic acid molecule.
16. The use of claim 15, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to PNPLA3 mRNA.
17. The use of CIDEB according to claim 10 or claim 11, wherein the CIDEB inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within a CIDEB genomic nucleic acid molecule.
18. The use of claim 14, wherein the PNPLA3 inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within a PNPLA3 genomic nucleic acid molecule.
19. 19. The use according to claim 17 or claim 18, wherein the Cas protein is Cas9 or Cpf1.
20. 15. The use of claim 14, wherein the PNPLA3 inhibitor is AZD2693.
21. Use of a cell death-inducing DFFA-like effector B (CIDEB) inhibitor in the preparation of a medicament for treating liver disease in a subject who is homozygous or heterozygous for a reference HSD17B13 polypeptide or a nucleic acid molecule encoding a functional HSD17B13 polypeptide.
22. The use of claim 21 , wherein the CIDEB inhibitor comprises an inhibitory nucleic acid molecule.
23. The use of claim 22, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to a CIDEB nucleic acid molecule.
24. 24. The use according to any one of claims 21 to 23 in combination with a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor.
25. 25. The use of claim 24, wherein the HSD17B13 inhibitor comprises an inhibitory nucleic acid molecule.
26. 26. The use of claim 25, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to HSD17B13 mRNA.
27. The use of claim 21, wherein the CIDEB inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within a CIDEB genomic nucleic acid molecule.
28. The use of claim 24, wherein the HSD17B13 inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within a PNPLA3 genomic nucleic acid molecule.
29. 29. The use of claim 27 or claim 28, wherein the Cas protein is Cas9 or Cpf1.
30. The use according to any one of claims 24 to 26 and 28, wherein the HSD17B13 inhibitor is an ARO-HSD or an ALN-HSD.
31. The method described in any one of claims 1 to 3, wherein the liver disease is fatty liver disease, cirrhosis, fibrosis, or increased liver enzymes.
32. The use described in any one of claims 4 to 30, wherein the liver disease is fatty liver disease, cirrhosis, fibrosis, or increased liver enzymes.
33. The method described in claim 31, wherein the fatty liver disease is nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
34. The use described in claim 32, wherein the fatty liver disease is nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
35. The method of claim 31, wherein the liver enzyme is alanine transaminase (ALT) or aspartate transaminase (AST).
36. The use of claim 32, wherein the liver enzyme is alanine transaminase (ALT) or aspartate transaminase (AST).
